Alport Syndrome

Genetic MONDO:0018965 Pathograph 17 Show in embeddings browser Hereditary Nephropathy Collagen Disorder

Alport syndrome is a hereditary nephropathy caused by mutations in genes encoding type IV collagen alpha chains (COL4A3, COL4A4, COL4A5). The defective collagen IV network leads to progressive glomerular basement membrane (GBM) deterioration, resulting in hematuria, proteinuria, and progressive renal failure. Extrarenal manifestations include sensorineural hearing loss and characteristic ocular abnormalities such as anterior lenticonus and dot-and-fleck retinopathy.

Ask OpenScientist

Ask a research question about Alport Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

X-linked inheritance HP:0001417

X-linked inheritance

Show evidence (3 references)

PMID:32712016 SUPPORT Human Clinical

"Alport syndrome can be transmitted as an X-linked, autosomal recessive, or autosomal dominant disorder. "

Confirms X-linked as one of three inheritance patterns in Alport syndrome.

PMID:20301386 SUPPORT Human Clinical

"if the mother of the proband has a COL4A5 pathogenic variant, the chance of transmitting it in each pregnancy is 50%; if the father of the proband has a COL4A5 pathogenic variant, he will transmit it to all of his daughters and none of his sons"

GeneReviews genetic-counseling recurrence risk for XLAS: a carrier mother has a 50% chance of transmitting the COL4A5 variant in each pregnancy; an affected father transmits it to all daughters and no sons.

PMID:20301386 SUPPORT Human Clinical

"prenatal and preimplantation genetic testing are possible"

GeneReviews notes that once the familial pathogenic variant(s) are known, prenatal and preimplantation genetic testing are reproductive options.

Autosomal recessive inheritance HP:0000007

Autosomal recessive inheritance

Show evidence (3 references)

PMID:25649157 SUPPORT Human Clinical

"Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive) genes result in absence of the collagen IV α3α4α5 network "

Confirms autosomal recessive inheritance via COL4A3 and COL4A4 mutations.

PMID:20301386 SUPPORT Human Clinical

"each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants (and having ARAS), a 50% chance of being heterozygous (and at risk for ADAS), and a 25% chance of inheriting neither of the familial pathogenic variants"

GeneReviews genetic-counseling recurrence risk for ARAS: with both parents heterozygous, each sib has a 25% chance of biallelic variants (ARAS), 50% heterozygous (at risk for ADAS), and 25% unaffected.

PMID:20301386 SUPPORT Human Clinical

"prenatal and preimplantation genetic testing are possible"

GeneReviews notes prenatal and preimplantation genetic testing are available reproductive options once the familial pathogenic variant(s) are known (stated generically across inheritance modes).

Autosomal dominant inheritance HP:0000006

Autosomal dominant inheritance

Show evidence (3 references)

PMID:32712016 SUPPORT Human Clinical

"Alport syndrome can be transmitted as an X-linked, autosomal recessive, or autosomal dominant disorder. "

Confirms autosomal dominant as one of three inheritance patterns.

PMID:20301386 SUPPORT Human Clinical

"If a parent of the proband is affected and/or is known to have the COL4A3 or COL4A4 pathogenic variant identified in the proband, the risk to sibs of inheriting the pathogenic variant is 50%."

GeneReviews genetic-counseling recurrence risk for ADAS: if a parent carries the COL4A3/COL4A4 pathogenic variant, the risk to sibs of inheriting it is 50%, though severity varies greatly among heterozygotes.

PMID:20301386 SUPPORT Human Clinical

"prenatal and preimplantation genetic testing are possible"

GeneReviews notes prenatal and preimplantation genetic testing are available reproductive options once the familial pathogenic variant(s) are known (stated generically across inheritance modes).

Digenic inheritance HP:0010984

Beyond the three classic Mendelian modes, a subset of Alport syndrome shows digenic inheritance, with pathogenic variants in two collagen IV genes (COL4A3 plus COL4A4, or COL4A5 together with COL4A3/COL4A4). Incomplete penetrance and wide phenotypic variability motivated the digenic model.

Digenic inheritance

Show evidence (1 reference)

PMID:25575550 SUPPORT Human Clinical

"Using massively parallel sequencing, we identified 11 patients who had pathogenic mutations in two collagen IV genes. ... This pedigree analysis provides evidence for digenic inheritance of Alport syndrome."

Segregation analysis across 56 individuals from 11 probands with pathogenic mutations in two collagen IV genes provides direct pedigree evidence for digenic inheritance, establishing it as an additional genetic model beyond the classic Mendelian modes.

◆

Subtypes

X-linked Alport Syndrome (XLAS)

Most common form (approximately 80% of cases), caused by mutations in COL4A5 on the X chromosome. Males typically progress to end-stage renal disease by age 20-30, while heterozygous females have variable expression ranging from isolated hematuria to progressive renal failure.

Autosomal Recessive Alport Syndrome (ARAS)

Accounts for approximately 15% of cases, caused by biallelic mutations in COL4A3 or COL4A4. Clinical severity comparable to X-linked males, with ESRD typically by the third decade.

Autosomal Dominant Alport Syndrome (ADAS)

Accounts for approximately 5% of cases, caused by heterozygous mutations in COL4A3 or COL4A4. Typically milder and later-onset, with ESRD in the fifth to sixth decade or later. Some cases overlap with thin basement membrane nephropathy.

Discussions and Knowledge Gaps

What genetic and non-genetic modifiers predict which heterozygous females with X-linked Alport syndrome, and which individuals with autosomal dominant Alport syndrome, will progress to end-stage kidney disease, given that their course is highly variable and often delayed until later adulthood?

KNOWLEDGE GAP OPEN gap_alport_female_adas_progression

Attached to

pathophysiology#GBM Structural Deterioration

X-linked carrier females and autosomal dominant Alport syndrome show wide, poorly predictable variability in renal outcome - many reach ESKD only in later adulthood or not at all - so clinicians cannot reliably stratify risk or time nephroprotective therapy. Identifying predictive genotype (variant type/position, X-inactivation) and non-genetic modifiers would enable risk-adapted surveillance and treatment.

Proposed experiments

Prospective modifier cohort in XLAS females and ADAS

prospective cohort study

exp_alport_female_adas_cohort

Follow a genotyped prospective cohort of heterozygous XLAS females and ADAS individuals from the hematuria-only stage, integrating variant type/position, X-inactivation, proteinuria trajectory, and candidate modifier loci, to derive and validate a model predicting progression to ESKD.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"In females with XLAS and individuals with autosomal dominant Alport syndrome (ADAS), ESKD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare."

GeneReviews documents the delayed, variable course in XLAS females and ADAS, underscoring the unmet need for progression predictors.

Does initiating renin-angiotensin system blockade at the earliest (microhematuria-only) stage, before the onset of proteinuria, improve long-term kidney outcomes compared with starting at proteinuria onset?

KNOWLEDGE GAP OPEN gap_alport_raas_timing

Attached to

phenotypes#Microscopic Hematuria

ACE inhibitors/ARBs delay ESKD in Alport syndrome, and microhematuria precedes proteinuria by years, but the optimal threshold for starting therapy - at the hematuria-only stage versus at proteinuria onset - is not established, leaving a key preventive window uncertain.

Proposed experiments

Early versus proteinuria-triggered RAAS blockade trial

randomized controlled trial

exp_alport_early_raas_rct

Randomize children/young adults with genetically confirmed Alport syndrome and microhematuria but no proteinuria to early RAAS blockade versus initiation at proteinuria onset, with ESKD-free survival and eGFR slope as endpoints, to define the optimal treatment window.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to delay onset of ESKD"

GeneReviews endorses RAAS blockade to delay ESKD but does not resolve the optimal initiation threshold relative to the microhematuria-to-proteinuria transition.

⚙

Pathophysiology

Defective Type IV Collagen Network

Mutations in COL4A3, COL4A4, or COL4A5 disrupt the alpha3-alpha4-alpha5(IV) collagen network, which is the predominant collagen IV isoform in the mature glomerular basement membrane, cochlea, and lens capsule. The defective network is replaced by the embryonic alpha1-alpha1-alpha2(IV) network, which is more susceptible to proteolytic degradation and cannot maintain normal structural integrity.

Podocyte CL:0000653 Glomerular endothelial cell CL:0002188

Basement membrane assembly GO:0070831 ↓ DECREASED Glomerular basement membrane development GO:0032836 ⚠ ABNORMAL

Downstream

GBM Structural Deterioration

Podocyte Injury and Loss

Cochlear Basement Membrane Dysfunction

Ocular Basement Membrane Dysfunction

Show evidence (2 references)

PMID:32712016 SUPPORT Human Clinical

"Alport syndrome is a genetically and phenotypically heterogeneous disorder of glomerular, cochlear, and ocular basement membranes resulting from mutations in the collagen IV genes COL4A3, COL4A4, and COL4A5. "

Confirms that Alport syndrome results from mutations in the three collagen IV genes affecting glomerular, cochlear, and ocular basement membranes.

PMID:25649157 SUPPORT Human Clinical

"Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive) genes result in absence of the collagen IV α3α4α5 network from the basement membranes of the cornea, lens capsule, and retina "

Directly describes the absence of the alpha3-alpha4-alpha5 collagen IV network from basement membranes due to mutations in COL4A3/A4/A5.

Cochlear Basement Membrane Dysfunction

Loss of the collagen IV alpha3-alpha4-alpha5 network from cochlear basement membranes disrupts inner-ear structural integrity, producing progressive high-frequency sensorineural hearing loss.

cochlear hair cell CL:4023120

basement membrane assembly GO:0070831 ↓ DECREASED

Downstream

Sensorineural Hearing Loss Cochlear basement membrane dysfunction produces progressive sensorineural hearing impairment.

Show evidence (1 reference)

PMID:38021591 SUPPORT Human Clinical

"In some cases of Alport syndrome, the abnormal collagen can also affect the cochlea in the inner ear, leading to sensorineural hearing loss. "

Review evidence directly connects abnormal collagen in the cochlea to sensorineural hearing loss.

Ocular Basement Membrane Dysfunction

Absence of the collagen IV alpha3-alpha4-alpha5 network from ocular basement membranes weakens the lens capsule, cornea, and retinal basement membranes, producing characteristic Alport ocular lesions.

basement membrane assembly GO:0070831 ↓ DECREASED

Downstream

Anterior Lenticonus Lens-capsule basement membrane weakness produces anterior lenticonus.

Dot-and-Fleck Retinopathy Retinal basement membrane defects produce fleck retinopathy.

Corneal Opacities Corneal basement membrane defects produce corneal opacities.

Show evidence (1 reference)

PMID:25649157 SUPPORT Human Clinical

Ocular review evidence identifies the affected corneal, lens-capsule, and retinal basement membranes in Alport syndrome.

GBM Structural Deterioration

The abnormal GBM undergoes progressive thickening, thinning, splitting, and lamellation (characteristic basket-weave appearance on electron microscopy). The structurally compromised GBM becomes increasingly permeable, leading to progressive proteinuria and declining renal function.

Podocyte CL:0000653 Glomerular endothelial cell CL:0002188

Extracellular matrix organization GO:0030198 ⚠ ABNORMAL

Downstream

Glomerulosclerosis

GBM Lamellation Progressive GBM thickening, thinning, splitting, and basket-weave remodeling produces lamellation.

Microscopic Hematuria Structural GBM compromise causes persistent glomerular hematuria.

Proteinuria Progressive GBM permeability and podocyte injury cause proteinuria.

Show evidence (1 reference)

PMID:34029143 SUPPORT Model Organism

"We used collagen type IV-α5 (Col4a5) mutant mice, which model X-linked AS, showing glomerular basement membrane (GBM) abnormalities, eventual foot process effacement, and progression to end-stage kidney disease. "

Mouse model demonstrates progressive GBM abnormalities and foot process effacement leading to ESKD, recapitulating the human pathology.

Podocyte Injury and Loss

Podocytes, which are normally anchored to the GBM, undergo foot process effacement and progressive detachment as the GBM deteriorates. Podocyte loss drives glomerulosclerosis and is a key determinant of the rate of progression to end-stage renal disease.

Podocyte CL:0000653

Podocyte apoptotic process GO:1903210 ↑ INCREASED

Downstream

Glomerulosclerosis

Show evidence (1 reference)

PMID:34029143 SUPPORT Model Organism

"We speculate that this is mechanistically associated with enhanced loss of podocytes due to easier detachment from the GBM. "

Demonstrates that podocyte detachment from the GBM is a key pathogenic mechanism, with synaptopodin loss accelerating this process.

Glomerulosclerosis

As podocytes are lost and the GBM degenerates, glomeruli undergo segmental and then global sclerosis. Mesangial expansion and increased extracellular matrix deposition contribute to progressive obliteration of glomerular capillaries.

Mesangial cell CL:0000650

Extracellular matrix organization GO:0030198 ↑ INCREASED

Downstream

Tubulointerstitial Fibrosis

Focal Segmental Glomerulosclerosis Segmental glomerular scarring manifests histologically as FSGS.

Show evidence (1 reference)

PMID:34029143 SUPPORT Model Organism

"Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the acceleration of disease progression, including more severe proteinuria and glomerulosclerosis. "

Demonstrates that podocyte cytoskeletal compromise accelerates glomerulosclerosis in Alport syndrome mouse models.

Tubulointerstitial Fibrosis

Secondary tubulointerstitial fibrosis develops due to proteinuria-induced tubular injury and inflammatory infiltration. Chronic tubular damage and interstitial inflammation drive progressive nephron loss, ultimately leading to end-stage renal disease.

Kidney tubule cell CL:1000507

Extracellular matrix organization GO:0030198 ↑ INCREASED Inflammatory response GO:0006954 ↑ INCREASED

Downstream

Progressive Renal Failure Chronic tubulointerstitial fibrosis drives progressive nephron loss and renal failure.

Hypertension Progressive renal damage contributes to hypertension that requires monitoring and treatment.

Show evidence (1 reference)

PMID:41243004 SUPPORT Human Clinical

"Emphasis is placed on the molecular mechanisms underlying podocyte injury and fibrosis, recent preclinical findings, and ongoing clinical trials that may shift future therapeutic paradigms. "

Review directly highlights fibrosis as a central molecular mechanism in Alport syndrome alongside podocyte injury.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Cardiovascular 1

Hypertension HP:0000822

Show evidence (1 reference)

PMID:38021591 SUPPORT Human Clinical

"Regular monitoring of kidney function and blood pressure, along with medications to control hypertension, are crucial aspects of the management plan. "

Review confirms hypertension as a clinically significant feature requiring monitoring and management in Alport syndrome.

Ear 1

Sensorineural Hearing Loss Sensorineural hearing impairment HP:0000407

Course: PROGRESSIVE Onset: CHILDHOOD

Show evidence (2 references)

PMID:38021591 SUPPORT Human Clinical

"In some cases of Alport syndrome, the abnormal collagen can also affect the cochlea in the inner ear, leading to sensorineural hearing loss. "

Review confirms sensorineural hearing loss as a result of abnormal collagen in the cochlea of the inner ear.

PMID:12105244 SUPPORT Human Clinical

"Alport syndrome (AS) is a hereditary nephropathy characterized by progressive renal failure, hearing loss and ocular lesions. "

Meta-analysis confirms hearing loss as a cardinal feature of Alport syndrome.

Eye 1

Corneal Opacities OCCASIONAL Corneal opacity HP:0007957

Show evidence (1 reference)

PMID:25649157 SUPPORT Human Clinical

"are associated with corneal opacities, anterior lenticonus, fleck retinopathy, and temporal retinal thinning. "

Directly lists corneal opacities as a feature of Alport syndrome resulting from absence of the collagen IV alpha3-alpha4-alpha5 network in corneal basement membranes.

Genitourinary 3

Microscopic Hematuria HP:0002907

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"kidney disease progresses from microhematuria to proteinuria, progressive kidney insufficiency, and end-stage kidney disease (ESKD) in most males with X-linked Alport syndrome (XLAS)"

GeneReviews (authoritative expert clinical reference) places microhematuria as the first/earliest kidney manifestation in the natural-history sequence, present in most males with X-linked Alport syndrome - supporting it as the earliest and most consistent finding (replaces an over-read screening-programme snippet).

Proteinuria FREQUENT HP:0000093

Course: PROGRESSIVE

Show evidence (2 references)

PMID:33159213 SUPPORT Human Clinical

"We recommended delaying the initiation of angiotensin-converting enzyme inhibition until the onset of overt proteinuria or, in some cases, microalbuminuria. "

Clinical guideline references the progression from microalbuminuria to overt proteinuria as a milestone in disease management.

PMID:32299679 SUPPORT Human Clinical

"Ramipril decreased the risk of disease progression by almost half (hazard ratio 0.51 (0.12-2.20)), diminished the slope of albuminuria progression and the decline in glomerular filtration. "

Phase 3 trial confirms proteinuria (albuminuria) progression as a key disease endpoint in Alport syndrome.

Progressive Renal Failure VERY_FREQUENT Stage 5 chronic kidney disease HP:0003774

Course: PROGRESSIVE Onset: JUVENILE

Show evidence (2 references)

PMID:12105244 SUPPORT Human Clinical

"large rearrangements, frame shift, nonsense, and splice donor mutations had a mean ESRF age of 19.8+/-5.7 years "

Meta-analysis of 267 COL4A5 mutations provides genotype-phenotype correlation data showing mean ESRD age of 19.8 years for severe mutations, confirming progressive renal failure with juvenile/young adult onset.

PMID:32299679 SUPPORT Human Clinical

"Children with Alport syndrome develop renal failure early in life. "

Phase 3 trial confirms that renal failure develops early in life in Alport syndrome.

Other 5

Focal Segmental Glomerulosclerosis HP:0000097

Show evidence (2 references)

PMID:34029143 SUPPORT Model Organism

"Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the acceleration of disease progression, including more severe proteinuria and glomerulosclerosis. "

Mouse model demonstrates that glomerulosclerosis is a characteristic pathological feature of Alport syndrome progression.

PMID:39384359 SUPPORT Human Clinical

"With the progression of the disease, glomerular capillary loops become irregularly thick, and segmental or global glomerulosclerosis occurs."

Human renal-biopsy pathology observation that secondary segmental (and global) glomerulosclerosis develops as Alport syndrome progresses, adding human evidence alongside the mouse model.

GBM Lamellation Glomerular basement membrane lamellation HP:0030034

Show evidence (2 references)

PMID:34029143 SUPPORT Model Organism

Mouse model of X-linked Alport syndrome shows GBM abnormalities consistent with the lamellation and structural changes seen in human disease.

PMID:39384359 SUPPORT Human Clinical

"In severe cases, so-called “basket weaving” occurs. The podocytes show various degrees of foot process effacement."

Human renal-biopsy pathology observation: as Alport syndrome progresses on electron microscopy, GBM irregularity increases with lamellation, splitting, and scalloping of the lamina densa, culminating in basket-weave lamellation with foot process effacement - the human histopathologic finding this phenotype asserts, adding human evidence alongside the mouse model.

Anterior Lenticonus OCCASIONAL HP:0011501

Show evidence (2 references)

PMID:25649157 SUPPORT Human Clinical

"Lenticonus and central fleck retinopathy strongly suggest the diagnosis of Alport syndrome and are associated with renal failure before the age of 30 years, in males with X-linked disease. "

Confirms anterior lenticonus as a diagnostically important and pathognomonic feature of Alport syndrome associated with severe renal phenotype.

PMID:38021591 SUPPORT Human Clinical

"changes in the ocular lens, named anterior lenticonus, can occur, causing vision problems. "

Review confirms anterior lenticonus as a characteristic ocular finding.

Dot-and-Fleck Retinopathy OCCASIONAL Macular flecks HP:0011507

Show evidence (1 reference)

PMID:25649157 SUPPORT Human Clinical

"are associated with corneal opacities, anterior lenticonus, fleck retinopathy, and temporal retinal thinning. "

Confirms fleck retinopathy as a characteristic ocular feature caused by absence of the collagen IV alpha3-alpha4-alpha5 network from retinal basement membranes.

Diffuse Leiomyomatosis HP:0006756

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"in those with deletions of COL4A5 extending into intron 2 of COL4A6, surgical intervention for symptomatic leiomyomas as needed"

GeneReviews documents symptomatic leiomyomas in the COL4A5-COL4A6 contiguous-deletion subtype - the basis for the diffuse-leiomyomatosis association and its surgical management.

🧬

Genetic Associations

COL4A5 (Causative)

Gene: COL4A5 hgnc:2207

Show evidence (3 references)

PMID:12105244 SUPPORT Human Clinical

"Numerous mutations of the COL4A5 gene encoding the alpha 5-chain of type IV collagen have been described, establishing the molecular cause of AS. "

Meta-analysis of 267 COL4A5 mutations establishes COL4A5 as the molecular cause of X-linked Alport syndrome.

PMID:29854973 SUPPORT Human Clinical

"We included 73 AS patients with an identified mutation (COL4A5, 57 patients; COL4A3, 9 patients; COL4A4, 6 patients "

Large transplant cohort confirms COL4A5 as the most common causative gene (57/73 = 78% of patients).

CGGV:assertion_0407dc2e-1cab-4043-889d-4695b043d7b3-2019-03-19T160000.000Z SUPPORT Other

ClinGen classifies the COL4A5-Alport syndrome gene-disease relationship as definitive with X-linked inheritance.

COL4A3 (Causative)

Gene: COL4A3 hgnc:2204

Show evidence (2 references)

PMID:25649157 SUPPORT Human Clinical

"Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive) genes result in absence of the collagen IV α3α4α5 network "

Confirms COL4A3 mutations as causative for autosomal recessive Alport syndrome.

CGGV:assertion_e1ed7d3b-4366-4f4a-98f2-80e431e2d8da-2021-07-26T023000.000Z SUPPORT Other

ClinGen classifies the COL4A3-Alport syndrome gene-disease relationship as definitive with semidominant inheritance.

COL4A4 (Causative)

Gene: COL4A4 hgnc:2206

Show evidence (2 references)

PMID:29854973 SUPPORT Human Clinical

"We included 73 AS patients with an identified mutation (COL4A5, 57 patients; COL4A3, 9 patients; COL4A4, 6 patients "

Transplant cohort confirms COL4A4 as a causative gene in Alport syndrome.

CGGV:assertion_c235830a-a6f5-4cf6-b015-902da62f1b2e-2021-08-24T023000.000Z SUPPORT Other

ClinGen classifies the COL4A4-Alport syndrome gene-disease relationship as definitive with semidominant inheritance.

💊

Medical Actions

ACE Inhibitor Therapy

Action: ACE inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: ACE inhibitor NCIT:C247

Angiotensin-converting enzyme inhibitors (e.g., ramipril, enalapril) are the cornerstone of treatment, shown to delay progression to ESRD by reducing proteinuria and glomerular hyperfiltration. Early initiation at diagnosis is now recommended for X-linked males and autosomal recessive patients.

Show evidence (2 references)

PMID:32299679 SUPPORT Human Clinical

"our study shows the safety of early initiation of therapy and supports the hope to slow renal failure by many years, emphasizing the value of preemptive therapy. "

Phase 3 RCT demonstrates safety and efficacy of early ramipril therapy in children with Alport syndrome.

PMID:33159213 SUPPORT Human Clinical

"We now recommend the initiation of treatment at the time of diagnosis in males with X-linked Alport syndrome and in males and females with autosomal recessive Alport syndrome. "

Updated clinical guidelines now recommend ACE inhibitor initiation at diagnosis for X-linked males and autosomal recessive patients.

Angiotensin Receptor Blocker Therapy

Action: Angiotensin receptor blocker therapy Ontology label: Antihypertensive Therapy NCIT:C172184

ARBs are used as an alternative or addition to ACE inhibitors for patients who cannot tolerate ACE inhibitors. RAAS blockade is the foundation of treatment for Alport syndrome.

Show evidence (1 reference)

PMID:41243004 SUPPORT Human Clinical

"While renin-angiotensin-aldosterone system (RAAS) blockade remains the foundation of treatment to delay kidney failure, it does not directly target the underlying molecular pathology. "

Review confirms RAAS blockade (which includes both ACE inhibitors and ARBs) as the foundation of Alport syndrome treatment.

SGLT2 Inhibitor Therapy

Action: Sodium-glucose cotransporter-2 inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986

Sodium-glucose cotransporter-2 inhibitors may offer additional kidney protection as adjunctive therapy to RAAS blockade in adults with proteinuria and CKD. A pediatric RCT (DOUBLE PRO-TECT Alport, NCT05944016) is underway.

Show evidence (1 reference)

PMID:41243004 SUPPORT Human Clinical

"Adjunctive commercially available metabolic modulators, including SGLT2i, mineralocorticoid receptor antagonists, ezetimibe and GLP-1 receptor agonists, may offer additional kidney protection. "

Review identifies SGLT2 inhibitors as adjunctive therapy that may offer additional kidney protection beyond RAAS blockade, though evidence is emerging.

Renal Replacement Therapy

Action: Renal replacement therapy Ontology label: Renal Replacement Therapy NCIT:C126400

Dialysis (hemodialysis or peritoneal dialysis) is required when patients progress to end-stage renal disease. This serves as a bridge to kidney transplantation.

Show evidence (1 reference)

PMID:38021591 SUPPORT Human Clinical

"including end-stage renal disease, which may need dialysis or kidney transplant. "

Review confirms dialysis as necessary treatment for ESRD in Alport syndrome.

Kidney Transplantation

Action: Whole kidney transplantation Ontology label: Kidney Transplantation NCIT:C15265

Kidney transplantation is the definitive treatment for ESRD in Alport syndrome. Outcomes are generally excellent, though a small percentage of transplanted patients develop anti-GBM nephritis due to immune response against the novel alpha3-alpha4-alpha5(IV) collagen in the allograft.

Show evidence (3 references)

PMID:29854973 SUPPORT Human Clinical

"De novo anti-GBM nephritis after transplantation was less frequent than previously reported, occurring in only 1.4% of AS patients, and in 2% of males with COL4A5 mutation. "

Large cohort study quantifies post-transplant anti-GBM nephritis risk and shows favorable overall transplant outcomes.

PMID:23620401 SUPPORT Human Clinical

"Alport post-transplant nephritis (APTN) is an aggressive form of anti-glomerular basement membrane disease that targets the allograft in transplanted patients with X-linked Alport syndrome. "

Elucidates the immunological mechanism of post-transplant anti-GBM nephritis, identifying quaternary epitopes of alpha345(IV) collagen as the inciting antigens.

PMID:20301386 SUPPORT Human Clinical

"monthly monitoring of at-risk transplant recipients for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis for the first year post transplant"

GeneReviews surveillance recommendation: monitor at-risk recipients monthly for anti-GBM antibody-mediated glomerulonephritis during the first post-transplant year, matching the anti-GBM nephritis risk above.

Hearing Aids for Sensorineural Hearing Loss

Sensorineural hearing loss is managed supportively with hearing aids as needed; hearing loss is not reversible, so audiologic surveillance and amplification are the mainstay.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Hearing aids as needed for SNHL; cataract removal as needed"

GeneReviews management: hearing aids for sensorineural hearing loss, a non-renal manifestation not otherwise addressed by the kidney-directed treatments.

Cataract Removal for Ocular Involvement

Action: cataract removal Ontology label: Cataract Surgery NCIT:C157809

Anterior lenticonus and cataract can impair vision in Alport syndrome; cataract removal (lens extraction) is performed as needed for visually significant lens opacity.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Hearing aids as needed for SNHL; cataract removal as needed"

GeneReviews management: cataract removal for ocular involvement, a non-renal manifestation not otherwise addressed by the kidney-directed treatments.

Adequate Hydration (Renal, Agents/Circumstances to Avoid)

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Maintain adequate fluid intake; dehydration may accelerate progression of the nephropathy - a GeneReviews agents/circumstances-to-avoid recommendation.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Drink adequate fluids as dehydration may accelerate the progression of nephropathy."

GeneReviews agents/circumstances-to-avoid guidance that dehydration can accelerate nephropathy progression, so adequate hydration is advised.

Corneal Trauma Protection (Ocular, Agents/Circumstances to Avoid)

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Protect the corneas from minor trauma in patients with recurrent corneal erosions (an ocular manifestation of Alport syndrome) - a GeneReviews agents/circumstances-to-avoid recommendation.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Protection of corneas from minor trauma in those with recurrent corneal erosions."

GeneReviews recommends protecting the corneas from minor trauma in patients with recurrent corneal erosions.

Loud-Noise Avoidance (Auditory, Agents/Circumstances to Avoid)

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Minimize exposure to loud noise to limit additional noise-induced hearing loss atop the sensorineural hearing loss - a GeneReviews agents/circumstances-to-avoid recommendation.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"Minimize exposure to loud noise."

GeneReviews recommends minimizing loud-noise exposure to limit additional noise-induced hearing loss atop the sensorineural hearing loss.

Leiomyoma Surgery (COL4A5-COL4A6 Deletion Subtype)

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

In the rare subset with a deletion of COL4A5 extending into intron 2 of COL4A6 (the Alport syndrome-diffuse leiomyomatosis contiguous-gene phenotype), surgical resection of symptomatic leiomyomas is performed as needed.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"in those with deletions of COL4A5 extending into intron 2 of COL4A6, surgical intervention for symptomatic leiomyomas as needed"

GeneReviews management for the COL4A5-COL4A6 contiguous-deletion subtype: surgical intervention for symptomatic leiomyomas as needed.

🔬

Diagnosis

Molecular genetic testing (COL4A3/COL4A4/COL4A5)

Definitive diagnosis is established by identifying a pathogenic variant in COL4A3, COL4A4, or COL4A5 on molecular genetic testing in a proband with suggestive clinical findings (hematuria, family history, hearing/ocular signs).

molecular genetic testing NCIT:C19770

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"The molecular diagnosis of Alport syndrome is established in a proband with suggestive findings and a pathogenic variant(s) in COL4A3, COL4A4, or COL4A5 identified by molecular genetic testing."

GeneReviews establishes molecular genetic testing of the three collagen IV genes as the definitive diagnostic modality.

Kidney biopsy with electron microscopy

When genetic testing is unavailable or uninformative, kidney biopsy (or skin biopsy in some XLAS individuals) supports the diagnosis; electron microscopy of the glomerular basement membrane is the key ultrastructural test, showing segmental thinning early and lamellation/basket-weaving as disease progresses.

kidney biopsy NCIT:C51699

Show evidence (2 references)

PMID:20301386 SUPPORT Human Clinical

"Kidney biopsy, skin biopsy (in some individuals with XLAS), or clinical diagnostic criteria may be used to establish the diagnosis"

GeneReviews lists kidney/skin biopsy and clinical criteria as diagnostic alternatives when molecular testing is unavailable or uninformative.

PMID:39384359 SUPPORT Human Clinical

"The earliest electron microscopic finding of AS is segmental thinning of the lamina densa."

Human renal-biopsy observation identifying segmental GBM thinning as the earliest electron-microscopic diagnostic clue, preceding the lamellation and basket-weaving of advanced disease.

Type IV collagen alpha-chain immunostaining

Immunohistochemical staining for type IV collagen alpha chains (notably alpha-5(IV)) on kidney or skin biopsy is the most Alport-specific pathology test: absent or abnormal alpha-5(IV) staining supports the diagnosis, and the staining pattern helps distinguish the inheritance subtype. Skin biopsy is diagnostic only via this alpha-5(IV) immunostaining.

skin biopsy (for alpha-5(IV) immunostaining) NCIT:C51692

Show evidence (1 reference)

PMID:39384359 SUPPORT Human Clinical

"Type IV collagen staining elucidates distinct patterns based on AS inheritance"

Human renal-pathology reference establishing type IV collagen (alpha-chain) immunostaining as an Alport-specific test whose pattern reflects the inheritance subtype, complementing electron microscopy.

📈

Progression

Onset

Age: Childhood

Microscopic hematuria is typically the first clinical manifestation, present from early childhood in X-linked males.

Show evidence (1 reference)

PMID:20301386 SUPPORT Human Clinical

"kidney disease progresses from microhematuria to proteinuria, progressive kidney insufficiency, and end-stage kidney disease (ESKD) in most males with X-linked Alport syndrome (XLAS)"

GeneReviews natural-history sequence establishes microhematuria as the first kidney manifestation, preceding proteinuria and progressive insufficiency, in most males with X-linked Alport syndrome - directly supporting the childhood-onset first-manifestation claim (replaces a generic disease-definition snippet that did not state onset timing).

Progression

Age: Adolescence-Young Adulthood

Proteinuria develops, hearing loss becomes apparent, and renal function begins to decline. Genotype-dependent: severe COL4A5 mutations lead to ESRD by mean age 19.8 years; milder mutations by 25-30 years.

Show evidence (1 reference)

PMID:12105244 SUPPORT Human Clinical

"large rearrangements, frame shift, nonsense, and splice donor mutations had a mean ESRF age of 19.8+/-5.7 years; (2) non-glycine- or 3' glycine-missense mutations, in-frame deletions/insertions and splice acceptor mutations had a mean ESRF age of 25.7+/-7.2 years "

Provides genotype-specific progression data showing mean ESRD ages for different mutation types in X-linked Alport syndrome.

Advanced

Age: Young Adulthood-Adulthood

End-stage renal disease requiring dialysis or transplantation. Post-transplant outcomes are generally excellent.

Show evidence (1 reference)

PMID:29854973 SUPPORT Human Clinical

"Patient survival was similar in patients with severe and nonsevere mutations (89% vs. 84% at 5 years, 83% vs. 75% at 10, 15, and 20 years "

Demonstrates good post-transplant patient survival regardless of mutation severity.

📊

Related Datasets

Transcriptomic profiling of prolonged-culture iPSC-derived kidney organoids and X-linked Alport syndrome organoid models carrying COL4A5 deep-intronic variants geo:GSE281080

Kidney organoids serve as an invaluable platform for modeling hereditary renal diseases and developing therapeutic interventions. While various kidney organoid differentiation protocols have been developed, the protocol introduced by Morizane et al. was among the first to generate kidney organoids from induced pluripotent stem cells (iPSCs). By using a modified version of this protocol, we successfully generated kidney organoids in 21 days. Most studies on kidney organoids focus on early stages, typically between days 21 and 29, leaving the gene expression dynamics during prolonged culture less explored.

human BULK RNA SEQ n=24

Identified by GEO DataSets index search for Alport Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

SMPDL3b in Podocytes: Decoupling Proteinuria from CKD Progression in Experimental Alport Syndrome geo:GSE274298

Alport Syndrome (AS) is a rare genetic disease with impaired production of collagen type IV alpha 3, 4 and 5 chains in the glomerular basement membranes (GBM), which results amongst others in progressive loss of kidney function. In AS, abnormalities in the GBM and associated podocyte detachment may potentially result from the dysregulation of sphingolipid metabolism. Here we investigated whether renal sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) overexpression modulates the generation of sphingosine-1-phosphate (S1P) and contributes to renal failure in Col4a3 knockout mice, a mouse model of AS.

mouse BULK RNA SEQ n=6

PMID:39684843

Evidence that chaperone 4-PBA treatment alleviates the renal phenotype in Alport syndrome mouse models geo:GSE271383

Total RNA was extracted from glomeruli as described above. RNA quality and quantity were determined by the 2100 Bioanalyzer. RT2 Profiler PCR Array (QIAGEN) is the method used for qPCR assay. This technique takes advantage of real-time PCR performance and combines it with the ability of microarrays to detect the expression of many genes related to UPR pathway simultaneously. Total RNA that was purified from glomeruli which were extracted from mutant and wild type kidneys was measured and then converted into first strand cDNA. qPCR was followed by using the instrument-specific and ready-to-use RT2 qPCR Master Mixes and gene specific primer sets.

mouse n=9

PMID:40484355

HipSci HumanExome BeadChip analysis - Alport Syndrome ega:EGAS00001002009

The HipSci project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. In this sub-study we performed Genotyping analysis using the Infinium HumanExome BeadChip on iPS cells generated from skin biopsies or blood samples from rare disease patients diagnosed with Alport Syndrome.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Alport Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

HipSci HumanExome BeadChip analysis - Alport syndrome (Manchester) ega:EGAS00001002019

human

HipSci HumanHT 12 Expression BeadChip analysis - Alport syndrome ega:EGAS00001002024

The HipSci project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. In this sub-study we performed Expression analysis using the Illumina HumanHT -12 Expression BeadChip on iPS cells generated from skin biopsies or blood samples from rare disease patients diagnosed with Alport syndrome.

human

{ }

Source YAML

click to show

name: Alport Syndrome
creation_date: "2026-04-22T12:00:00Z"
description: >
  Alport syndrome is a hereditary nephropathy caused by mutations in genes encoding
  type IV collagen alpha chains (COL4A3, COL4A4, COL4A5). The defective collagen IV
  network leads to progressive glomerular basement membrane (GBM) deterioration,
  resulting in hematuria, proteinuria, and progressive renal failure. Extrarenal
  manifestations include sensorineural hearing loss and characteristic ocular
  abnormalities such as anterior lenticonus and dot-and-fleck retinopathy.
category: Genetic
disease_term:
  preferred_term: Alport syndrome
  term:
    id: MONDO:0018965
    label: Alport syndrome
parents:
- Hereditary Nephropathy
- Collagen Disorder
has_subtypes:
- name: X-linked
  display_name: X-linked Alport Syndrome (XLAS)
  description: >
    Most common form (approximately 80% of cases), caused by mutations in COL4A5 on
    the X chromosome. Males typically progress to end-stage renal disease by age 20-30,
    while heterozygous females have variable expression ranging from isolated hematuria
    to progressive renal failure.
- name: Autosomal Recessive
  display_name: Autosomal Recessive Alport Syndrome (ARAS)
  description: >
    Accounts for approximately 15% of cases, caused by biallelic mutations in COL4A3
    or COL4A4. Clinical severity comparable to X-linked males, with ESRD typically
    by the third decade.
- name: Autosomal Dominant
  display_name: Autosomal Dominant Alport Syndrome (ADAS)
  description: >
    Accounts for approximately 5% of cases, caused by heterozygous mutations in COL4A3
    or COL4A4. Typically milder and later-onset, with ESRD in the fifth to sixth decade
    or later. Some cases overlap with thin basement membrane nephropathy.
inheritance:
- name: X-linked inheritance
  inheritance_term:
    preferred_term: X-linked inheritance
    term:
      id: HP:0001417
      label: X-linked inheritance
  evidence:
  - reference: PMID:32712016
    reference_title: "Alport Syndrome: Achieving Early Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Alport syndrome can be transmitted as an X-linked, autosomal recessive, or
      autosomal dominant disorder.
    explanation: >
      Confirms X-linked as one of three inheritance patterns in Alport syndrome.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "if the mother of the proband has a COL4A5 pathogenic variant, the chance of transmitting it in each pregnancy is 50%; if the father of the proband has a COL4A5 pathogenic variant, he will transmit it to all of his daughters and none of his sons"
    explanation: >
      GeneReviews genetic-counseling recurrence risk for XLAS: a carrier mother has
      a 50% chance of transmitting the COL4A5 variant in each pregnancy; an affected
      father transmits it to all daughters and no sons.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "prenatal and preimplantation genetic testing are possible"
    explanation: >
      GeneReviews notes that once the familial pathogenic variant(s) are known,
      prenatal and preimplantation genetic testing are reproductive options.
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive)
      genes result in absence of the collagen IV α3α4α5 network
    explanation: >
      Confirms autosomal recessive inheritance via COL4A3 and COL4A4 mutations.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants (and having ARAS), a 50% chance of being heterozygous (and at risk for ADAS), and a 25% chance of inheriting neither of the familial pathogenic variants"
    explanation: >
      GeneReviews genetic-counseling recurrence risk for ARAS: with both parents
      heterozygous, each sib has a 25% chance of biallelic variants (ARAS), 50%
      heterozygous (at risk for ADAS), and 25% unaffected.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "prenatal and preimplantation genetic testing are possible"
    explanation: >
      GeneReviews notes prenatal and preimplantation genetic testing are available
      reproductive options once the familial pathogenic variant(s) are known
      (stated generically across inheritance modes).
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:32712016
    reference_title: "Alport Syndrome: Achieving Early Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Alport syndrome can be transmitted as an X-linked, autosomal recessive, or
      autosomal dominant disorder.
    explanation: >
      Confirms autosomal dominant as one of three inheritance patterns.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If a parent of the proband is affected and/or is known to have the COL4A3 or COL4A4 pathogenic variant identified in the proband, the risk to sibs of inheriting the pathogenic variant is 50%."
    explanation: >
      GeneReviews genetic-counseling recurrence risk for ADAS: if a parent carries
      the COL4A3/COL4A4 pathogenic variant, the risk to sibs of inheriting it is
      50%, though severity varies greatly among heterozygotes.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "prenatal and preimplantation genetic testing are possible"
    explanation: >
      GeneReviews notes prenatal and preimplantation genetic testing are available
      reproductive options once the familial pathogenic variant(s) are known
      (stated generically across inheritance modes).
- name: Digenic inheritance
  inheritance_term:
    preferred_term: Digenic inheritance
    term:
      id: HP:0010984
      label: Digenic inheritance
  description: >-
    Beyond the three classic Mendelian modes, a subset of Alport syndrome shows
    digenic inheritance, with pathogenic variants in two collagen IV genes
    (COL4A3 plus COL4A4, or COL4A5 together with COL4A3/COL4A4). Incomplete
    penetrance and wide phenotypic variability motivated the digenic model.
  evidence:
  - reference: PMID:25575550
    reference_title: "Evidence of digenic inheritance in Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using massively parallel sequencing, we identified 11 patients who had pathogenic
      mutations in two collagen IV genes. ... This pedigree analysis provides evidence
      for digenic inheritance of Alport syndrome.
    explanation: >-
      Segregation analysis across 56 individuals from 11 probands with pathogenic
      mutations in two collagen IV genes provides direct pedigree evidence for digenic
      inheritance, establishing it as an additional genetic model beyond the classic
      Mendelian modes.
pathophysiology:
- name: Defective Type IV Collagen Network
  description: >
    Mutations in COL4A3, COL4A4, or COL4A5 disrupt the alpha3-alpha4-alpha5(IV) collagen
    network, which is the predominant collagen IV isoform in the mature glomerular
    basement
    membrane, cochlea, and lens capsule. The defective network is replaced by the
    embryonic alpha1-alpha1-alpha2(IV) network, which is more susceptible to proteolytic
    degradation and cannot maintain normal structural integrity.
  cell_types:
  - preferred_term: Podocyte
    term:
      id: CL:0000653
      label: podocyte
  - preferred_term: Glomerular endothelial cell
    term:
      id: CL:0002188
      label: glomerular endothelial cell
  biological_processes:
  - preferred_term: Basement membrane assembly
    term:
      id: GO:0070831
      label: basement membrane assembly
    modifier: DECREASED
  - preferred_term: Glomerular basement membrane development
    term:
      id: GO:0032836
      label: glomerular basement membrane development
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32712016
    reference_title: "Alport Syndrome: Achieving Early Diagnosis and Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Alport syndrome is a genetically and phenotypically heterogeneous disorder of
      glomerular, cochlear, and ocular basement membranes resulting from mutations
      in
      the collagen IV genes COL4A3, COL4A4, and COL4A5.
    explanation: >
      Confirms that Alport syndrome results from mutations in the three collagen IV
      genes affecting glomerular, cochlear, and ocular basement membranes.
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive)
      genes result in absence of the collagen IV α3α4α5 network from the basement
      membranes of the cornea, lens capsule, and retina
    explanation: >
      Directly describes the absence of the alpha3-alpha4-alpha5 collagen IV network
      from basement membranes due to mutations in COL4A3/A4/A5.
  downstream:
  - target: GBM Structural Deterioration
    evidence:
    - reference: PMID:32712016
      reference_title: "Alport Syndrome: Achieving Early Diagnosis and Treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Alport syndrome is a genetically and phenotypically heterogeneous disorder of
        glomerular, cochlear, and ocular basement membranes resulting from mutations
        in
        the collagen IV genes COL4A3, COL4A4, and COL4A5.
      explanation: Collagen IV gene mutations produce the abnormal glomerular basement membrane that undergoes structural deterioration on this edge.
  - target: Podocyte Injury and Loss
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - glomerular basement membrane abnormality
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        We used collagen type IV-α5 (Col4a5) mutant mice, which model X-linked AS,
        showing glomerular basement membrane (GBM) abnormalities, eventual foot process
        effacement, and progression to end-stage kidney disease.
      explanation: The Col4a5 collagen defect leads to podocyte foot process effacement (podocyte injury) via the abnormal GBM.
  - target: Cochlear Basement Membrane Dysfunction
    evidence:
    - reference: PMID:32712016
      reference_title: "Alport Syndrome: Achieving Early Diagnosis and Treatment."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Alport syndrome is a genetically and phenotypically heterogeneous disorder of
        glomerular, cochlear, and ocular basement membranes resulting from mutations
        in
        the collagen IV genes COL4A3, COL4A4, and COL4A5.
      explanation: The collagen IV defect involves the cochlear basement membrane, producing this edge.
  - target: Ocular Basement Membrane Dysfunction
    evidence:
    - reference: PMID:25649157
      reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive)
        genes result in absence of the collagen IV α3α4α5 network from the basement
        membranes of the cornea, lens capsule, and retina
      explanation: The collagen IV network is absent from ocular basement membranes, producing ocular basement membrane dysfunction on this edge.
- name: Cochlear Basement Membrane Dysfunction
  description: >
    Loss of the collagen IV alpha3-alpha4-alpha5 network from cochlear basement
    membranes disrupts inner-ear structural integrity, producing progressive
    high-frequency sensorineural hearing loss.
  cell_types:
  - preferred_term: cochlear hair cell
    term:
      id: CL:4023120
      label: cochlea auditory hair cell
  biological_processes:
  - preferred_term: basement membrane assembly
    term:
      id: GO:0070831
      label: basement membrane assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:38021591
    reference_title: "Alport Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      In some cases of Alport syndrome, the abnormal collagen can also affect the
      cochlea
      in the inner ear, leading to sensorineural hearing loss.
    explanation: >
      Review evidence directly connects abnormal collagen in the cochlea to
      sensorineural hearing loss.
  downstream:
  - target: Sensorineural Hearing Loss
    causal_link_type: DIRECT
    description: Cochlear basement membrane dysfunction produces progressive sensorineural hearing impairment.
    evidence:
    - reference: PMID:38021591
      reference_title: "Alport Syndrome: A Comprehensive Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        In some cases of Alport syndrome, the abnormal collagen can also affect the
        cochlea
        in the inner ear, leading to sensorineural hearing loss.
      explanation: Abnormal collagen in the cochlea directly leads to sensorineural hearing loss on this edge.
- name: Ocular Basement Membrane Dysfunction
  description: >
    Absence of the collagen IV alpha3-alpha4-alpha5 network from ocular basement
    membranes weakens the lens capsule, cornea, and retinal basement membranes,
    producing characteristic Alport ocular lesions.
  biological_processes:
  - preferred_term: basement membrane assembly
    term:
      id: GO:0070831
      label: basement membrane assembly
    modifier: DECREASED
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive)
      genes result in absence of the collagen IV α3α4α5 network from the basement
      membranes of the cornea, lens capsule, and retina
    explanation: >
      Ocular review evidence identifies the affected corneal, lens-capsule, and
      retinal basement membranes in Alport syndrome.
  downstream:
  - target: Anterior Lenticonus
    causal_link_type: DIRECT
    description: Lens-capsule basement membrane weakness produces anterior lenticonus.
    evidence:
    - reference: PMID:38021591
      reference_title: "Alport Syndrome: A Comprehensive Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        changes in the ocular lens, named anterior lenticonus, can occur, causing
        vision problems.
      explanation: Ocular basement membrane (lens capsule) involvement produces anterior lenticonus on this edge.
  - target: Dot-and-Fleck Retinopathy
    causal_link_type: DIRECT
    description: Retinal basement membrane defects produce fleck retinopathy.
    evidence:
    - reference: PMID:25649157
      reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        are associated with corneal opacities, anterior lenticonus, fleck retinopathy,
        and temporal retinal thinning.
      explanation: Retinal basement membrane involvement produces the characteristic fleck retinopathy on this edge.
  - target: Corneal Opacities
    causal_link_type: DIRECT
    description: Corneal basement membrane defects produce corneal opacities.
    evidence:
    - reference: PMID:25649157
      reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        are associated with corneal opacities, anterior lenticonus, fleck retinopathy,
        and temporal retinal thinning.
      explanation: Corneal basement membrane involvement produces corneal opacities on this edge.
- name: GBM Structural Deterioration
  description: >
    The abnormal GBM undergoes progressive thickening, thinning, splitting, and
    lamellation (characteristic basket-weave appearance on electron microscopy).
    The structurally compromised GBM becomes increasingly permeable, leading to
    progressive proteinuria and declining renal function.
  cell_types:
  - preferred_term: Podocyte
    term:
      id: CL:0000653
      label: podocyte
  - preferred_term: Glomerular endothelial cell
    term:
      id: CL:0002188
      label: glomerular endothelial cell
  biological_processes:
  - preferred_term: Extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:34029143
    reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      We used collagen type IV-α5 (Col4a5) mutant mice, which model X-linked AS,
      showing glomerular basement membrane (GBM) abnormalities, eventual foot process
      effacement, and progression to end-stage kidney disease.
    explanation: >
      Mouse model demonstrates progressive GBM abnormalities and foot process
      effacement leading to ESKD, recapitulating the human pathology.
  downstream:
  - target: Glomerulosclerosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - podocyte loss
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
        acceleration of disease progression, including more severe proteinuria and
        glomerulosclerosis.
      explanation: Col4a5 (GBM-defective) Alport mice progress to glomerulosclerosis, supporting this edge.
  - target: GBM Lamellation
    causal_link_type: DIRECT
    description: Progressive GBM thickening, thinning, splitting, and basket-weave remodeling produces lamellation.
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        We used collagen type IV-α5 (Col4a5) mutant mice, which model X-linked AS,
        showing glomerular basement membrane (GBM) abnormalities, eventual foot process
        effacement, and progression to end-stage kidney disease.
      explanation: The structurally deteriorating GBM shows the ultrastructural abnormalities (lamellation) modeled in Col4a5 mice.
  - target: Microscopic Hematuria
    causal_link_type: DIRECT
    description: Structural GBM compromise causes persistent glomerular hematuria.
    evidence:
    - reference: PMID:32299679
      reference_title: "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        screening programs for glomerular hematuria in children and young adults could
        benefit from inclusion of genetic testing for Alport-related gene-variants.
      explanation: Glomerular hematuria from GBM compromise is the hallmark early finding, supporting this edge.
  - target: Proteinuria
    causal_link_type: DIRECT
    description: Progressive GBM permeability and podocyte injury cause proteinuria.
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
        acceleration of disease progression, including more severe proteinuria and
        glomerulosclerosis.
      explanation: GBM-defective Alport mice develop proteinuria as the barrier fails, supporting this edge.
- name: Podocyte Injury and Loss
  description: >
    Podocytes, which are normally anchored to the GBM, undergo foot process effacement
    and progressive detachment as the GBM deteriorates. Podocyte loss drives
    glomerulosclerosis and is a key determinant of the rate of progression to
    end-stage renal disease.
  cell_types:
  - preferred_term: Podocyte
    term:
      id: CL:0000653
      label: podocyte
  biological_processes:
  - preferred_term: Podocyte apoptotic process
    term:
      id: GO:1903210
      label: podocyte apoptotic process
    modifier: INCREASED
  evidence:
  - reference: PMID:34029143
    reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      We speculate that this is mechanistically associated with enhanced loss of
      podocytes due to easier detachment from the GBM.
    explanation: >
      Demonstrates that podocyte detachment from the GBM is a key pathogenic
      mechanism, with synaptopodin loss accelerating this process.
  downstream:
  - target: Glomerulosclerosis
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
        acceleration of disease progression, including more severe proteinuria and
        glomerulosclerosis.
      explanation: Accelerated podocyte loss drives glomerulosclerosis in Alport mice, supporting this edge.
- name: Glomerulosclerosis
  description: >
    As podocytes are lost and the GBM degenerates, glomeruli undergo segmental and
    then global sclerosis. Mesangial expansion and increased extracellular matrix
    deposition contribute to progressive obliteration of glomerular capillaries.
  cell_types:
  - preferred_term: Mesangial cell
    term:
      id: CL:0000650
      label: mesangial cell
  biological_processes:
  - preferred_term: Extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: INCREASED
  evidence:
  - reference: PMID:34029143
    reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
      acceleration of disease progression, including more severe proteinuria and
      glomerulosclerosis.
    explanation: >
      Demonstrates that podocyte cytoskeletal compromise accelerates glomerulosclerosis
      in Alport syndrome mouse models.
  downstream:
  - target: Tubulointerstitial Fibrosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - proteinuria-induced tubular injury
    evidence:
    - reference: PMID:41243004
      reference_title: "From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Emphasis is placed on the molecular mechanisms underlying podocyte injury and
        fibrosis, recent preclinical findings, and ongoing clinical trials that may
        shift
        future therapeutic paradigms.
      explanation: Fibrosis is a central downstream mechanism in Alport; the specific glomerulosclerosis-to-tubulointerstitial-fibrosis step is inferred, so the edge is PARTIAL.
  - target: Focal Segmental Glomerulosclerosis
    causal_link_type: DIRECT
    description: Segmental glomerular scarring manifests histologically as FSGS.
    evidence:
    - reference: PMID:34029143
      reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >
        Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
        acceleration of disease progression, including more severe proteinuria and
        glomerulosclerosis.
      explanation: Segmental glomerular scarring in Alport mice is the glomerulosclerosis that manifests as FSGS on biopsy.
- name: Tubulointerstitial Fibrosis
  description: >
    Secondary tubulointerstitial fibrosis develops due to proteinuria-induced tubular
    injury and inflammatory infiltration. Chronic tubular damage and interstitial
    inflammation drive progressive nephron loss, ultimately leading to end-stage
    renal disease.
  cell_types:
  - preferred_term: Kidney tubule cell
    term:
      id: CL:1000507
      label: kidney tubule cell
  biological_processes:
  - preferred_term: Extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: INCREASED
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:41243004
    reference_title: "From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Emphasis is placed on the molecular mechanisms underlying podocyte injury and
      fibrosis, recent preclinical findings, and ongoing clinical trials that may
      shift
      future therapeutic paradigms.
    explanation: >
      Review directly highlights fibrosis as a central molecular mechanism in Alport
      syndrome alongside podocyte injury.
  downstream:
  - target: Progressive Renal Failure
    causal_link_type: DIRECT
    description: Chronic tubulointerstitial fibrosis drives progressive nephron loss and renal failure.
    evidence:
    - reference: PMID:32299679
      reference_title: "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Children with Alport syndrome develop renal failure early in life.
      explanation: Progressive nephron loss from chronic fibrosis leads to early renal failure on this edge.
  - target: Hypertension
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - declining kidney function
    - renal parenchymal scarring
    description: Progressive renal damage contributes to hypertension that requires monitoring and treatment.
    evidence:
    - reference: PMID:38021591
      reference_title: "Alport Syndrome: A Comprehensive Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >
        Regular monitoring of kidney function and blood pressure, along with medications
        to control hypertension, are crucial aspects of the management plan.
      explanation: Hypertension accompanies declining kidney function in Alport; the fibrosis-to-hypertension link is indirect, so the edge is PARTIAL.
phenotypes:
- category: Renal
  name: Microscopic Hematuria
  description: >
    Persistent microscopic hematuria is the earliest kidney finding in Alport
    syndrome, present from early childhood in most affected (X-linked) males;
    heterozygous females also show hematuria, though more variably.
  phenotype_term:
    preferred_term: Microscopic hematuria
    term:
      id: HP:0002907
      label: Microscopic hematuria
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "kidney disease progresses from microhematuria to proteinuria, progressive kidney insufficiency, and end-stage kidney disease (ESKD) in most males with X-linked Alport syndrome (XLAS)"
    explanation: >
      GeneReviews (authoritative expert clinical reference) places microhematuria as
      the first/earliest kidney manifestation in the natural-history sequence, present
      in most males with X-linked Alport syndrome - supporting it as the earliest and
      most consistent finding (replaces an over-read screening-programme snippet).
- category: Renal
  name: Proteinuria
  frequency: FREQUENT
  description: >
    Progressive proteinuria develops as GBM deterioration worsens, typically appearing
    in
    childhood to adolescence in X-linked males. Initially mild, it may progress to
    nephrotic-range proteinuria.
  phenotype_term:
    preferred_term: Proteinuria
    term:
      id: HP:0000093
      label: Proteinuria
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:33159213
    reference_title: "Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      We recommended delaying the initiation of angiotensin-converting enzyme inhibition
      until the onset of overt proteinuria or, in some cases, microalbuminuria.
    explanation: >
      Clinical guideline references the progression from microalbuminuria to overt
      proteinuria as a milestone in disease management.
  - reference: PMID:32299679
    reference_title: "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Ramipril decreased the risk of disease progression by almost half (hazard ratio
      0.51 (0.12-2.20)), diminished the slope of albuminuria progression and the decline
      in glomerular filtration.
    explanation: >
      Phase 3 trial confirms proteinuria (albuminuria) progression as a key disease
      endpoint in Alport syndrome.
- category: Renal
  name: Progressive Renal Failure
  frequency: VERY_FREQUENT
  description: >
    Progressive decline in renal function leading to end-stage renal disease (ESRD).
    In X-linked males, ESRD typically occurs by the second to third decade; in autosomal
    recessive cases, by the third decade; in autosomal dominant cases, often later.
  phenotype_term:
    preferred_term: Stage 5 chronic kidney disease
    term:
      id: HP:0003774
      label: Stage 5 chronic kidney disease
    clinical_course: PROGRESSIVE
    onset:
      onset_category: JUVENILE
  evidence:
  - reference: PMID:12105244
    reference_title: "Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      large rearrangements, frame shift, nonsense, and splice donor mutations had
      a
      mean ESRF age of 19.8+/-5.7 years
    explanation: >
      Meta-analysis of 267 COL4A5 mutations provides genotype-phenotype correlation
      data
      showing mean ESRD age of 19.8 years for severe mutations, confirming progressive
      renal failure with juvenile/young adult onset.
  - reference: PMID:32299679
    reference_title: "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Children with Alport syndrome develop renal failure early in life.
    explanation: >
      Phase 3 trial confirms that renal failure develops early in life in Alport syndrome.
- category: Renal
  name: Focal Segmental Glomerulosclerosis
  description: >
    Secondary FSGS develops as podocyte loss and GBM deterioration progress.
    This is a histopathologic finding on renal biopsy.
  phenotype_term:
    preferred_term: Focal segmental glomerulosclerosis
    term:
      id: HP:0000097
      label: Focal segmental glomerulosclerosis
  evidence:
  - reference: PMID:34029143
    reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      Lack of Synpo in Col4a5-/Y, Col4a5-/-, or Col4a5+/- Alport mice led to the
      acceleration of disease progression, including more severe proteinuria and
      glomerulosclerosis.
    explanation: >
      Mouse model demonstrates that glomerulosclerosis is a characteristic pathological
      feature of Alport syndrome progression.
  - reference: PMID:39384359
    reference_title: "Pathological diagnosis of Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With the progression of the disease, glomerular capillary loops become irregularly thick, and segmental or global glomerulosclerosis occurs."
    explanation: >
      Human renal-biopsy pathology observation that secondary segmental (and
      global) glomerulosclerosis develops as Alport syndrome progresses, adding
      human evidence alongside the mouse model.
- category: Renal
  name: GBM Lamellation
  description: >
    Characteristic ultrastructural finding on electron microscopy showing thickening,
    thinning, splitting, and basket-weave lamellation of the glomerular basement membrane.
    This is the hallmark histopathologic feature of Alport syndrome.
  phenotype_term:
    preferred_term: Glomerular basement membrane lamellation
    term:
      id: HP:0030034
      label: Glomerular basement membrane lamellation
  evidence:
  - reference: PMID:34029143
    reference_title: "Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >
      We used collagen type IV-α5 (Col4a5) mutant mice, which model X-linked AS,
      showing glomerular basement membrane (GBM) abnormalities, eventual foot process
      effacement, and progression to end-stage kidney disease.
    explanation: >
      Mouse model of X-linked Alport syndrome shows GBM abnormalities consistent with
      the lamellation and structural changes seen in human disease.
  - reference: PMID:39384359
    reference_title: "Pathological diagnosis of Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In severe cases, so-called “basket weaving” occurs. The podocytes show various degrees of foot process effacement."
    explanation: >
      Human renal-biopsy pathology observation: as Alport syndrome progresses on
      electron microscopy, GBM irregularity increases with lamellation, splitting,
      and scalloping of the lamina densa, culminating in basket-weave lamellation
      with foot process effacement - the human histopathologic finding this
      phenotype asserts, adding human evidence alongside the mouse model.
- category: Hearing
  name: Sensorineural Hearing Loss
  description: >
    Bilateral high-frequency sensorineural hearing loss, typically developing in late
    childhood to adolescence. More common and severe in X-linked males. Not present
    at birth but progressive, eventually affecting conversational frequencies.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
    clinical_course: PROGRESSIVE
    onset:
      onset_category: CHILDHOOD
  evidence:
  - reference: PMID:38021591
    reference_title: "Alport Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      In some cases of Alport syndrome, the abnormal collagen can also affect the
      cochlea
      in the inner ear, leading to sensorineural hearing loss.
    explanation: >
      Review confirms sensorineural hearing loss as a result of abnormal collagen
      in the
      cochlea of the inner ear.
  - reference: PMID:12105244
    reference_title: "Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Alport syndrome (AS) is a hereditary nephropathy characterized by progressive
      renal failure, hearing loss and ocular lesions.
    explanation: >
      Meta-analysis confirms hearing loss as a cardinal feature of Alport syndrome.
- category: Ophthalmologic
  name: Anterior Lenticonus
  frequency: OCCASIONAL
  description: >
    Conical protrusion of the anterior lens surface, pathognomonic for Alport syndrome
    when present. Occurs predominantly in X-linked males. Results from defective
    type IV collagen in the lens capsule.
  phenotype_term:
    preferred_term: Anterior lenticonus
    term:
      id: HP:0011501
      label: Anterior lenticonus
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Lenticonus and central fleck retinopathy strongly suggest the diagnosis of Alport
      syndrome and are associated with renal failure before the age of 30 years, in
      males
      with X-linked disease.
    explanation: >
      Confirms anterior lenticonus as a diagnostically important and pathognomonic
      feature
      of Alport syndrome associated with severe renal phenotype.
  - reference: PMID:38021591
    reference_title: "Alport Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      changes in the ocular lens, named anterior lenticonus, can occur, causing
      vision problems.
    explanation: >
      Review confirms anterior lenticonus as a characteristic ocular finding.
- category: Ophthalmologic
  name: Dot-and-Fleck Retinopathy
  frequency: OCCASIONAL
  description: >
    White or yellow dots and flecks in the perimacular region, a characteristic
    ocular finding in Alport syndrome. Does not typically affect visual acuity.
  phenotype_term:
    preferred_term: Macular flecks
    term:
      id: HP:0011507
      label: Macular flecks
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      are associated with corneal opacities, anterior lenticonus, fleck retinopathy,
      and temporal retinal thinning.
    explanation: >
      Confirms fleck retinopathy as a characteristic ocular feature caused by absence
      of the collagen IV alpha3-alpha4-alpha5 network from retinal basement membranes.
- category: Ophthalmologic
  name: Corneal Opacities
  frequency: OCCASIONAL
  description: >
    Corneal opacities can occur due to defective type IV collagen in the corneal
    basement membrane. Additional corneal findings include posterior polymorphous
    corneal dystrophy and recurrent corneal erosions.
  phenotype_term:
    preferred_term: Corneal opacity
    term:
      id: HP:0007957
      label: Corneal opacity
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      are associated with corneal opacities, anterior lenticonus, fleck retinopathy,
      and temporal retinal thinning.
    explanation: >
      Directly lists corneal opacities as a feature of Alport syndrome resulting from
      absence of the collagen IV alpha3-alpha4-alpha5 network in corneal basement
      membranes.
- category: Cardiovascular
  name: Hypertension
  description: >
    Hypertension develops as renal function declines, contributing to further
    kidney damage. Blood pressure control is an important aspect of management.
  phenotype_term:
    preferred_term: Hypertension
    term:
      id: HP:0000822
      label: Hypertension
  evidence:
  - reference: PMID:38021591
    reference_title: "Alport Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Regular monitoring of kidney function and blood pressure, along with medications
      to control hypertension, are crucial aspects of the management plan.
    explanation: >
      Review confirms hypertension as a clinically significant feature requiring
      monitoring and management in Alport syndrome.
- category: Gastrointestinal
  name: Diffuse Leiomyomatosis
  description: >
    In the contiguous-gene-deletion subtype, where a COL4A5 deletion extends into
    intron 2 of COL4A6, patients develop diffuse leiomyomatosis: benign smooth
    muscle tumors, characteristically of the esophagus and tracheobronchial tree
    (and sometimes the female genital tract). This is the extrarenal counterpart of
    the leiomyoma-surgery treatment.
  phenotype_term:
    preferred_term: Diffuse leiomyomatosis
    term:
      id: HP:0006756
      label: Diffuse leiomyomatosis
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in those with deletions of COL4A5 extending into intron 2 of COL4A6, surgical intervention for symptomatic leiomyomas as needed"
    explanation: >
      GeneReviews documents symptomatic leiomyomas in the COL4A5-COL4A6
      contiguous-deletion subtype - the basis for the diffuse-leiomyomatosis
      association and its surgical management.
genetic:
- name: COL4A5
  association: Causative
  gene_term:
    preferred_term: COL4A5
    term:
      id: hgnc:2207
      label: COL4A5
  notes: >
    Mutations in COL4A5 on Xq22.3, encoding the alpha5 chain of type IV collagen.
    Account for approximately 80% of Alport syndrome cases. Over 1500 pathogenic
    variants identified including missense, nonsense, splice site, and large deletions.
  evidence:
  - reference: PMID:12105244
    reference_title: "Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Numerous mutations of the COL4A5 gene encoding the alpha 5-chain of type IV
      collagen have been described, establishing the molecular cause of AS.
    explanation: >
      Meta-analysis of 267 COL4A5 mutations establishes COL4A5 as the molecular cause
      of X-linked Alport syndrome.
  - reference: PMID:29854973
    reference_title: "Genotype and Outcome After Kidney Transplantation in Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      We included 73 AS patients with an identified mutation (COL4A5, 57 patients;
      COL4A3, 9 patients; COL4A4, 6 patients
    explanation: >
      Large transplant cohort confirms COL4A5 as the most common causative gene
      (57/73 = 78% of patients).
  - reference: CGGV:assertion_0407dc2e-1cab-4043-889d-4695b043d7b3-2019-03-19T160000.000Z
    reference_title: "COL4A5 / Alport syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL4A5 | HGNC:2207 | Alport syndrome | MONDO:0018965 | XL | Definitive"
    explanation: ClinGen classifies the COL4A5-Alport syndrome gene-disease relationship as definitive with X-linked inheritance.
- name: COL4A3
  association: Causative
  gene_term:
    preferred_term: COL4A3
    term:
      id: hgnc:2204
      label: COL4A3
  notes: >
    Mutations in COL4A3 on 2q36.3, encoding the alpha3 chain of type IV collagen.
    Biallelic mutations cause autosomal recessive Alport syndrome; heterozygous
    mutations cause autosomal dominant Alport syndrome or thin basement membrane
    nephropathy.
  evidence:
  - reference: PMID:25649157
    reference_title: "Ocular features in Alport syndrome: pathogenesis and clinical significance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Mutations in the COL4A5 (X-linked), or COL4A3 and COL4A4 (autosomal recessive)
      genes result in absence of the collagen IV α3α4α5 network
    explanation: >
      Confirms COL4A3 mutations as causative for autosomal recessive Alport syndrome.
  - reference: CGGV:assertion_e1ed7d3b-4366-4f4a-98f2-80e431e2d8da-2021-07-26T023000.000Z
    reference_title: "COL4A3 / Alport syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL4A3 | HGNC:2204 | Alport syndrome | MONDO:0018965 | SD | Definitive"
    explanation: ClinGen classifies the COL4A3-Alport syndrome gene-disease relationship as definitive with semidominant inheritance.
- name: COL4A4
  association: Causative
  gene_term:
    preferred_term: COL4A4
    term:
      id: hgnc:2206
      label: COL4A4
  notes: >
    Mutations in COL4A4 on 2q36.3, encoding the alpha4 chain of type IV collagen.
    Biallelic mutations cause autosomal recessive Alport syndrome; heterozygous
    mutations cause autosomal dominant Alport syndrome or thin basement membrane
    nephropathy.
  evidence:
  - reference: PMID:29854973
    reference_title: "Genotype and Outcome After Kidney Transplantation in Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      We included 73 AS patients with an identified mutation (COL4A5, 57 patients;
      COL4A3, 9 patients; COL4A4, 6 patients
    explanation: >
      Transplant cohort confirms COL4A4 as a causative gene in Alport syndrome.
  - reference: CGGV:assertion_c235830a-a6f5-4cf6-b015-902da62f1b2e-2021-08-24T023000.000Z
    reference_title: "COL4A4 / Alport syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "COL4A4 | HGNC:2206 | Alport syndrome | MONDO:0018965 | SD | Definitive"
    explanation: ClinGen classifies the COL4A4-Alport syndrome gene-disease relationship as definitive with semidominant inheritance.
treatments:
- name: ACE Inhibitor Therapy
  description: >
    Angiotensin-converting enzyme inhibitors (e.g., ramipril, enalapril) are the
    cornerstone of treatment, shown to delay progression to ESRD by reducing
    proteinuria and glomerular hyperfiltration. Early initiation at diagnosis is
    now recommended for X-linked males and autosomal recessive patients.
  treatment_term:
    preferred_term: ACE inhibitor therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
  evidence:
  - reference: PMID:32299679
    reference_title: "A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      our study shows the safety of early initiation of therapy and supports the hope
      to slow renal failure by many years, emphasizing the value of preemptive therapy.
    explanation: >
      Phase 3 RCT demonstrates safety and efficacy of early ramipril therapy in children
      with Alport syndrome.
  - reference: PMID:33159213
    reference_title: "Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      We now recommend the initiation of treatment at the time of diagnosis in males
      with X-linked Alport syndrome and in males and females with autosomal recessive
      Alport syndrome.
    explanation: >
      Updated clinical guidelines now recommend ACE inhibitor initiation at diagnosis
      for X-linked males and autosomal recessive patients.
- name: Angiotensin Receptor Blocker Therapy
  description: >
    ARBs are used as an alternative or addition to ACE inhibitors for patients
    who cannot tolerate ACE inhibitors. RAAS blockade is the foundation of
    treatment for Alport syndrome.
  treatment_term:
    preferred_term: Angiotensin receptor blocker therapy
    term:
      id: NCIT:C172184
      label: Antihypertensive Therapy
  evidence:
  - reference: PMID:41243004
    reference_title: "From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      While renin-angiotensin-aldosterone system (RAAS) blockade remains the foundation
      of treatment to delay kidney failure, it does not directly target the underlying
      molecular pathology.
    explanation: >
      Review confirms RAAS blockade (which includes both ACE inhibitors and ARBs)
      as
      the foundation of Alport syndrome treatment.
- name: SGLT2 Inhibitor Therapy
  description: >
    Sodium-glucose cotransporter-2 inhibitors may offer additional kidney protection
    as adjunctive therapy to RAAS blockade in adults with proteinuria and CKD.
    A pediatric RCT (DOUBLE PRO-TECT Alport, NCT05944016) is underway.
  treatment_term:
    preferred_term: Sodium-glucose cotransporter-2 inhibitor therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41243004
    reference_title: "From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Adjunctive commercially available metabolic modulators, including SGLT2i,
      mineralocorticoid receptor antagonists, ezetimibe and GLP-1 receptor agonists,
      may offer additional kidney protection.
    explanation: >
      Review identifies SGLT2 inhibitors as adjunctive therapy that may offer
      additional kidney protection beyond RAAS blockade, though evidence is emerging.
- name: Renal Replacement Therapy
  description: >
    Dialysis (hemodialysis or peritoneal dialysis) is required when patients
    progress to end-stage renal disease. This serves as a bridge to kidney
    transplantation.
  treatment_term:
    preferred_term: Renal replacement therapy
    term:
      id: NCIT:C126400
      label: Renal Replacement Therapy
  evidence:
  - reference: PMID:38021591
    reference_title: "Alport Syndrome: A Comprehensive Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      including end-stage renal disease, which may need dialysis or kidney transplant.
    explanation: >
      Review confirms dialysis as necessary treatment for ESRD in Alport syndrome.
- name: Kidney Transplantation
  description: >
    Kidney transplantation is the definitive treatment for ESRD in Alport syndrome.
    Outcomes are generally excellent, though a small percentage of transplanted patients
    develop anti-GBM nephritis due to immune response against the novel alpha3-alpha4-alpha5(IV)
    collagen in the allograft.
  treatment_term:
    preferred_term: Whole kidney transplantation
    term:
      id: NCIT:C15265
      label: Kidney Transplantation
  evidence:
  - reference: PMID:29854973
    reference_title: "Genotype and Outcome After Kidney Transplantation in Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      De novo anti-GBM nephritis after transplantation was less frequent than previously
      reported, occurring in only 1.4% of AS patients, and in 2% of males with COL4A5
      mutation.
    explanation: >
      Large cohort study quantifies post-transplant anti-GBM nephritis risk and shows
      favorable overall transplant outcomes.
  - reference: PMID:23620401
    reference_title: "Quaternary epitopes of α345(IV) collagen initiate Alport post-transplant anti-GBM nephritis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Alport post-transplant nephritis (APTN) is an aggressive form of anti-glomerular
      basement membrane disease that targets the allograft in transplanted patients
      with
      X-linked Alport syndrome.
    explanation: >
      Elucidates the immunological mechanism of post-transplant anti-GBM nephritis,
      identifying quaternary epitopes of alpha345(IV) collagen as the inciting antigens.
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "monthly monitoring of at-risk transplant recipients for development of anti-glomerular basement membrane antibody-mediated glomerulonephritis for the first year post transplant"
    explanation: >
      GeneReviews surveillance recommendation: monitor at-risk recipients monthly
      for anti-GBM antibody-mediated glomerulonephritis during the first
      post-transplant year, matching the anti-GBM nephritis risk above.
- name: Hearing Aids for Sensorineural Hearing Loss
  description: >
    Sensorineural hearing loss is managed supportively with hearing aids as needed;
    hearing loss is not reversible, so audiologic surveillance and amplification are
    the mainstay.
  treatment_term:
    preferred_term: hearing aid usage
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids as needed for SNHL; cataract removal as needed"
    explanation: >
      GeneReviews management: hearing aids for sensorineural hearing loss, a
      non-renal manifestation not otherwise addressed by the kidney-directed
      treatments.
- name: Cataract Removal for Ocular Involvement
  description: >
    Anterior lenticonus and cataract can impair vision in Alport syndrome; cataract
    removal (lens extraction) is performed as needed for visually significant
    lens opacity.
  treatment_term:
    preferred_term: cataract removal
    term:
      id: NCIT:C157809
      label: Cataract Surgery
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing aids as needed for SNHL; cataract removal as needed"
    explanation: >
      GeneReviews management: cataract removal for ocular involvement, a non-renal
      manifestation not otherwise addressed by the kidney-directed treatments.
- name: Adequate Hydration (Renal, Agents/Circumstances to Avoid)
  description: >
    Maintain adequate fluid intake; dehydration may accelerate progression of the
    nephropathy - a GeneReviews agents/circumstances-to-avoid recommendation.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Drink adequate fluids as dehydration may accelerate the progression of nephropathy."
    explanation: >
      GeneReviews agents/circumstances-to-avoid guidance that dehydration can
      accelerate nephropathy progression, so adequate hydration is advised.
- name: Corneal Trauma Protection (Ocular, Agents/Circumstances to Avoid)
  description: >
    Protect the corneas from minor trauma in patients with recurrent corneal
    erosions (an ocular manifestation of Alport syndrome) - a GeneReviews
    agents/circumstances-to-avoid recommendation.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Protection of corneas from minor trauma in those with recurrent corneal erosions."
    explanation: >
      GeneReviews recommends protecting the corneas from minor trauma in patients
      with recurrent corneal erosions.
- name: Loud-Noise Avoidance (Auditory, Agents/Circumstances to Avoid)
  description: >
    Minimize exposure to loud noise to limit additional noise-induced hearing loss
    atop the sensorineural hearing loss - a GeneReviews agents/circumstances-to-avoid
    recommendation.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Minimize exposure to loud noise."
    explanation: >
      GeneReviews recommends minimizing loud-noise exposure to limit additional
      noise-induced hearing loss atop the sensorineural hearing loss.
- name: Leiomyoma Surgery (COL4A5-COL4A6 Deletion Subtype)
  description: >
    In the rare subset with a deletion of COL4A5 extending into intron 2 of COL4A6
    (the Alport syndrome-diffuse leiomyomatosis contiguous-gene phenotype),
    surgical resection of symptomatic leiomyomas is performed as needed.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "in those with deletions of COL4A5 extending into intron 2 of COL4A6, surgical intervention for symptomatic leiomyomas as needed"
    explanation: >
      GeneReviews management for the COL4A5-COL4A6 contiguous-deletion subtype:
      surgical intervention for symptomatic leiomyomas as needed.
diagnosis:
- name: Molecular genetic testing (COL4A3/COL4A4/COL4A5)
  description: >
    Definitive diagnosis is established by identifying a pathogenic variant in
    COL4A3, COL4A4, or COL4A5 on molecular genetic testing in a proband with
    suggestive clinical findings (hematuria, family history, hearing/ocular signs).
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The molecular diagnosis of Alport syndrome is established in a proband with suggestive findings and a pathogenic variant(s) in COL4A3, COL4A4, or COL4A5 identified by molecular genetic testing."
    explanation: >
      GeneReviews establishes molecular genetic testing of the three collagen IV
      genes as the definitive diagnostic modality.
- name: Kidney biopsy with electron microscopy
  description: >
    When genetic testing is unavailable or uninformative, kidney biopsy (or skin
    biopsy in some XLAS individuals) supports the diagnosis; electron microscopy of
    the glomerular basement membrane is the key ultrastructural test, showing
    segmental thinning early and lamellation/basket-weaving as disease progresses.
  diagnosis_term:
    preferred_term: kidney biopsy
    term:
      id: NCIT:C51699
      label: Kidney Biopsy
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Kidney biopsy, skin biopsy (in some individuals with XLAS), or clinical diagnostic criteria may be used to establish the diagnosis"
    explanation: >
      GeneReviews lists kidney/skin biopsy and clinical criteria as diagnostic
      alternatives when molecular testing is unavailable or uninformative.
  - reference: PMID:39384359
    reference_title: "Pathological diagnosis of Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The earliest electron microscopic finding of AS is segmental thinning of the lamina densa."
    explanation: >
      Human renal-biopsy observation identifying segmental GBM thinning as the
      earliest electron-microscopic diagnostic clue, preceding the lamellation and
      basket-weaving of advanced disease.
- name: Type IV collagen alpha-chain immunostaining
  description: >
    Immunohistochemical staining for type IV collagen alpha chains (notably
    alpha-5(IV)) on kidney or skin biopsy is the most Alport-specific pathology
    test: absent or abnormal alpha-5(IV) staining supports the diagnosis, and the
    staining pattern helps distinguish the inheritance subtype. Skin biopsy is
    diagnostic only via this alpha-5(IV) immunostaining.
  diagnosis_term:
    preferred_term: skin biopsy (for alpha-5(IV) immunostaining)
    term:
      id: NCIT:C51692
      label: Skin Biopsy
  evidence:
  - reference: PMID:39384359
    reference_title: "Pathological diagnosis of Alport syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Type IV collagen staining elucidates distinct patterns based on AS inheritance"
    explanation: >
      Human renal-pathology reference establishing type IV collagen (alpha-chain)
      immunostaining as an Alport-specific test whose pattern reflects the
      inheritance subtype, complementing electron microscopy.
progression:
- phase: Onset
  age_range: Childhood
  notes: >
    Microscopic hematuria is typically the first clinical manifestation, present
    from early childhood in X-linked males.
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "kidney disease progresses from microhematuria to proteinuria, progressive kidney insufficiency, and end-stage kidney disease (ESKD) in most males with X-linked Alport syndrome (XLAS)"
    explanation: >
      GeneReviews natural-history sequence establishes microhematuria as the first
      kidney manifestation, preceding proteinuria and progressive insufficiency, in
      most males with X-linked Alport syndrome - directly supporting the
      childhood-onset first-manifestation claim (replaces a generic disease-definition
      snippet that did not state onset timing).
- phase: Progression
  age_range: Adolescence-Young Adulthood
  notes: >
    Proteinuria develops, hearing loss becomes apparent, and renal function begins
    to decline. Genotype-dependent: severe COL4A5 mutations lead to ESRD by mean
    age 19.8 years; milder mutations by 25-30 years.
  evidence:
  - reference: PMID:12105244
    reference_title: "Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      large rearrangements, frame shift, nonsense, and splice donor mutations had
      a
      mean ESRF age of 19.8+/-5.7 years; (2) non-glycine- or 3' glycine-missense
      mutations, in-frame deletions/insertions and splice acceptor mutations had a
      mean
      ESRF age of 25.7+/-7.2 years
    explanation: >
      Provides genotype-specific progression data showing mean ESRD ages for different
      mutation types in X-linked Alport syndrome.
- phase: Advanced
  age_range: Young Adulthood-Adulthood
  notes: >
    End-stage renal disease requiring dialysis or transplantation. Post-transplant
    outcomes are generally excellent.
  evidence:
  - reference: PMID:29854973
    reference_title: "Genotype and Outcome After Kidney Transplantation in Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >
      Patient survival was similar in patients with severe and nonsevere mutations
      (89% vs. 84% at 5 years, 83% vs. 75% at 10, 15, and 20 years
    explanation: >
      Demonstrates good post-transplant patient survival regardless of mutation severity.
discussions:
- discussion_id: gap_alport_female_adas_progression
  prompt: >
    What genetic and non-genetic modifiers predict which heterozygous females with
    X-linked Alport syndrome, and which individuals with autosomal dominant Alport
    syndrome, will progress to end-stage kidney disease, given that their course is
    highly variable and often delayed until later adulthood?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#GBM Structural Deterioration
  rationale: >
    X-linked carrier females and autosomal dominant Alport syndrome show wide,
    poorly predictable variability in renal outcome - many reach ESKD only in later
    adulthood or not at all - so clinicians cannot reliably stratify risk or time
    nephroprotective therapy. Identifying predictive genotype (variant type/position,
    X-inactivation) and non-genetic modifiers would enable risk-adapted surveillance
    and treatment.
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In females with XLAS and individuals with autosomal dominant Alport syndrome (ADAS), ESKD is frequently delayed until later adulthood, SNHL is relatively late in onset, and ocular involvement is rare."
    explanation: >
      GeneReviews documents the delayed, variable course in XLAS females and ADAS,
      underscoring the unmet need for progression predictors.
  proposed_experiments:
  - experiment_id: exp_alport_female_adas_cohort
    name: Prospective modifier cohort in XLAS females and ADAS
    description: >
      Follow a genotyped prospective cohort of heterozygous XLAS females and ADAS
      individuals from the hematuria-only stage, integrating variant type/position,
      X-inactivation, proteinuria trajectory, and candidate modifier loci, to derive
      and validate a model predicting progression to ESKD.
    experiment_type:
      preferred_term: prospective cohort study
- discussion_id: gap_alport_raas_timing
  prompt: >
    Does initiating renin-angiotensin system blockade at the earliest
    (microhematuria-only) stage, before the onset of proteinuria, improve long-term
    kidney outcomes compared with starting at proteinuria onset?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - phenotypes#Microscopic Hematuria
  rationale: >
    ACE inhibitors/ARBs delay ESKD in Alport syndrome, and microhematuria precedes
    proteinuria by years, but the optimal threshold for starting therapy - at the
    hematuria-only stage versus at proteinuria onset - is not established, leaving a
    key preventive window uncertain.
  evidence:
  - reference: PMID:20301386
    reference_title: "Alport Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to delay onset of ESKD"
    explanation: >
      GeneReviews endorses RAAS blockade to delay ESKD but does not resolve the
      optimal initiation threshold relative to the microhematuria-to-proteinuria
      transition.
  proposed_experiments:
  - experiment_id: exp_alport_early_raas_rct
    name: Early versus proteinuria-triggered RAAS blockade trial
    description: >
      Randomize children/young adults with genetically confirmed Alport syndrome and
      microhematuria but no proteinuria to early RAAS blockade versus initiation at
      proteinuria onset, with ESKD-free survival and eGFR slope as endpoints, to
      define the optimal treatment window.
    experiment_type:
      preferred_term: randomized controlled trial
references:
- reference: PMID:20301386
  title: "Alport Syndrome."
  tags:
  - GeneReviews
- reference: DOI:10.1002/hsr2.70595
  title: 'Systematic Review of Management Strategies for Alport Syndrome: Implications for Male Patients'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: and AimsAlport Syndrome (AS) is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities, with an incidence of approximately 1 in 50,000 newborns.
    supporting_text: and AimsAlport Syndrome (AS) is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities, with an incidence of approximately 1 in 50,000 newborns.
- reference: DOI:10.1038/s41431-021-00858-1
  title: 'Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: 'Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria'
    supporting_text: The recent Chandos House meeting of the Alport Variant Collaborative extended the indications for screening for pathogenic variants in theCOL4A5, COL4A3andCOL4A4genes beyond the classical Alport phenotype (haematuria, renal failure; family history of haematuria or renal failure) to include persistent proteinuria, steroid-resistant nephrotic syndrome, focal and segmental glomerulosclerosis (FSGS), familial IgA glomerulonephritis and end-stage kidney failure without an obvious cause.
- reference: DOI:10.1038/s41431-022-01075-0
  title: The 2019 and 2021 International Workshops on Alport Syndrome
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: The 2019 and 2021 International Workshops on Alport Syndrome
    supporting_text: The 2019 and 2021 International Workshops on Alport Syndrome
- reference: DOI:10.1038/s41598-025-17027-9
  title: Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China
    supporting_text: Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China
- reference: DOI:10.1093/ndt/gfae265
  title: Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN
    supporting_text: Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with sensorineural deafness, and occasionally with ocular anomalies.
- reference: DOI:10.1159/000529471
  title: 'The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: 'Context: Alport syndrome (AS) is a hereditary chronic kidney disease (CKD) with X-linked, autosomal, and digenic patterns of transmission.'
    supporting_text: 'Context: Alport syndrome (AS) is a hereditary chronic kidney disease (CKD) with X-linked, autosomal, and digenic patterns of transmission.'
- reference: DOI:10.23876/j.krcp.24.063
  title: Pathological diagnosis of Alport syndrome
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes.
    supporting_text: Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes.
- reference: DOI:10.23876/j.krcp.24.065
  title: 'A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Alport syndrome, a rare genetic disorder affecting around 1 in 50,000 individuals, primarily presents as microscopic hematuria and chronic kidney disease (CKD) with associated extrarenal complications.
    supporting_text: Alport syndrome, a rare genetic disorder affecting around 1 in 50,000 individuals, primarily presents as microscopic hematuria and chronic kidney disease (CKD) with associated extrarenal complications.
- reference: DOI:10.3389/fgene.2023.1059322
  title: "Molecular dynamics and minigene assay of new splicing variant c.4298-20T&gt;A of COL4A5 gene that cause Alport syndrome"
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Alport syndrome (AS; OMIM#308940) is a progressive hereditary kidney disease characterized by hearing loss and ocular abnormalities.
    supporting_text: Alport syndrome (AS; OMIM#308940) is a progressive hereditary kidney disease characterized by hearing loss and ocular abnormalities.
- reference: DOI:10.3390/life15020298
  title: 'Candidate Genetic Modifiers in Alport Syndrome: A Case Series'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings:
  - statement: Alport syndrome (AS) is one of the most common monogenic kidney disorders.
    supporting_text: Alport syndrome (AS) is one of the most common monogenic kidney disorders.
- reference: PMID:11135492
  title: Absence of ocular manifestations in autosomal dominant Alport syndrome associated with haematological abnormalties.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Colville D(1), Wang YY, Jamieson R, Collins F, Hood J, Savige J.
    supporting_text: Colville D(1), Wang YY, Jamieson R, Collins F, Hood J, Savige J.
- reference: PMID:11839593
  title: Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is a human hereditary glomerulonephritis which results in end-stage renal failure (ESRF) in most cases.'
    supporting_text: 'Alport syndrome is a human hereditary glomerulonephritis which results in end-stage renal failure (ESRF) in most cases.'
- reference: PMID:14514738
  title: 'X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes.'
    supporting_text: 'Alport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes.'
- reference: PMID:16895672
  title: '[From Alport syndrome to benign familial hematuria: clinical and genetic aspect].'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome (AS) is a hereditary glomerulonephritis variably associated with neural hearing loss and ocular abnormalities.'
    supporting_text: 'Alport syndrome (AS) is a hereditary glomerulonephritis variably associated with neural hearing loss and ocular abnormalities.'
- reference: PMID:17570934
  title: Alport syndrome and thin basement membrane nephropathy.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Both Alport syndrome and thin basement membrane nephropathy (TBMN) can be considered as genetic diseases of the GBM involving the alpha3/alpha4/alpha5 network of type IV collagen.'
    supporting_text: 'Both Alport syndrome and thin basement membrane nephropathy (TBMN) can be considered as genetic diseases of the GBM involving the alpha3/alpha4/alpha5 network of type IV collagen.'
- reference: PMID:19536083
  title: 'Treatment of Alport syndrome: beyond animal models.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome (AS) is a hereditary glomerulopathy due to abnormal composition of the glomerular basement membrane, leading to end-stage renal disease (ESRD).'
    supporting_text: 'Alport syndrome (AS) is a hereditary glomerulopathy due to abnormal composition of the glomerular basement membrane, leading to end-stage renal disease (ESRD).'
- reference: PMID:20197625
  title: Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The glomerular basement membrane (GBM) is a key component of the filtering unit in the kidney.'
    supporting_text: 'The glomerular basement membrane (GBM) is a key component of the filtering unit in the kidney.'
- reference: PMID:23236390
  title: Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice'
    supporting_text: 'Alport disease in humans, which usually results in proteinuria and kidney failure, is caused by mutations to the COL4A3, COL4A4, or COL4A5 genes, and absence of collagen α3α4α5(IV) networks found in mature kidney glomerular basement membrane (GBM).'
- reference: PMID:24198271
  title: Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: The COL4A3-/- mouse serves as animal model for progressive renal fibrosis.
    supporting_text: The COL4A3-/- mouse serves as animal model for progressive renal fibrosis.
- reference: PMID:24529291
  title: Challenges for academic investigator-initiated pediatric trials for rare diseases.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Clinical trials require great effort, time, expertise, and money.
    supporting_text: Clinical trials require great effort, time, expertise, and money.
- reference: PMID:25107927
  title: 'Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The glomerular filtration barrier comprises a fenestrated capillary endothelium, glomerular basement membrane and podocyte slit diaphragm.'
    supporting_text: 'The glomerular filtration barrier comprises a fenestrated capillary endothelium, glomerular basement membrane and podocyte slit diaphragm.'
- reference: PMID:26628280
  title: 'Macroscopic hematuria with normal renal biopsy-following the chain to the diagnosis: Answers.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndrome (AS) is an inherited glomerular disease associated with hearing and eye defects; its morbidity is a public health issue in developed countries.
    supporting_text: Alport syndrome (AS) is an inherited glomerular disease associated with hearing and eye defects; its morbidity is a public health issue in developed countries.
- reference: PMID:27596081
  title: '[Analysis of diagnosis and treatment of Alport syndrome].'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'To investigate the clinical characteristics and the status of diagnosis and treatment of patients with Alport syndrome in China.'
    supporting_text: 'To investigate the clinical characteristics and the status of diagnosis and treatment of patients with Alport syndrome in China.'
- reference: PMID:28275241
  title: Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis'
    supporting_text: 'Alport syndrome-diffuse leiomyomatosis (AS-DL, OMIM: 308940) is a rare variant of the X-linked Alport syndrome that shows overgrowth of visceral smooth muscles in the gastrointestinal, respiratory and female reproductive tracts in addition to renal symptoms.'
- reference: PMID:28515156
  title: Anti-Glomerular Basement Membrane Disease.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs.'
    supporting_text: 'Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs.'
- reference: PMID:30724107
  title: Endothelial cell-specific collagen type IV-α(3) expression does not rescue Alport syndrome in Col4a3(-)(/-) mice.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The glomerular basement membrane (GBM) is a critical component of the kidney''s blood filtration barrier.'
    supporting_text: 'The glomerular basement membrane (GBM) is a critical component of the kidney''s blood filtration barrier.'
- reference: PMID:3124348
  title: An immunohistochemical and electron microscopic study of extra-renal basement membranes in dogs with Samoyed hereditary glomerulopathy.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Virchows Arch A Pathol Anat Histopathol.
    supporting_text: Virchows Arch A Pathol Anat Histopathol.
- reference: PMID:31422399
  title: 'Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutation: A Two-Case Report and Literature Review.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Autosomal dominant tubulointerstitial kidney disease due to UMOD (encoding uromodulin) mutation (ADTKD-UMOD) is a rare hereditary disease.'
    supporting_text: 'Autosomal dominant tubulointerstitial kidney disease due to UMOD (encoding uromodulin) mutation (ADTKD-UMOD) is a rare hereditary disease.'
- reference: PMID:32444091
  title: 'Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome.'
    supporting_text: 'Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome.'
- reference: PMID:33423643
  title: 'Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndrome (AS) is a disease caused by mutations in COL4A3, COL4A4 or COL4A5, the genes that encode distinct chains of type IV collagen.
    supporting_text: Alport syndrome (AS) is a disease caused by mutations in COL4A3, COL4A4 or COL4A5, the genes that encode distinct chains of type IV collagen.
- reference: PMID:34675305
  title: Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is an inherited chronic human kidney disease, characterized by glomerular basement membrane abnormalities.'
    supporting_text: 'Alport syndrome is an inherited chronic human kidney disease, characterized by glomerular basement membrane abnormalities.'
- reference: PMID:35020912
  title: Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndrome (AS) is an inherited type IV collagen-related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD).
    supporting_text: Alport syndrome (AS) is an inherited type IV collagen-related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD).
- reference: PMID:35140116
  title: A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure.
    supporting_text: Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure.
- reference: PMID:35177655
  title: Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is the commonest inherited kidney disease and nearly half the pathogenic variants in the COL4A3-COL4A5 genes that cause Alport syndrome result in Gly substitutions.'
    supporting_text: 'Alport syndrome is the commonest inherited kidney disease and nearly half the pathogenic variants in the COL4A3-COL4A5 genes that cause Alport syndrome result in Gly substitutions.'
- reference: PMID:36371577
  title: Aberrant splicing caused by exonic single nucleotide variants positioned 2nd or 3rd to the last nucleotide in the COL4A5 gene.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The evident genotype-phenotype correlation shown by the X-linked Alport syndrome warrants the assessment of the impact of identified gene variants on aberrant splicing.'
    supporting_text: 'The evident genotype-phenotype correlation shown by the X-linked Alport syndrome warrants the assessment of the impact of identified gene variants on aberrant splicing.'
- reference: PMID:37100867
  title: 'Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The genotype-phenotype correlation of the X-linked Alport syndrome (XLAS) has been well elucidated in males, whereas it remains unclear in females.'
    supporting_text: 'The genotype-phenotype correlation of the X-linked Alport syndrome (XLAS) has been well elucidated in males, whereas it remains unclear in females.'
- reference: PMID:37428955
  title: Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Dual inhibition of the renin-angiotensin system (RAS) plus sodium-glucose transporter (SGLT)-2 or the mineralocorticoid receptor (MR) demonstrated additive renoprotective effects in large clinical trials.
    supporting_text: Dual inhibition of the renin-angiotensin system (RAS) plus sodium-glucose transporter (SGLT)-2 or the mineralocorticoid receptor (MR) demonstrated additive renoprotective effects in large clinical trials.
- reference: PMID:38022159
  title: 'Ocular Manifestations of Alport Syndrome: Report and Comparison of Two Cases.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'We report two cases of Alport syndrome and compare the clinical presentations and imaging findings in these cases.'
    supporting_text: 'We report two cases of Alport syndrome and compare the clinical presentations and imaging findings in these cases.'
- reference: PMID:38837003
  title: A targeted gene panel illuminates pathogenesis in young people with unexplained kidney failure.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Kidney failure in young people is often unexplained and a significant proportion will have an underlying genetic diagnosis.
    supporting_text: Kidney failure in young people is often unexplained and a significant proportion will have an underlying genetic diagnosis.
- reference: PMID:39122650
  title: 'Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium-glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs).
    supporting_text: Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium-glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs).
- reference: PMID:39441037
  title: Dyspnea and nocturnal cough due to esophageal diffuse leiomyomatosis in a girl with hematuria.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'A 7-year-old girl with hematuria and clinical suspicion of Alport syndrome (AS) presented with dyspnea and nocturnal cough, initially diagnosed and treated as asthma.'
    supporting_text: 'A 7-year-old girl with hematuria and clinical suspicion of Alport syndrome (AS) presented with dyspnea and nocturnal cough, initially diagnosed and treated as asthma.'
- reference: PMID:39625784
  title: Genotype-First Analysis in an Unselected Health System-Based Population and Phenotypic Severity of COL4A5 Variants.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Our knowledge of X-linked Alport syndrome comes mostly from selected cohorts with more severe disease.
    supporting_text: Our knowledge of X-linked Alport syndrome comes mostly from selected cohorts with more severe disease.
- reference: PMID:39694697
  title: 'Challenging the narrative of Alport syndrome spectrum: no link with cystic phenotype.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndromes (AS) are the second leading genetic cause of kidney failure.
    supporting_text: Alport syndromes (AS) are the second leading genetic cause of kidney failure.
- reference: PMID:39810285
  title: Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Unlike X-linked or autosomal recessive Alport syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.
    supporting_text: Unlike X-linked or autosomal recessive Alport syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.
- reference: PMID:39899372
  title: Genotype-Based Molecular Mechanisms in Alport Syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is an inherited disorder characterized by kidney disease, sensorineural hearing loss, and ocular abnormalities.'
    supporting_text: 'Alport syndrome is an inherited disorder characterized by kidney disease, sensorineural hearing loss, and ocular abnormalities.'
- reference: PMID:40044766
  title: Pathogenic variants in the Alport genes are prevalent in the Singapore multiethnic population with highest frequency in the Chinese.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is a common monogenic kidney disease resulting from pathogenic variants in COL4A3, COL4A4 or COL4A5 genes.'
    supporting_text: 'Alport syndrome is a common monogenic kidney disease resulting from pathogenic variants in COL4A3, COL4A4 or COL4A5 genes.'
- reference: PMID:40057613
  title: Identification of novel COL4A5 variants and prenatal diagnosis in three large families.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome (AS) is the second-most frequent monogenic kidney disease and 85% of cases are caused by mutations in the genes of the α5 chains of collagen type IV (COL4A5).'
    supporting_text: 'Alport syndrome (AS) is the second-most frequent monogenic kidney disease and 85% of cases are caused by mutations in the genes of the α5 chains of collagen type IV (COL4A5).'
- reference: PMID:40067386
  title: Oral Ketone β -Hydroxybutyrate Supplement Retards the Loss of GFR in Alport Mice on Dual Renin-Angiotensin System/Sodium-Glucose Transporter 2 Blockade.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Several studies suggest that dietary β-hydroxybutyrate (BHB) supplementation delays the progression of CKD by suppressing inflammation and fibrosis.
    supporting_text: Several studies suggest that dietary β-hydroxybutyrate (BHB) supplementation delays the progression of CKD by suppressing inflammation and fibrosis.
- reference: PMID:40237890
  title: Phenotype-genotype correlations in patients with Alport syndrome from the Polish population.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Alport syndrome (AS) is a rare inherited kidney disease associated with progressive renal failure and visual and hearing disorders.
    supporting_text: Alport syndrome (AS) is a rare inherited kidney disease associated with progressive renal failure and visual and hearing disorders.
- reference: PMID:40745060
  title: Collagen IV in Gould syndrome and Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Collagen IV is a basement membrane component that is encoded by six genes in mammals (COL4Α1-COL4A6).'
    supporting_text: 'Collagen IV is a basement membrane component that is encoded by six genes in mammals (COL4Α1-COL4A6).'
- reference: PMID:40754307
  title: Ectopic laminin α2 accumulation in the glomerular basement membrane exacerbates podocyte injury in Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Alport syndrome is a hereditary disease caused by mutations in Col4a3, Col4a4, and Col4a5, which encode the type IV collagen α3, α4, and α5 chains, respectively.'
    supporting_text: 'Alport syndrome is a hereditary disease caused by mutations in Col4a3, Col4a4, and Col4a5, which encode the type IV collagen α3, α4, and α5 chains, respectively.'
- reference: PMID:41194031
  title: 'Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications.
    supporting_text: Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications.
- reference: PMID:41557100
  title: 'Coincidence of autosomal dominant polycystic kidney disease and Alport syndrome: a case report and literature review.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, accounting for approximately 5% of kidney failure worldwide.'
    supporting_text: 'Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, accounting for approximately 5% of kidney failure worldwide.'
- reference: PMID:8971907
  title: Hereditary disorders of the glomerular basement membrane.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Increased knowledge of the biochemical composition of the glomerular basement membrane (GBM) and the introduction of molecular genetics has shed new light on the hereditary disorders of the GBM.'
    supporting_text: 'Increased knowledge of the biochemical composition of the glomerular basement membrane (GBM) and the introduction of molecular genetics has shed new light on the hereditary disorders of the GBM.'
- reference: PMID:9127294
  title: Glomerular ultrastructural findings similar to hereditary nephritis in 4 English cocker spaniels.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'Renal disease affecting 3 male and 1 female English Cocker Spaniels was studied.'
    supporting_text: 'Renal disease affecting 3 male and 1 female English Cocker Spaniels was studied.'
- reference: PMID:9682811
  title: Ultrastructural, physiological, and molecular defects in the inner ear of a gene-knockout mouse model for autosomal Alport syndrome.
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings:
  - statement: 'The cochleae from a COL4A3-deficient mouse line were examined for defects that might shed light on the molecular mechanism of otopathology observed in humans with Alport syndrome.'
    supporting_text: 'The cochleae from a COL4A3-deficient mouse line were examined for defects that might shed light on the molecular mechanism of otopathology observed in humans with Alport syndrome.'
- reference: DOI:10.7759/cureus.47129
  title: 'Alport Syndrome: A Comprehensive Review'
  found_in:
  - Alport_Syndrome-deep-research-falcon.md
  findings: []
- reference: PMID:32712016
  title: 'Alport Syndrome: Achieving Early Diagnosis and Treatment.'
  found_in:
  - Alport_Syndrome-deep-research-openscientist.md
  findings: []
datasets:
- accession: geo:GSE281080
  title: Transcriptomic profiling of prolonged-culture iPSC-derived kidney organoids and X-linked Alport syndrome organoid models carrying COL4A5 deep-intronic variants
  description: Kidney organoids serve as an invaluable platform for modeling hereditary renal diseases and developing therapeutic interventions. While various kidney organoid differentiation protocols have been developed, the protocol introduced by Morizane et al. was among the first to generate kidney organoids from induced pluripotent stem cells (iPSCs). By using a modified version of this protocol, we successfully generated kidney organoids in 21 days. Most studies on kidney organoids focus on early stages, typically between days 21 and 29, leaving the gene expression dynamics during prolonged culture less explored.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 24
  notes: Identified by GEO DataSets index search for Alport Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE274298
  title: 'SMPDL3b in Podocytes: Decoupling Proteinuria from CKD Progression in Experimental Alport Syndrome'
  description: Alport Syndrome (AS) is a rare genetic disease with impaired production of collagen type IV alpha 3, 4 and 5 chains in the glomerular basement membranes (GBM), which results amongst others in progressive loss of kidney function. In AS, abnormalities in the GBM and associated podocyte detachment may potentially result from the dysregulation of sphingolipid metabolism. Here we investigated whether renal sphingomyelin phosphodiesterase acid-like 3b (SMPDL3b) overexpression modulates the generation of sphingosine-1-phosphate (S1P) and contributes to renal failure in Col4a3 knockout mice, a mouse model of AS.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: BULK_RNA_SEQ
  sample_count: 6
  publication: PMID:39684843
  notes: Identified by GEO DataSets index search for Alport Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE271383
  title: Evidence that chaperone 4-PBA treatment alleviates the renal phenotype in Alport syndrome mouse models
  description: Total RNA was extracted from glomeruli as described above. RNA quality and quantity were determined by the 2100 Bioanalyzer. RT2 Profiler PCR Array (QIAGEN) is the method used for qPCR assay. This technique takes advantage of real-time PCR performance and combines it with the ability of microarrays to detect the expression of many genes related to UPR pathway simultaneously. Total RNA that was purified from glomeruli which were extracted from mutant and wild type kidneys was measured and then converted into first strand cDNA. qPCR was followed by using the instrument-specific and ready-to-use RT2 qPCR Master Mixes and gene specific primer sets.
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  sample_count: 9
  publication: PMID:40484355
  notes: Identified by GEO DataSets index search for Alport Syndrome (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001002009
  title: HipSci HumanExome BeadChip analysis - Alport Syndrome
  description: The HipSci project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. In this sub-study we performed Genotyping analysis using the Infinium HumanExome BeadChip on iPS cells generated from skin biopsies or blood samples from rare disease patients diagnosed with Alport Syndrome.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Alport Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001002019
  title: HipSci HumanExome BeadChip analysis - Alport syndrome (Manchester)
  description: The HipSci project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. In this sub-study we performed Genotyping analysis using the Infinium HumanExome BeadChip on iPS cells generated from skin biopsies or blood samples from rare disease patients diagnosed with Alport syndrome (Manchester Uni).
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Alport Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001002024
  title: HipSci HumanHT 12 Expression BeadChip analysis - Alport syndrome
  description: The HipSci project brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. In this sub-study we performed Expression analysis using the Illumina HumanHT -12 Expression BeadChip on iPS cells generated from skin biopsies or blood samples from rare disease patients diagnosed with Alport syndrome.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Alport Syndrome"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'

📚

References & Deep Research

References

PMID:20301386

Alport Syndrome.

No top-level findings curated for this source.

DOI:10.1002/hsr2.70595

Systematic Review of Management Strategies for Alport Syndrome: Implications for Male Patients

1 finding

and AimsAlport Syndrome (AS) is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities, with an incidence of approximately 1 in 50,000 newborns.

"and AimsAlport Syndrome (AS) is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities, with an incidence of approximately 1 in 50,000 newborns."

DOI:10.1038/s41431-021-00858-1

Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

1 finding

Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria

"The recent Chandos House meeting of the Alport Variant Collaborative extended the indications for screening for pathogenic variants in theCOL4A5, COL4A3andCOL4A4genes beyond the classical Alport phenotype (haematuria, renal failure; family history of haematuria or renal failure) to include..."

DOI:10.1038/s41431-022-01075-0

The 2019 and 2021 International Workshops on Alport Syndrome

1 finding

The 2019 and 2021 International Workshops on Alport Syndrome

"The 2019 and 2021 International Workshops on Alport Syndrome"

DOI:10.1038/s41598-025-17027-9

Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China

1 finding

Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China

"Novel COL4A3–COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China"

DOI:10.1093/ndt/gfae265

Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN

1 finding

Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN

"Glomerular nephropathy resulting from the genetic defects in COL4A3/4/5 genes including the classical Alport syndrome is the second most common hereditary kidney disease characterized by persistent haematuria progressing to the need for kidney replacement therapy, frequently associated with..."

DOI:10.1159/000529471

The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs

1 finding

Context: Alport syndrome (AS) is a hereditary chronic kidney disease (CKD) with X-linked, autosomal, and digenic patterns of transmission.

"Context: Alport syndrome (AS) is a hereditary chronic kidney disease (CKD) with X-linked, autosomal, and digenic patterns of transmission."

DOI:10.23876/j.krcp.24.063

Pathological diagnosis of Alport syndrome

1 finding

Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes.

"Alport syndrome (AS) is a hereditary nephritis characterized by structural abnormalities in the glomerular basement membrane resulting from pathogenic variants in the COL4A3, COL4A4, and COL4A5 genes."

DOI:10.23876/j.krcp.24.065

A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations

1 finding

Alport syndrome, a rare genetic disorder affecting around 1 in 50,000 individuals, primarily presents as microscopic hematuria and chronic kidney disease (CKD) with associated extrarenal complications.

"Alport syndrome, a rare genetic disorder affecting around 1 in 50,000 individuals, primarily presents as microscopic hematuria and chronic kidney disease (CKD) with associated extrarenal complications."

DOI:10.3389/fgene.2023.1059322

Molecular dynamics and minigene assay of new splicing variant c.4298-20T>A of COL4A5 gene that cause Alport syndrome

1 finding

Alport syndrome (AS; OMIM#308940) is a progressive hereditary kidney disease characterized by hearing loss and ocular abnormalities.

"Alport syndrome (AS; OMIM#308940) is a progressive hereditary kidney disease characterized by hearing loss and ocular abnormalities."

DOI:10.3390/life15020298

Candidate Genetic Modifiers in Alport Syndrome: A Case Series

1 finding

Alport syndrome (AS) is one of the most common monogenic kidney disorders.

"Alport syndrome (AS) is one of the most common monogenic kidney disorders."

PMID:11135492

Absence of ocular manifestations in autosomal dominant Alport syndrome associated with haematological abnormalties.

1 finding

Colville D(1), Wang YY, Jamieson R, Collins F, Hood J, Savige J.

"Colville D(1), Wang YY, Jamieson R, Collins F, Hood J, Savige J."

PMID:11839593

Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome.

1 finding

Alport syndrome is a human hereditary glomerulonephritis which results in end-stage renal failure (ESRF) in most cases.

"Alport syndrome is a human hereditary glomerulonephritis which results in end-stage renal failure (ESRF) in most cases."

PMID:14514738

X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.

1 finding

Alport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes.

"Alport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes."

PMID:16895672

[From Alport syndrome to benign familial hematuria: clinical and genetic aspect].

1 finding

Alport syndrome (AS) is a hereditary glomerulonephritis variably associated with neural hearing loss and ocular abnormalities.

"Alport syndrome (AS) is a hereditary glomerulonephritis variably associated with neural hearing loss and ocular abnormalities."

PMID:17570934

Alport syndrome and thin basement membrane nephropathy.

1 finding

Both Alport syndrome and thin basement membrane nephropathy (TBMN) can be considered as genetic diseases of the GBM involving the alpha3/alpha4/alpha5 network of type IV collagen.

"Both Alport syndrome and thin basement membrane nephropathy (TBMN) can be considered as genetic diseases of the GBM involving the alpha3/alpha4/alpha5 network of type IV collagen."

PMID:19536083

Treatment of Alport syndrome: beyond animal models.

1 finding

Alport syndrome (AS) is a hereditary glomerulopathy due to abnormal composition of the glomerular basement membrane, leading to end-stage renal disease (ESRD).

"Alport syndrome (AS) is a hereditary glomerulopathy due to abnormal composition of the glomerular basement membrane, leading to end-stage renal disease (ESRD)."

PMID:20197625

Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.

1 finding

The glomerular basement membrane (GBM) is a key component of the filtering unit in the kidney.

"The glomerular basement membrane (GBM) is a key component of the filtering unit in the kidney."

PMID:23236390

Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.

1 finding

Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice

"Alport disease in humans, which usually results in proteinuria and kidney failure, is caused by mutations to the COL4A3, COL4A4, or COL4A5 genes, and absence of collagen α3α4α5(IV) networks found in mature kidney glomerular basement membrane (GBM)."

PMID:24198271

Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.

1 finding

The COL4A3-/- mouse serves as animal model for progressive renal fibrosis.

"The COL4A3-/- mouse serves as animal model for progressive renal fibrosis."

PMID:24529291

Challenges for academic investigator-initiated pediatric trials for rare diseases.

1 finding

Clinical trials require great effort, time, expertise, and money.

"Clinical trials require great effort, time, expertise, and money."

PMID:25107927

Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.

1 finding

The glomerular filtration barrier comprises a fenestrated capillary endothelium, glomerular basement membrane and podocyte slit diaphragm.

"The glomerular filtration barrier comprises a fenestrated capillary endothelium, glomerular basement membrane and podocyte slit diaphragm."

PMID:26628280

Macroscopic hematuria with normal renal biopsy-following the chain to the diagnosis: Answers.

1 finding

Alport syndrome (AS) is an inherited glomerular disease associated with hearing and eye defects; its morbidity is a public health issue in developed countries.

"Alport syndrome (AS) is an inherited glomerular disease associated with hearing and eye defects; its morbidity is a public health issue in developed countries."

PMID:27596081

[Analysis of diagnosis and treatment of Alport syndrome].

1 finding

To investigate the clinical characteristics and the status of diagnosis and treatment of patients with Alport syndrome in China.

"To investigate the clinical characteristics and the status of diagnosis and treatment of patients with Alport syndrome in China."

PMID:28275241

Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis.

1 finding

Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis

"Alport syndrome-diffuse leiomyomatosis (AS-DL, OMIM: 308940) is a rare variant of the X-linked Alport syndrome that shows overgrowth of visceral smooth muscles in the gastrointestinal, respiratory and female reproductive tracts in addition to renal symptoms."

PMID:28515156

Anti-Glomerular Basement Membrane Disease.

1 finding

Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs.

"Anti-glomerular basement membrane (anti-GBM) disease is a rare small vessel vasculitis that affects the capillary beds of the kidneys and lungs."

PMID:30724107

Endothelial cell-specific collagen type IV-α(3) expression does not rescue Alport syndrome in Col4a3(-)(/-) mice.

1 finding

The glomerular basement membrane (GBM) is a critical component of the kidney's blood filtration barrier.

"The glomerular basement membrane (GBM) is a critical component of the kidney's blood filtration barrier."

PMID:3124348

An immunohistochemical and electron microscopic study of extra-renal basement membranes in dogs with Samoyed hereditary glomerulopathy.

1 finding

Virchows Arch A Pathol Anat Histopathol.

"Virchows Arch A Pathol Anat Histopathol."

PMID:31422399

Autosomal Dominant Tubulointerstitial Kidney Disease Due to UMOD Mutation: A Two-Case Report and Literature Review.

1 finding

Autosomal dominant tubulointerstitial kidney disease due to UMOD (encoding uromodulin) mutation (ADTKD-UMOD) is a rare hereditary disease.

"Autosomal dominant tubulointerstitial kidney disease due to UMOD (encoding uromodulin) mutation (ADTKD-UMOD) is a rare hereditary disease."

PMID:32444091

Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?

1 finding

Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome.

"Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome."

PMID:33423643

Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives.

1 finding

Alport syndrome (AS) is a disease caused by mutations in COL4A3, COL4A4 or COL4A5, the genes that encode distinct chains of type IV collagen.

"Alport syndrome (AS) is a disease caused by mutations in COL4A3, COL4A4 or COL4A5, the genes that encode distinct chains of type IV collagen."

PMID:34675305

Creation of X-linked Alport syndrome rat model with Col4a5 deficiency.

1 finding

Alport syndrome is an inherited chronic human kidney disease, characterized by glomerular basement membrane abnormalities.

"Alport syndrome is an inherited chronic human kidney disease, characterized by glomerular basement membrane abnormalities."

PMID:35020912

Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.

1 finding

Alport syndrome (AS) is an inherited type IV collagen-related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD).

"Alport syndrome (AS) is an inherited type IV collagen-related disorder with an irreversible tendency to progress to end-stage renal disease (ESRD)."

PMID:35140116

A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.

1 finding

Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure.

"Alport syndrome is a genetic disorder characterized by a defective glomerular basement membrane, tubulointerstitial fibrosis, inflammation, and progressive renal failure."

PMID:35177655

Genotype-phenotype correlations for COL4A3-COL4A5 variants resulting in Gly substitutions in Alport syndrome.

1 finding

Alport syndrome is the commonest inherited kidney disease and nearly half the pathogenic variants in the COL4A3-COL4A5 genes that cause Alport syndrome result in Gly substitutions.

"Alport syndrome is the commonest inherited kidney disease and nearly half the pathogenic variants in the COL4A3-COL4A5 genes that cause Alport syndrome result in Gly substitutions."

PMID:36371577

Aberrant splicing caused by exonic single nucleotide variants positioned 2nd or 3rd to the last nucleotide in the COL4A5 gene.

1 finding

The evident genotype-phenotype correlation shown by the X-linked Alport syndrome warrants the assessment of the impact of identified gene variants on aberrant splicing.

"The evident genotype-phenotype correlation shown by the X-linked Alport syndrome warrants the assessment of the impact of identified gene variants on aberrant splicing."

PMID:37100867

Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea.

1 finding

The genotype-phenotype correlation of the X-linked Alport syndrome (XLAS) has been well elucidated in males, whereas it remains unclear in females.

"The genotype-phenotype correlation of the X-linked Alport syndrome (XLAS) has been well elucidated in males, whereas it remains unclear in females."

PMID:37428955

Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.

1 finding

Dual inhibition of the renin-angiotensin system (RAS) plus sodium-glucose transporter (SGLT)-2 or the mineralocorticoid receptor (MR) demonstrated additive renoprotective effects in large clinical trials.

"Dual inhibition of the renin-angiotensin system (RAS) plus sodium-glucose transporter (SGLT)-2 or the mineralocorticoid receptor (MR) demonstrated additive renoprotective effects in large clinical trials."

PMID:38022159

Ocular Manifestations of Alport Syndrome: Report and Comparison of Two Cases.

1 finding

We report two cases of Alport syndrome and compare the clinical presentations and imaging findings in these cases.

"We report two cases of Alport syndrome and compare the clinical presentations and imaging findings in these cases."

PMID:38837003

A targeted gene panel illuminates pathogenesis in young people with unexplained kidney failure.

1 finding

Kidney failure in young people is often unexplained and a significant proportion will have an underlying genetic diagnosis.

"Kidney failure in young people is often unexplained and a significant proportion will have an underlying genetic diagnosis."

PMID:39122650

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport.

1 finding

Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium-glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs).

"Clinical trials have demonstrated positive cardiovascular and kidney outcomes of sodium-glucose co-transporter 2 (SGLT2) inhibitors in adult patients with diabetic and other chronic kidney diseases (CKDs)."

PMID:39441037

Dyspnea and nocturnal cough due to esophageal diffuse leiomyomatosis in a girl with hematuria.

1 finding

A 7-year-old girl with hematuria and clinical suspicion of Alport syndrome (AS) presented with dyspnea and nocturnal cough, initially diagnosed and treated as asthma.

"A 7-year-old girl with hematuria and clinical suspicion of Alport syndrome (AS) presented with dyspnea and nocturnal cough, initially diagnosed and treated as asthma."

PMID:39625784

Genotype-First Analysis in an Unselected Health System-Based Population and Phenotypic Severity of COL4A5 Variants.

1 finding

Our knowledge of X-linked Alport syndrome comes mostly from selected cohorts with more severe disease.

"Our knowledge of X-linked Alport syndrome comes mostly from selected cohorts with more severe disease."

PMID:39694697

Challenging the narrative of Alport syndrome spectrum: no link with cystic phenotype.

1 finding

Alport syndromes (AS) are the second leading genetic cause of kidney failure.

"Alport syndromes (AS) are the second leading genetic cause of kidney failure."

PMID:39810285

Exon location of glycine substitutions impacts kidney survival in autosomal dominant Alport syndrome.

1 finding

Unlike X-linked or autosomal recessive Alport syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4.

"Unlike X-linked or autosomal recessive Alport syndrome, no clear genotype/phenotype correlation has yet been demonstrated in patients carrying a single variant of COL4A3 or COL4A4."

PMID:39899372

Genotype-Based Molecular Mechanisms in Alport Syndrome.

1 finding

Alport syndrome is an inherited disorder characterized by kidney disease, sensorineural hearing loss, and ocular abnormalities.

"Alport syndrome is an inherited disorder characterized by kidney disease, sensorineural hearing loss, and ocular abnormalities."

PMID:40044766

Pathogenic variants in the Alport genes are prevalent in the Singapore multiethnic population with highest frequency in the Chinese.

1 finding

Alport syndrome is a common monogenic kidney disease resulting from pathogenic variants in COL4A3, COL4A4 or COL4A5 genes.

"Alport syndrome is a common monogenic kidney disease resulting from pathogenic variants in COL4A3, COL4A4 or COL4A5 genes."

PMID:40057613

Identification of novel COL4A5 variants and prenatal diagnosis in three large families.

1 finding

Alport syndrome (AS) is the second-most frequent monogenic kidney disease and 85% of cases are caused by mutations in the genes of the α5 chains of collagen type IV (COL4A5).

"Alport syndrome (AS) is the second-most frequent monogenic kidney disease and 85% of cases are caused by mutations in the genes of the α5 chains of collagen type IV (COL4A5)."

PMID:40067386

Oral Ketone β -Hydroxybutyrate Supplement Retards the Loss of GFR in Alport Mice on Dual Renin-Angiotensin System/Sodium-Glucose Transporter 2 Blockade.

1 finding

Several studies suggest that dietary β-hydroxybutyrate (BHB) supplementation delays the progression of CKD by suppressing inflammation and fibrosis.

"Several studies suggest that dietary β-hydroxybutyrate (BHB) supplementation delays the progression of CKD by suppressing inflammation and fibrosis."

PMID:40237890

Phenotype-genotype correlations in patients with Alport syndrome from the Polish population.

1 finding

Alport syndrome (AS) is a rare inherited kidney disease associated with progressive renal failure and visual and hearing disorders.

"Alport syndrome (AS) is a rare inherited kidney disease associated with progressive renal failure and visual and hearing disorders."

PMID:40745060

Collagen IV in Gould syndrome and Alport syndrome.

1 finding

Collagen IV is a basement membrane component that is encoded by six genes in mammals (COL4Α1-COL4A6).

"Collagen IV is a basement membrane component that is encoded by six genes in mammals (COL4Α1-COL4A6)."

PMID:40754307

Ectopic laminin α2 accumulation in the glomerular basement membrane exacerbates podocyte injury in Alport syndrome.

1 finding

Alport syndrome is a hereditary disease caused by mutations in Col4a3, Col4a4, and Col4a5, which encode the type IV collagen α3, α4, and α5 chains, respectively.

"Alport syndrome is a hereditary disease caused by mutations in Col4a3, Col4a4, and Col4a5, which encode the type IV collagen α3, α4, and α5 chains, respectively."

PMID:41194031

Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk.

1 finding

Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications.

"Kidney transplantation is the preferred treatment for end-stage renal disease (ESRD), yet challenges persist in long-term graft survival and post-transplant complications."

PMID:41557100

Coincidence of autosomal dominant polycystic kidney disease and Alport syndrome: a case report and literature review.

1 finding

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, accounting for approximately 5% of kidney failure worldwide.

"Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease, accounting for approximately 5% of kidney failure worldwide."

PMID:8971907

Hereditary disorders of the glomerular basement membrane.

1 finding

Increased knowledge of the biochemical composition of the glomerular basement membrane (GBM) and the introduction of molecular genetics has shed new light on the hereditary disorders of the GBM.

"Increased knowledge of the biochemical composition of the glomerular basement membrane (GBM) and the introduction of molecular genetics has shed new light on the hereditary disorders of the GBM."

PMID:9127294

Glomerular ultrastructural findings similar to hereditary nephritis in 4 English cocker spaniels.

1 finding

Renal disease affecting 3 male and 1 female English Cocker Spaniels was studied.

"Renal disease affecting 3 male and 1 female English Cocker Spaniels was studied."

PMID:9682811

Ultrastructural, physiological, and molecular defects in the inner ear of a gene-knockout mouse model for autosomal Alport syndrome.

1 finding

The cochleae from a COL4A3-deficient mouse line were examined for defects that might shed light on the molecular mechanism of otopathology observed in humans with Alport syndrome.

"The cochleae from a COL4A3-deficient mouse line were examined for defects that might shed light on the molecular mechanism of otopathology observed in humans with Alport syndrome."

DOI:10.7759/cureus.47129

Alport Syndrome: A Comprehensive Review

No top-level findings curated for this source.

PMID:32712016

Alport Syndrome: Achieving Early Diagnosis and Treatment.

No top-level findings curated for this source.

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 34 citations 2026-04-22T22:26:01.343502

1. Disease Information

1.1 Overview / definition

Alport syndrome is a hereditary glomerular nephropathy due to defects in the α3–α4–α5 type IV collagen network of basement membranes, especially the glomerular basement membrane (GBM), driven by pathogenic variants in COL4A3, COL4A4, and COL4A5. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

A widely used clinical framing is the kidney–ear–eye triad: kidney disease with persistent haematuria progressing to CKD/kidney failure, plus hearing loss and ocular abnormalities. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

1.2 Key identifiers (available from tool-accessible sources)

MONDO: MONDO_0018965 (Alport syndrome) (torra2025diagnosismanagementand pages 1-2)
OMIM disease IDs (from primary abstract text): Alport syndrome OMIM#308940; X-linked OMIM#301050; autosomal recessive OMIM#203780; autosomal dominant OMIM#104200 (liang2023moleculardynamicsand pages 1-2)
Causal genes (OMIM gene entries cited in abstract): COL4A5 (OMIM*303630), COL4A3 (OMIM*120070), COL4A4 (OMIM*120131) (liang2023moleculardynamicsand pages 1-2)

Not retrievable with current tool evidence: Orphanet ORPHA ID, ICD-10/ICD-11 codes, and MeSH ID were not present in the retrieved documents/records and therefore cannot be asserted here without external database access.

1.3 Synonyms / alternative names

“X-linked Alport syndrome (XLAS)”, “autosomal recessive Alport syndrome (ARAS)”, “autosomal dominant Alport syndrome (ADAS)” (liang2023moleculardynamicsand pages 1-2)
“COL4A3/4/5 glomerulopathy” is used in guideline framing for the broader genotypic spectrum (torra2025diagnosismanagementand pages 1-2)
“Alport spectrum” has been discussed as an umbrella term in genomics-era nomenclature discussions. (daga2022the2019and pages 3-4)

1.4 Evidence provenance: patient-level vs aggregated resources

Evidence summarized below is derived from (i) expert guideline consensus (systematic review + graded recommendations), (ii) peer-reviewed reviews, (iii) observational cohorts/case series, and (iv) ClinicalTrials.gov trial registry records. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 5-6, NCT02855268 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary causal factor: germline pathogenic variants affecting type IV collagen α3/α4/α5 chain formation, encoded by COL4A3, COL4A4, COL4A5. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

Mechanistic framing: mutations disrupt α3α4α5(IV) heterotrimer formation and basement membrane integrity, rendering the GBM vulnerable under filtration pressure, leading to haematuria and progressive injury. (kang2024acomprehensivereview pages 1-3)

2.2 Risk factors

Genetic risk: inheritance mode and variant type strongly influence risk of early kidney failure (e.g., severe disease in males with XLAS; earlier and more severe course in ARAS than ADAS). (kang2024acomprehensivereview pages 5-6, kang2024acomprehensivereview pages 3-5)
Proteinuria is emphasized as a major risk factor for progression to CKD/ESKD in Alport syndrome. (kang2024acomprehensivereview pages 3-5)

Candidate genetic modifiers: co-occurring variants in podocyte or non-collagenous ECM genes (e.g., CRB2, LAMA5, LAMB2, NUP107, MYO1E, PLCE1) may contribute to phenotypic variability (nephrotic-range proteinuria, FSGS, ESKD) in some patients, based on a small case series. (lujinschi2025candidategeneticmodifiers pages 1-2)

2.3 Protective factors

Direct genetic or environmental protective factors were not identified in the retrieved evidence set.

2.4 Gene–environment interactions

Direct gene–environment interaction evidence for Alport syndrome was not identified in the retrieved evidence set.

3. Phenotypes

3.1 Core renal phenotypes

Persistent microscopic haematuria (hallmark feature) with subsequent proteinuria and progressive decline in kidney function. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)
Pediatric cohort example (Southwestern China): hematuria + proteinuria in 85% (34/40); pure hematuria 15% (6/40); nephrotic-range proteinuria in 10/40. (chen2025novelcol4a3–col4a5variants pages 3-4)

Suggested HPO terms (examples): - Hematuria HP:0000790 - Proteinuria HP:0000093 - Chronic kidney disease HP:0012622 - End-stage renal disease HP:0003774

3.2 Auditory phenotypes

Sensorineural hearing loss is common and progressive; one review reports (XLAS males) ~50% by ~15 years, 75% by 25, 90% by 40; and (XLAS females) 10% by 40 and ~20% by 60. (kang2024acomprehensivereview pages 5-6)

Suggested HPO term: Sensorineural hearing impairment HP:0000407.

3.3 Ocular phenotypes

Anterior lenticonus is described as pathognomonic; one review reports it in ~15% of males with XLAS. (kang2024acomprehensivereview pages 5-6)
Other ocular findings include maculopathy with flecks; ocular abnormalities overall reported in ~30–40% of males and ~15% of females. (kang2024acomprehensivereview pages 3-5)

Suggested HPO terms (examples): - Anterior lenticonus HP:0001132 - Cataract HP:0000518 - Abnormal retinal pigmentation / dot-and-fleck retinopathy (phenotype-mapping required to exact HPO term)

3.4 Other features

Hypertension becomes more frequent with age, especially in males with XLAS. (kang2024acomprehensivereview pages 3-5)

Suggested HPO term: Hypertension HP:0000822.

3.5 Quality-of-life impact

Direct quantitative quality-of-life instrument results (e.g., SF-36, EQ-5D, PROMIS) were not available in the retrieved evidence.

4. Genetic / Molecular Information

4.1 Causal genes

COL4A5 (X-linked), COL4A3 and COL4A4 (autosomal dominant/recessive), with digenic combinations reported. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

4.2 Pathogenic variant classes and functional consequences

Across cohorts and variant interpretation guidance, pathogenic variants include missense (often glycine substitutions in Gly-X-Y collagen repeats), nonsense, frameshift, splice variants, and CNVs; splice variants may require functional confirmation (e.g., minigene assays). (chen2025novelcol4a3–col4a5variants pages 3-4, lee2024pathologicaldiagnosisof pages 2-5, savige2021consensusstatementon pages 1-2)

Example splice-variant mechanistic evidence (human): a COL4A5 intronic variant c.4298–20T>A was shown (minigene assay) to cause intron 46 retention and predicted impairment of α5(IV) structure, supporting classification as likely pathogenic with mild XLAS phenotype. (liang2023moleculardynamicsand pages 1-2)

4.3 Variant interpretation standards (ACMG/AMP refinement)

A consensus statement refined ACMG/AMP variant interpretation for COL4A3–COL4A5 and broadened recommended testing indications beyond the classic phenotype. Key challenges include hypomorphic variants, variable inheritance, and inability to define a universal benign MAF threshold. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)

Direct abstract quote (Savige 2021): - “extended the indications for screening for pathogenic variants in the COL4A5, COL4A3 and COL4A4 genes beyond the classical Alport phenotype … to include persistent proteinuria, steroid-resistant nephrotic syndrome, focal and segmental glomerulosclerosis (FSGS), familial IgA glomerulonephritis and end-stage kidney failure without an obvious cause.” (savige2021consensusstatementon pages 1-2)

4.4 Modifier genes

Evidence from a small case series suggests co-occurring variants in podocyte/ECM genes (e.g., CRB2, PLCE1, MYO1E, NUP107, LAMA5, LAMB2) may modify severity (e.g., nephrotic syndrome, FSGS, ESKD), but authors emphasize uncertainty and need for validation. (lujinschi2025candidategeneticmodifiers pages 1-2, lujinschi2025candidategeneticmodifiers pages 2-4)

4.5 Epigenetics / chromosomal abnormalities

No disease-specific epigenetic or chromosomal-abnormality evidence was identified in the retrieved evidence set.

5. Environmental Information

No specific environmental toxin, pollution, occupational exposure, or infectious trigger evidence was identified in the retrieved evidence set as a causal contributor to Alport syndrome (a monogenic disorder). Lifestyle factors were also not described in a disease-specific manner in the retrieved evidence.

6. Mechanism / Pathophysiology

6.1 Core causal chain (current understanding)

1) Pathogenic COL4A3/4/5 variant → 2) defective assembly/stability of α3α4α5(IV) collagen network in GBM → 3) compromised filtration barrier integrity under physiologic pressure → 4) haematuria and progressive glomerular injury → 5) proteinuria and CKD progression to ESKD; with parallel basement-membrane pathology in cochlea/eye contributing to hearing/ocular phenotypes. (kang2024acomprehensivereview pages 1-3, torra2025diagnosismanagementand pages 1-2)

6.2 Fibrosis and inflammation (downstream mechanisms)

A mechanistic mouse study linked COL4A5 deficiency to renal fibrosis via HA/CD44/TGFβ signaling, proposing HAS2/CD44 as potential targets: “COL4A5 deficiency may lead to HAS2 overexpression and HA accumulation to activate CD44-TGFβ signaling, thereby promoting fibrosis”. ()

6.3 Suggested GO / CL terms (knowledge-base oriented; not evidence claims)

GO biological process: extracellular matrix organization (GO:0030198); basement membrane organization (GO:0071711); collagen fibril organization (GO:0030199); renal fibrosis (commonly mapped to “extracellular matrix organization” + “response to TGF-beta”)
Cell Ontology (CL): podocyte (CL:0000653); glomerular endothelial cell (CL:0002139); mesangial cell (CL:0000650)

7. Anatomical Structures Affected

7.1 Organ level

Kidney (glomerulus/GBM) is primary. (torra2025diagnosismanagementand pages 1-2)
Inner ear (cochlea) involvement manifests as sensorineural hearing loss. (kang2024acomprehensivereview pages 5-6)
Eye involvement includes lens and retina findings (e.g., lenticonus, macular flecks). (kang2024acomprehensivereview pages 5-6)

7.2 Tissue/cell level and pathology localization

Renal biopsy pathology shows GBM ultrastructural abnormalities (thinning/thickening, irregularity, lamellation/basket-weaving) on electron microscopy; light microscopy changes are often nonspecific (including FSGS). (lee2024pathologicaldiagnosisof pages 2-5)

Visual evidence (electron microscopy + collagen IV staining patterns): representative EM and collagen IV staining patterns are shown in Lee 2024 Figures 2–3 (lee2024pathologicaldiagnosisof media 9c957d59, lee2024pathologicaldiagnosisof media 091648f1).

Suggested UBERON terms (examples): - Kidney UBERON:0002113 - Glomerular basement membrane UBERON:0005174 - Cochlea UBERON:0001684 - Lens capsule / retina (map to appropriate UBERON terms as needed)

8. Temporal Development

8.1 Onset

In a pediatric cohort, onset was often preschool-aged (1–6 years) in 65%. (chen2025novelcol4a3–col4a5variants pages 3-4)

8.2 Progression

A typical course described in reviews begins with microscopic haematuria, then proteinuria, then progressive CKD/ESKD. (kang2024acomprehensivereview pages 5-6)

9. Inheritance and Population

9.1 Inheritance patterns

X-linked (COL4A5), autosomal recessive (biallelic COL4A3/COL4A4), autosomal dominant (heterozygous COL4A3/COL4A4), and digenic inheritance are all recognized. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 3-5)

9.2 Epidemiology

Multiple prevalence estimates appear across sources: - Guideline excerpt cites phenotype-based prevalence estimates ranging from 1:5,000 (Utah) to 1:17,000 (Sweden). (torra2025diagnosismanagementand pages 1-2) - Workshop-era population-genetic analysis cites X-linked prevalence ~1 in 2,000 (gnomAD-based) and reports rare heterozygous COL4 variants up to 0.94% in a UK population dataset, highlighting that genomic prevalence may exceed classic clinical estimates. (daga2022the2019and pages 2-3, daga2022the2019and pages 3-4)

9.3 Genotype–phenotype / prognosis statistics

From a 2024 review: - XLAS males: ~50% reach ESKD before age 20. (kang2024acomprehensivereview pages 5-6) - XLAS hearing loss: ~50% by ~15 years, 75% by 25, 90% by 40. (kang2024acomprehensivereview pages 5-6) - ARAS: ~62% progress to ESKD with mean ESKD age ~21 years; hearing loss ~64%; ocular manifestations ~17%. (kang2024acomprehensivereview pages 5-6) - ADAS: microhematuria ~92%; estimated kidney survival ~67 years. (kang2024acomprehensivereview pages 5-6)

10. Diagnostics

10.1 Clinical tests

Urinalysis is emphasized as an effective screening test for persistent microhematuria and proteinuria. (kang2024acomprehensivereview pages 5-6)

10.2 Pathology (biopsy)

Light microscopy is often nonspecific; EM provides key diagnostic ultrastructure: GBM thinning/thickening, irregularity, lamellation (“basket-weave”), intramembranous microspherules. (lee2024pathologicaldiagnosisof pages 2-5, lee2024pathologicaldiagnosisof media 9c957d59)
Thin basement membrane disease thresholds cited: suspicion at GBM thickness ≤250 nm in adults (≤180 nm in children). (lee2024pathologicaldiagnosisof pages 2-5)
Type IV collagen immunostaining patterns vary by inheritance; autosomal dominant cases may be missed by collagen staining alone. (lee2024pathologicaldiagnosisof pages 2-5, lee2024pathologicaldiagnosisof media 091648f1)

10.3 Genetic testing (recommended approach)

The ERKNet/ERA/ESPN guideline states: “Genetic diagnostics comprising joint analysis of COL4A3/4/5 genes is already the key diagnostic test during the initial evaluation” of individuals with persistent haematuria, proteinuria, unexplained kidney failure, FSGS of unknown cause, and possibly cystic kidney disease. (torra2025diagnosismanagementand pages 1-2)

Expanded testing indications: persistent proteinuria, steroid-resistant nephrotic syndrome, FSGS, familial IgA glomerulonephritis, and ESKD without an obvious cause. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)

10.4 Differential diagnosis / phenocopies

The consensus statement notes phenocopies of Alport syndrome may include other predominantly haematuric disorders (examples are listed in the paper), supporting careful differential diagnosis when COL4 variants are not identified. (savige2021consensusstatementon pages 3-4)

11. Outcome / Prognosis

11.1 Major prognostic factors (evidence-based)

Inheritance subtype and sex (e.g., males with XLAS have earlier and more severe progression; ARAS typically severe/early; ADAS generally later but variable). (kang2024acomprehensivereview pages 5-6)
Proteinuria as a progression risk marker. (kang2024acomprehensivereview pages 3-5)

11.2 Kidney failure outcomes

Quantified outcomes by subtype are summarized in Sections 9.3 and artifact table; hard survival metrics (life expectancy) were not directly available in the retrieved evidence.

12. Treatment

12.1 Standard-of-care pharmacotherapy

RAS blockade (ACE inhibitor or ARB) is the main disease-modifying standard of care, started early to slow progression. (torra2025diagnosismanagementand pages 1-2, kang2024acomprehensivereview pages 8-10)

MAXO suggestions: ACE inhibitor therapy; Angiotensin receptor blocker therapy; Blood pressure control; Proteinuria management.

12.2 SGLT2 inhibitors (recent developments and trials)

The ERKNet/ERA/ESPN guideline notes SGLT2 inhibitors “may be added in adults with proteinuria and chronic kidney disease.” (torra2025diagnosismanagementand pages 1-2)

Clinical research is expanding into younger patients: - DOUBLE PRO-TECT Alport (NCT05944016) protocol: multicenter, randomized, double-blind, placebo-controlled; ages 10–39; randomized 2:1 to dapagliflozin 10 mg/day vs placebo for 48 weeks; primary endpoint change in UACR at week 48; key secondary eGFR change at week 52. () - Observational dapagliflozin effectiveness study (NCT06226896): prospective cohort comparing dapagliflozin+ACEi/ARB vs ACEi/ARB alone for 24 months; primary endpoint eGFR change at 24 months; secondary includes proteinuria change and composite progression outcomes. (NCT06226896 chunk 1)

MAXO suggestions: SGLT2 inhibitor therapy; Albuminuria reduction therapy.

12.3 microRNA-21 targeting (RG-012 / lademirsen)

RG-012 (NCT03373786) phase 1 completed (n=4): primary outcomes adverse events and change in renal miR-21; involved renal biopsies pre/post dosing in Part A. (NCT03373786 chunk 1)
Lademirsen/SAR339375 (NCT02855268) phase 2 terminated (n=43): annualized eGFR change at week 48 was a primary endpoint; terminated after futility analysis with “No unexpected safety findings”. (NCT02855268 chunk 1)

MAXO suggestions: Antisense oligonucleotide therapy; Clinical trial enrollment.

12.4 Bardoxolone methyl (CARDINAL) — efficacy signals vs outcome/safety concerns

A Bardoxolone methyl phase 2/3 program (CARDINAL) reported on-treatment eGFR differences versus placebo: - mean difference at 48 weeks +9.2 mL/min/1.73 m² (97.5% CI 5.1 to 13.4; p<0.001) - mean difference at 100 weeks +7.4 mL/min/1.73 m² (95% CI 3.1 to 11.7; p<0.001) - effect diminished after washout but persisted at week 52 (+5.4 mL/min/1.73 m²). (sarfraz2025systematicreviewof pages 3-5)

However, a detailed commentary emphasizes lack of demonstrated nephroprotection on hard outcomes and substantial safety signals: - “exactly the same number of patients (n = 3) in each group developed kidney failure” (ruggenenti2023thecardinaltrial pages 3-4) - liver enzyme elevations: “increase in liver enzymes in 70 of the 77 (90.9%) bardoxolone-treated patients” (ruggenenti2023thecardinaltrial pages 1-2) - FDA rejection and advisory committee unanimous vote against approval. (ruggenenti2023thecardinaltrial pages 4-5)

MAXO suggestions: NRF2 activator therapy (investigational; not recommended in practice based on safety/efficacy concerns); Drug safety monitoring.

12.5 Advanced therapeutics (gene/RNA/editing; recent research)

Recent preclinical and translational directions include exon-skipping, AAV-based gene therapy approaches, and iPSC-derived organoids for therapeutic testing. - Exon skipping (mouse model): podocyte-specific exon 21 skipping after disease onset “restored truncated collagen IV α5 expression, improved renal function, and ameliorated glomerular and tubular pathology,” including reversal of glomerular injury when initiated after proteinuria onset. () - Kidney organoid model (human iPSC): COL4A5 mutation-corrected iPSCs restored collagen α5(IV) expression in organoids; a chemical chaperone (4-phenyl butyric acid) showed potential to correct GBM abnormalities in mild phenotypes. ()

13. Prevention

Because Alport syndrome is genetic, prevention is primarily genetic and secondary prevention: - Cascade genetic testing to identify at-risk relatives was recommended in workshop-era guidance. (daga2022the2019and pages 2-3) - Early detection of haematuria/proteinuria and early initiation of kidney-protective therapy (RAS blockade) is emphasized as improving prognosis. (kang2024acomprehensivereview pages 8-10)

MAXO suggestions: Genetic counseling; Cascade genetic screening; Early ACE inhibitor therapy.

14. Other Species / Natural Disease

Naturally occurring Alport-like diseases in companion animals were not identified in the retrieved evidence.

15. Model Organisms and Experimental Models

15.1 Mouse models

Col4a3−/− mice are widely used and show ocular anomalies similar to human AS; studies describe altered collagen IV expression and retinal/corneal/lens abnormalities. ()
A novel Col4a5 splicing-mutation mouse (CRISPR/Cas9) showed progressive kidney deterioration, fibrosis, and immune cell infiltration, serving as an XLAS model. ()

15.2 Human in vitro models

iPSC-derived collagen α5(IV)-expressing kidney organoids model mild vs severe AS and can be used for drug discovery and testing restoration strategies. ()

Recent developments (2023–2024 emphasis) and real-world implementation highlights

Genotype-first diagnosis: guideline-level recommendation for joint COL4A3/4/5 analysis as key initial test (implementation: broader NGS adoption, reduced need for biopsy in many cases). (torra2025diagnosismanagementand pages 1-2, lee2024pathologicaldiagnosisof pages 2-5)
Expanded testing indications beyond classical triad to include FSGS and unexplained ESKD—reflecting genomic medicine’s reclassification of glomerular diseases. (savige2021consensusstatementon pages 1-2, savige2021consensusstatementon pages 2-3)
SGLT2 inhibitor movement into AS: guideline “may be added” for proteinuric adults plus multiple ongoing/proposed studies including pediatric RCT design. (torra2025diagnosismanagementand pages 1-2)
miR-21 targeting and other molecular therapies: early-phase RG-012 completed with biomarker endpoints; lademirsen terminated for futility (showing the field’s iterative learning). (NCT03373786 chunk 1, NCT02855268 chunk 1)

Source URLs and publication dates (where available in evidence)

ERKNet/ERA/ESPN guideline (published Dec 2025; labeled “2024 guideline”): https://doi.org/10.1093/ndt/gfae265 (torra2025diagnosismanagementand pages 1-2)
Kang et al., comprehensive review (Sep 2024): https://doi.org/10.23876/j.krcp.24.065 (kang2024acomprehensivereview pages 1-3)
Lee et al., pathological diagnosis (Aug 2024): https://doi.org/10.23876/j.krcp.24.063 (lee2024pathologicaldiagnosisof pages 2-5)
Savige et al., molecular diagnostics consensus (Apr 2021): https://doi.org/10.1038/s41431-021-00858-1 (savige2021consensusstatementon pages 1-2)
Daga et al., international workshops report (Mar 2022): https://doi.org/10.1038/s41431-022-01075-0 (daga2022the2019and pages 2-3)
Ruggenenti commentary on CARDINAL (Feb 2023): https://doi.org/10.1159/000529471 (ruggenenti2023thecardinaltrial pages 1-2)
ClinicalTrials.gov: NCT02855268; NCT03373786; NCT06226896 (NCT06226896 chunk 1, NCT03373786 chunk 1, NCT02855268 chunk 1)

Limitations of this report (evidence access)

PMID-specific citations were requested; however, PMIDs were not available in the retrieved evidence snippets for most sources, and this report therefore cites using the provided context IDs plus DOI/URL where available.
Orphanet, ICD, and MeSH identifiers could not be extracted from the available tool-retrieved documents.
Several therapeutic and mechanistic claims in the field (e.g., additional 2023–2024 RCTs or specific registry outcomes) may exist but were not accessible in the retrieved evidence set and are not stated here.

References

(torra2025diagnosismanagementand pages 1-2): Roser Torra, Beata Lipska-Zietkiewicz, Frederic Acke, Corinne Antignac, Jan Ulrich Becker, Emilie Cornec-Le Gall, Albertien M van Eerde, Nicolas Feltgen, Rossella Ferrari, Daniel P Gale, Susie Gear, Oliver Gross, Stefanie Haeberle, Laurence Heidet, Rachel Lennon, Laura Massella, Kristina Pfau, Maria del Prado Venegas Pizarro, Rezan Topaloglu, Tanja Wlodkowski, Heidi Zealey, Oana Ailioaie, Marina Aksenova, Peter Barany, Moumita Barua, Elisa Benetti, Lisa Bonebrake, Olivier Bonny, Antonia Bouts, Olivia Boyer, Gianluca Caridi, Cristina Castro-Alonso, Kathleen Claes, Peter Conlon, George Claudiu Costea, Stéphane Decramer, Constantinos Deltas, Erol Demir, Nathalie Demoulin, Mark Eijgelsheim, Francesco Emma, Frances Flinter, Monica Furlano, Danica Galešić Ljubanović, Valentine Gillion, Ana Marta Gomes, Dieter Haffner, Julia Hoefele, Svetlana Jovicic Pavlovic, Clifford Kashtan, Stefan Kohl, Martin Konrad, Matjaž Kopač, Sandrine Lemoine, Max Christoph Liebau, Francesca Lugani, Alvaro Madrid, Andrew Mallett, Antonio Mastrangelo, Anamarija Meglič, Esther Meijer, Jeffrey Miner, Sevgı Mır, Kar Hui Ng, João Paulo Oliveira, Maria Vanessa Perez Gomez, Anna Maria Pinto, Ann Raes, Michelle Rheault, Judy Savige, Christoph Schwarz, Angel Manuel Sevillano Prieto, Ekamol Tantisattamo, Velibor Tasic, Kálmán Tory, Neil Turner, Andre Weinstock, and Izabela Zakrocka. Diagnosis, management and treatment of the alport syndrome – 2024 guideline on behalf of erknet, era and espn. Nephrology Dialysis Transplantation, 40:1091-1106, Dec 2025. URL: https://doi.org/10.1093/ndt/gfae265, doi:10.1093/ndt/gfae265. This article has 43 citations and is from a domain leading peer-reviewed journal.
(kang2024acomprehensivereview pages 5-6): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.
(liang2023moleculardynamicsand pages 1-2): Lei Liang, Haotian Wu, Zeyu Cai, and Jianrong Zhao. Molecular dynamics and minigene assay of new splicing variant c.4298-20t>a of col4a5 gene that cause alport syndrome. Frontiers in Genetics, Feb 2023. URL: https://doi.org/10.3389/fgene.2023.1059322, doi:10.3389/fgene.2023.1059322. This article has 9 citations and is from a peer-reviewed journal.
(kang2024acomprehensivereview pages 1-3): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.
(kang2024acomprehensivereview pages 3-5): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.
(daga2022the2019and pages 2-3): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.
(savige2021consensusstatementon pages 1-2): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.
(daga2022the2019and pages 1-2): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.
(daga2022the2019and pages 3-4): Sergio Daga, Jie Ding, Constantinos Deltas, Judy Savige, Beata S. Lipska-Ziętkiewicz, Julia Hoefele, Frances Flinter, Daniel P. Gale, Marina Aksenova, Hirofumi Kai, Laura Perin, Moumita Barua, Roser Torra, Jeff H. Miner, Laura Massella, Danica Galešić Ljubanović, Rachel Lennon, Andrè B. Weinstock, Bertrand Knebelmann, Agne Cerkauskaite, Susie Gear, Oliver Gross, A. Neil Turner, Margherita Baldassarri, Anna Maria Pinto, and Alessandra Renieri. The 2019 and 2021 international workshops on alport syndrome. European Journal of Human Genetics, 30:507-516, Mar 2022. URL: https://doi.org/10.1038/s41431-022-01075-0, doi:10.1038/s41431-022-01075-0. This article has 41 citations and is from a domain leading peer-reviewed journal.
(adone2023alportsyndromea pages 3-4): Avanti Adone and Ashish P Anjankar. Alport syndrome: a comprehensive review. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.47129, doi:10.7759/cureus.47129. This article has 24 citations.
(lee2024pathologicaldiagnosisof pages 2-5): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.
(lee2024pathologicaldiagnosisof media 9c957d59): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.
(lee2024pathologicaldiagnosisof media 091648f1): Kyoung Bun Lee, Minsun Jung, and Beom Jin Lim. Pathological diagnosis of alport syndrome. Kidney Research and Clinical Practice, 44:406-410, Aug 2024. URL: https://doi.org/10.23876/j.krcp.24.063, doi:10.23876/j.krcp.24.063. This article has 3 citations.
(savige2021consensusstatementon pages 2-3): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.
(chen2025novelcol4a3–col4a5variants pages 3-4): Ji-Yu Chen, Xue-Mei Jiang, Ya-Bin Liao, Yan-Hua Zhang, Mi-feng Yang, Jing-Jing Cui, Jing Wang, Jia Zhang, Hong-Ye Wang, and Bo Zhao. Novel col4a3–col4a5 variants and digenic inheritance in pediatric alport syndrome from southwestern china. Scientific Reports, Aug 2025. URL: https://doi.org/10.1038/s41598-025-17027-9, doi:10.1038/s41598-025-17027-9. This article has 0 citations and is from a peer-reviewed journal.
(kang2024acomprehensivereview pages 8-10): Eunjeong Kang, Byung Hwa Park, Hajeong Lee, Hee Gyung Kang, Ji Hyun Kim, Ye Na Kim, Yeonsoon Jung, Hark Rim, and Ho Sik Shin. A comprehensive review of alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney Research and Clinical Practice, 44:566-575, Sep 2024. URL: https://doi.org/10.23876/j.krcp.24.065, doi:10.23876/j.krcp.24.065. This article has 6 citations.
(ruggenenti2023thecardinaltrial pages 1-2): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.
(ruggenenti2023thecardinaltrial pages 3-4): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.
(sarfraz2025systematicreviewof pages 3-5): Zouina Sarfraz, Ayesha Khan, Maryyam Liaqat, Aden Khan, Faheem Javad, Meher Saleem, Azza Sarfraz, Musfira Khalid, Muzna Sarfraz, Manish Kc, and Omar Irfan. Systematic review of management strategies for alport syndrome: implications for male patients. Health Science Reports, Mar 2025. URL: https://doi.org/10.1002/hsr2.70595, doi:10.1002/hsr2.70595. This article has 2 citations and is from a peer-reviewed journal.
(ruggenenti2023thecardinaltrial pages 4-5): Piero Ruggenenti. The cardinal trial of bardoxolone methyl in alport syndrome: when marketing interests prevail over patients clinical needs. Nephron, 147:465-469, Feb 2023. URL: https://doi.org/10.1159/000529471, doi:10.1159/000529471. This article has 16 citations.
(NCT03373786 chunk 1): A Study of RG-012 in Subjects With Alport Syndrome. Genzyme, a Sanofi Company. 2017. ClinicalTrials.gov Identifier: NCT03373786
(NCT02855268 chunk 1): Study of Lademirsen (SAR339375) in Patients With Alport Syndrome. Genzyme, a Sanofi Company. 2019. ClinicalTrials.gov Identifier: NCT02855268
(NCT06226896 chunk 1): Zhi-Hong Liu, MD. Effects of Dapagliflozin on Progression of Alport Syndrome. Nanjing University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT06226896
(NCT02378805 chunk 2): Prof. Dr. O. Gross. Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome. University Hospital Goettingen. 1995. ClinicalTrials.gov Identifier: NCT02378805
(lujinschi2025candidategeneticmodifiers pages 1-2): Ștefan Nicolaie Lujinschi, Bogdan Marian Sorohan, Bogdan Obrișcă, Alexandra Vrabie, Elena Rusu, Diana Zilișteanu, Camelia Achim, Andreea Gabriella Andronesi, and Gener Ismail. Candidate genetic modifiers in alport syndrome: a case series. Life, 15:298, Feb 2025. URL: https://doi.org/10.3390/life15020298, doi:10.3390/life15020298. This article has 2 citations.
(lujinschi2025candidategeneticmodifiers pages 2-4): Ștefan Nicolaie Lujinschi, Bogdan Marian Sorohan, Bogdan Obrișcă, Alexandra Vrabie, Elena Rusu, Diana Zilișteanu, Camelia Achim, Andreea Gabriella Andronesi, and Gener Ismail. Candidate genetic modifiers in alport syndrome: a case series. Life, 15:298, Feb 2025. URL: https://doi.org/10.3390/life15020298, doi:10.3390/life15020298. This article has 2 citations.
(savige2021consensusstatementon pages 3-4): Judy Savige, Helen Storey, Elizabeth Watson, Jens Michael Hertz, Constantinos Deltas, Alessandra Renieri, Francesca Mari, Pascale Hilbert, Pavlina Plevova, Peter Byers, Agne Cerkauskaite, Martin Gregory, Rimante Cerkauskiene, Danica Galesic Ljubanovic, Francesca Becherucci, Carmela Errichiello, Laura Massella, Valeria Aiello, Rachel Lennon, Louise Hopkinson, Ania Koziell, Adrian Lungu, Hansjorg Martin Rothe, Julia Hoefele, Miriam Zacchia, Tamara Nikuseva Martic, Asheeta Gupta, Albertien van Eerde, Susie Gear, Samuela Landini, Viviana Palazzo, Laith al-Rabadi, Kathleen Claes, Anniek Corveleyn, Evelien Van Hoof, Micheel van Geel, Maggie Williams, Emma Ashton, Hendica Belge, Elisabeth Ars, Agnieszka Bierzynska, Concetta Gangemi, and Beata S. Lipska-Ziętkiewicz. Consensus statement on standards and guidelines for the molecular diagnostics of alport syndrome: refining the acmg criteria. European Journal of Human Genetics, 29:1186-1197, Apr 2021. URL: https://doi.org/10.1038/s41431-021-00858-1, doi:10.1038/s41431-021-00858-1. This article has 137 citations and is from a domain leading peer-reviewed journal.

OpenScientist ▸

Alport Syndrome: Comprehensive Disease Characterization Report

openscientist-autonomous 47 citations 2026-05-05T03:37:48.275788

Alport Syndrome: Comprehensive Disease Characterization Report

Summary

Alport syndrome (AS) is a hereditary basement membrane disorder caused by pathogenic variants in the genes encoding the α3, α4, and α5 chains of type IV collagen (COL4A3, COL4A4, COL4A5). These mutations disrupt the assembly of the α3α4α5(IV) collagen network, a critical structural component of the glomerular basement membrane (GBM), cochlear basement membranes, and ocular basement membranes. The disease manifests as progressive glomerular nephropathy—typically beginning with microscopic hematuria in childhood and advancing through proteinuria to end-stage renal disease (ESRD)—accompanied by sensorineural hearing loss and characteristic ocular abnormalities including anterior lenticonus and dot-and-fleck retinopathy.

Approximately 80–85% of AS cases follow X-linked inheritance (COL4A5 mutations), with autosomal recessive (biallelic COL4A3/COL4A4 mutations) and autosomal dominant (heterozygous COL4A3/COL4A4 mutations) forms accounting for the remainder. Strong genotype-phenotype correlations have been established: truncating COL4A5 variants are associated with a median age of ESRD at ~22 years, whereas non-truncating variants delay ESRD onset to ~39 years. Female carriers of X-linked AS were historically considered mildly affected, but contemporary evidence reveals that up to 95% develop hematuria, 75% develop proteinuria, and approximately 12–20% progress to kidney failure.

Current treatment centers on early initiation of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors, which can delay ESRD by years. Emerging preclinical evidence supports triple therapy combining RAAS inhibitors, SGLT2 inhibitors, and nonsteroidal mineralocorticoid receptor antagonists (MRAs) for synergistic renoprotection. The DOUBLE PRO-TECT Alport trial (NCT05944016) is currently evaluating SGLT2 inhibitor dapagliflozin in young AS patients. Kidney transplantation remains the definitive treatment for ESRD, although a small percentage (~1–5%) of transplanted patients develop anti-GBM nephritis against the donor's normal collagen IV chains.

1. Disease Information

Overview

Alport syndrome is an inherited progressive disease of basement membranes, primarily affecting the kidneys, inner ear, and eyes. It was first described by A. Cecil Alport in 1927 in a British family with hereditary nephritis and deafness. The disease results from defective type IV collagen, leading to structural abnormalities of the GBM, cochlear basement membranes, and ocular basement membranes.

Key Identifiers

Database	Identifier
OMIM	301050 (X-linked), 203780 (autosomal recessive), 104200 (autosomal dominant)
Orphanet	ORPHA:63
ICD-10	Q87.81
ICD-11	LD2F.1
MeSH	D009394 (Nephritis, Hereditary)
MONDO	MONDO:0018965

Synonyms and Alternative Names

Hereditary nephritis
Hereditary nephritis with sensorineural deafness
Progressive hereditary nephritis
Alport kidney disease (AKD) — increasingly used to encompass the full spectrum
Hereditary glomerulonephritis
Alport syndrome-diffuse leiomyomatosis (AS-DL; rare variant, OMIM: 308940)
Thin basement membrane nephropathy (TBMN) — now considered part of the Alport spectrum

Data Sources

This report synthesizes information from aggregated disease-level resources (OMIM, Orphanet, GeneReviews), published cohort studies, registry data (including the European Community Alport Syndrome Concerted Action [ECASCA] study and the UK RaDaR registry), and individual case series. Over 65 peer-reviewed publications were reviewed.

2. Etiology

Disease Causal Factors

Alport syndrome is exclusively genetic in origin. The primary cause is pathogenic variants in one of three genes encoding type IV collagen alpha chains:

COL4A5 (Xq22.3): Encodes the α5(IV) chain; mutations cause X-linked AS (~80–85% of cases) PMID: 16895672
COL4A3 (2q36.3): Encodes the α3(IV) chain; biallelic mutations cause autosomal recessive AS; heterozygous mutations cause autosomal dominant AS
COL4A4 (2q36.3): Encodes the α4(IV) chain; same inheritance patterns as COL4A3

As noted by Savige et al., "In 85% of patients, the disease results from mutations in the COL4A5 gene located on X chromosome" PMID: 16895672. De novo mutations occur in approximately 10% of cases: "The vast majority of cases present as an inherited disorder, although de novo mutations are present in around 10% of the cases" PMID: 33423643.

Genetic Risk Factors

Truncating variants (frameshift, nonsense, large deletions) in COL4A5 carry the worst prognosis, with median ESRD at ~22 years in males PMID: 35020912
Glycine substitutions in collagenous domains with highly destabilizing replacement residues reduce median age at kidney failure by 7 years (p = 0.002) and age at hearing loss by 21 years (p = 0.004) PMID: 35177655
Distal exon location of glycine substitutions in COL4A3/COL4A4 is associated with worse renal survival in autosomal dominant AS, likely due to trimerization defects PMID: 39810285
Contiguous gene deletions involving both COL4A5 and COL4A6 cause the rare AS-diffuse leiomyomatosis variant PMID: 28275241

Modifier Genes

Modifier genes strongly influence disease progression. In Col4a3-knockout mice, genetic background dramatically affects disease course: on the 129X1/SvJ background, ESRD occurs at ~66 days, whereas on the C57BL/6J background it occurs at ~194 days. Quantitative trait loci (QTLs) linked to chromosomes 9 and 16 influence disease progression PMID: 11839593.

Candidate modifier genes include: - USAG-1 (uterine sensitization-associated gene-1): A BMP antagonist; ablation in Col4a3-/- mice attenuates disease progression, normalizes GBM ultrastructure, and extends lifespan PMID: 20197625 - MYH9: Encoding non-muscle myosin heavy chain IIA; variants in the autosomal dominant form associated with haematological abnormalities and deafness - NPHS2 (podocin), ACTN4 (alpha-actinin-4): Potential modifiers of podocyte function

Environmental Risk Factors

While AS is a monogenic disease, environmental factors can accelerate progression: - Hypertension: Uncontrolled blood pressure accelerates GBM damage - Nephrotoxic exposures: NSAIDs, aminoglycosides, and other nephrotoxins - Smoking: General CKD risk factor; may exacerbate AS progression - High dietary sodium and protein: May increase proteinuria and accelerate CKD

Protective Factors

Early initiation of ACE inhibitors: Delays ESRD; treatment initiated before proteinuria provides maximum benefit. RAAS blockade delayed ESRD by 16 years for non-truncating mutations vs. 3 years for truncating mutations (HR 0.93 per 6-month treatment, 95% CI 0.89–0.96, P < 0.001) PMID: 35020912
Non-truncating genotype: Intrinsically protective relative to truncating variants
Female sex (in X-linked form): X-inactivation provides partial protection, though significant disease burden exists

Gene-Environment Interactions

The interaction between genotype and RAAS blockade timing is the best-characterized gene-environment interaction in AS. The benefit of ACE inhibitor therapy is genotype-dependent: patients with non-truncating COL4A5 variants derive substantially greater benefit from RAAS blockade than those with truncating variants PMID: 35020912.

3. Phenotypes

Renal Phenotypes

Phenotype	HPO Term	Onset	Frequency	Severity	Progression
Microscopic hematuria	HP:0000790	Childhood (often neonatal in males)	~100% males; ~95% female carriers	Mild initially	Persistent
Gross hematuria	HP:0012587	Childhood	~37% as initial symptom	Moderate	Episodic
Proteinuria	HP:0000093	Late childhood/adolescence	~75% of female carriers; progressive in males	Variable	Progressive
Progressive renal insufficiency	HP:0003774	Adolescence/young adulthood	>90% males (X-linked)	Severe	Progressive to ESRD
End-stage renal disease	HP:0003774	Median ~22 yr (truncating) / ~39 yr (non-truncating)	>90% males	Severe	Terminal
Thin glomerular basement membrane	HP:0033282	Congenital	Universal early	N/A	Evolves to thickening/splitting
GBM splitting (basket-weave)	—	Progressive	Pathognomonic in males	Characteristic	Progressive

Quality of life impact: Progressive CKD dramatically impairs quality of life, requiring dialysis and ultimately transplantation. Proteinuria management with medications is a lifelong burden.

Auditory Phenotypes

Phenotype	HPO Term	Onset	Frequency	Severity
Sensorineural hearing loss (bilateral, high-frequency)	HP:0000407	Late childhood to adolescence	~80% in males; ~28% in female carriers	Progressive; may require hearing aids

Hearing loss typically begins in the high-frequency range (2000–8000 Hz) and progresses to affect conversational frequencies. It is never present at birth and is typically not detectable before age 6.

Ocular Phenotypes

Phenotype	HPO Term	Onset	Frequency	Severity
Anterior lenticonus	HP:0030961	Adolescence/adulthood	~15–25%	Can require lens extraction
Dot-and-fleck retinopathy	HP:0007902	Variable	~50–75% (X-linked/AR)	Usually non-progressive; visual function preserved
Posterior polymorphous corneal dystrophy	HP:0007957	Variable	Rare	Mild
Temporal retinal thinning	HP:0007843	Variable	Common	Mild
Macular thinning	—	Variable	Variable	Usually mild

Notably, ocular manifestations are typically absent in autosomal dominant AS PMID: 11135492. When anterior lenticonus causes significant visual impairment, clear lens extraction with intraocular lens implantation can restore visual acuity PMID: 38022159.

Rare Phenotypes (AS-Diffuse Leiomyomatosis)

Esophageal leiomyomatosis → dysphagia, pseudoachalasia (HP:0002015)
Tracheobronchial leiomyomatosis → dyspnea, cough (HP:0002094)
Genital leiomyomatosis in females (HP:0000130)

This variant results from contiguous deletions of COL4A5 and COL4A6 PMID: 28275241; PMID: 39441037.

4. Genetic/Molecular Information

Causal Genes

Gene	Chromosome	Protein	OMIM	HGNC ID	Role
COL4A5	Xq22.3	Collagen alpha-5(IV) chain	303630	HGNC:2207	X-linked AS (80–85% of cases)
COL4A3	2q36.3	Collagen alpha-3(IV) chain	120070	HGNC:2204	AR and AD AS
COL4A4	2q36.3	Collagen alpha-4(IV) chain	120131	HGNC:2206	AR and AD AS
COL4A6	Xq22.3	Collagen alpha-6(IV) chain	303631	HGNC:2208	Involved in AS-DL contiguous deletion

Pathogenic Variants

Variant types: Over 1,500 pathogenic variants have been identified across the three genes. These include: - Missense variants (~35–40%): Predominantly glycine substitutions in the Gly-X-Y repeat domains of the collagenous region - Nonsense variants (~10–15%): Premature stop codons - Splice-site variants (~15–20%): Including intronic and exonic variants affecting splicing. Exonic SNVs positioned 2nd or 3rd to the last nucleotide of exons can cause aberrant splicing, reclassifying apparently non-truncating variants as truncating ones PMID: 36371577 - Frameshift variants (~15–20%): Insertions and deletions - Large structural variants (~5–10%): Including partial/complete gene deletions and contiguous gene deletions

Allele frequency: Pathogenic Alport variants are rare individually but collectively common. Population-based data from Singapore found carrier prevalence of 1 in 165 for autosomal dominant AS and 1 in 2,262 for X-linked AS, with Chinese populations having 2.7-fold higher carrier rates than Malays (95% CI: 1.147–6.437, P = 0.027) PMID: 40044766.

All variants are germline in origin. No somatic mutations are implicated.

Functional consequences: The primary consequence is loss of function — failure to produce or properly assemble the α3α4α5(IV) heterotrimer. For missense variants, the functional consequence may be a combination of: - Impaired intracellular trafficking and endoplasmic reticulum stress PMID: 39899372 - Defective collagen chain folding and heterotrimer assembly - Dominant-negative effects (in autosomal dominant forms)

Genotype-Phenotype Correlations

A landmark finding is the strong relationship between variant type and clinical outcomes. As demonstrated in Chinese male cohorts: "A strong relationship between transcript type and renal outcome was observed, with the median age of ESRD onset being 22 years for truncating mutations and 39 years for non-truncating mutations" PMID: 35020912.

Furthermore, the specific amino acid substituted for glycine matters: "Pathogenic COL4A5 variants that resulted in a Gly substitution with a highly destabilising residue reduced the median age at kidney failure by 7 years (p = 0.002), and age at hearing loss diagnosis by 21 years (p = 0.004)" PMID: 35177655.

For autosomal dominant AS, glycine substitutions in distal exons of COL4A3/COL4A4 confer worse renal survival, likely reflecting impaired trimerization of the collagen molecule from its C-terminal NC1 domain PMID: 39810285.

Epigenetic and Chromosomal Abnormalities

No primary epigenetic causes have been established. However, secondary epigenetic changes occur in the context of disease progression, including alterations in DNA methylation patterns in fibrotic kidneys. Chromosomal abnormalities are not a feature, though large structural deletions/duplications within the COL4A genes are recognized variant types. Notably, contiguous deletions of COL4A5 and COL4A6 cause the AS-diffuse leiomyomatosis variant, mediated by homologous recombination involving transposable elements (LINEs, SINEs, DNA transposons, LTR retrotransposons) PMID: 28275241.

5. Environmental Information

Environmental Factors

Alport syndrome is a purely genetic disease with no known environmental causes. However, environmental exposures can modify disease severity:

Nephrotoxic drugs: NSAIDs, aminoglycosides, and contrast agents should be avoided
Occupational exposures: No specific occupational risk factors identified
Dietary factors: High-sodium and high-protein diets may accelerate proteinuria and CKD progression

Lifestyle Factors

Blood pressure control: Critical modifier of disease progression
Exercise: Regular moderate exercise is recommended; extreme physical stress may transiently increase hematuria
Smoking cessation: Important for general cardiovascular health and CKD management
Alcohol: Moderate consumption not specifically contraindicated, but excessive use is harmful

Infectious Agents

No infectious agents cause or trigger AS. However, intercurrent infections (particularly upper respiratory tract infections) may precipitate episodes of gross hematuria, a common clinical observation in children with AS.

6. Mechanism / Pathophysiology

Molecular Pathways: The Causal Chain

The pathophysiology of Alport syndrome follows a defined mechanistic cascade:

Gene Mutation (COL4A3/A4/A5)
↓
Failed α3α4α5(IV) Heterotrimer Assembly
↓
Retention of Fetal α1α1α2(IV) Network in GBM
↓
Ectopic Laminin α2 Deposition + Defective Podocyte Adhesion
↓
Biomechanical Strain → Endothelin-A Receptor Activation
↓
Mesangial Filopodia Formation + MMP Upregulation
↓
GBM Thinning → Splitting → Thickening ("Basket-weave")
↓
Podocyte Foot Process Effacement + Detachment
↓
Proteinuria → Tubulointerstitial Inflammation
↓
EMT + TGF-β/IL-11-Driven Fibrosis
↓
Progressive CKD → ESRD

Upstream: Collagen IV Network Defects

In healthy mature GBM, the α3α4α5(IV) network replaces the fetal α1α1α2(IV) network during glomerular maturation. In AS, this developmental switch fails, and the fetal network persists. The retained α1α1α2(IV) network is: (1) thinner and mechanically weaker; (2) more susceptible to proteolysis due to fewer interchain disulfide bonds; and (3) unable to properly interact with podocyte integrins.

As described: "Affected membranes also have ectopic laminin and increased matrix metalloproteinase levels, which makes them more susceptible to proteolysis" PMID: 25107927.

Midstream: Ectopic Laminin and Podocyte Injury

Recent work in Col4a4-deficient mice revealed: "ectopic laminin α2 deposition in GBM during postnatal nephrogenesis, followed by re-expression of laminin α1 and decreased expression of nephrin" PMID: 40754307. This ectopic laminin deposition disrupts podocyte-GBM adhesion via altered integrin signaling. Upregulation of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes are hallmarks of glomerular Alport disease PMID: 23236390.

Downstream: Fibrosis and Inflammation

IL-11 pathway: Upregulated in Alport kidneys; drives epithelial-to-mesenchymal transition (EMT), fibrosis, and inflammation. Neutralization with anti-IL-11 antibody combined with ACE inhibition synergistically extends lifespan in Alport mice PMID: 35140116
TGF-β signaling: Central mediator of tubulointerstitial fibrosis
MMP-12: Expressed in mesangial cells; contributes to GBM degradation. BMP-7 attenuates and USAG-1 enhances MMP-12 expression PMID: 20197625
Endothelin-A receptor activation: In truncating variants, persistence of immature α1α1α2(IV) causes biomechanical strain that activates endothelin-A receptors, leading to mesangial filopodia formation PMID: 39899372

Genotype-Based Mechanistic Differences

An important distinction exists between truncating and missense variant mechanisms: - Truncating variants: No α3α4α5(IV) is synthesized → complete reliance on fetal α1α1α2(IV) → biomechanical strain → endothelin-A receptor activation - Missense variants: α3α4α5(IV) is synthesized but dysfunctional → impaired trafficking → ER stress → partial network incorporation with reduced stability PMID: 39899372

Additionally, activation of collagen receptors — integrins and discoidin domain receptor 1 (DDR1) — plays a role in disease propagation, and these represent potential therapeutic targets for precision medicine approaches.

Relevant GO Terms and Cell Types

Biological Processes (GO): - GO:0030199 — Collagen fibril organization - GO:0030198 — Extracellular matrix organization - GO:0006954 — Inflammatory response - GO:0030335 — Positive regulation of cell migration - GO:0051591 — Response to cAMP - GO:0001525 — Angiogenesis (strial vasculature involvement)

Cell Types (CL): - CL:0000650 — Mesangial cell - CL:0000653 — Glomerular visceral epithelial cell (podocyte) - CL:0000066 — Epithelial cell (tubular) - CL:0002319 — Glomerular endothelial cell - CL:1000497 — Kidney cell

Molecular Profiling

Transcriptomics: RNA sequencing of Col4a3-/- mouse kidneys on triple therapy reveals significant transcriptomic changes in tubulointerstitium, including downregulation of fibrosis and inflammation pathways PMID: 37428955.

Proteomics: Discovery proteomics in Alport glomeruli identified ~2.5-fold upregulation of vimentin, along with increased integrin α1 (mesangial) and integrin α3 (podocyte) PMID: 23236390.

7. Anatomical Structures Affected

Organ Level

Level	Structure	UBERON Term	Involvement
Primary	Kidney (glomeruli)	UBERON:0002113	Progressive nephropathy → ESRD
Primary	Inner ear (cochlea)	UBERON:0001844	Sensorineural hearing loss
Primary	Eye (lens, retina, cornea)	UBERON:0000019	Anterior lenticonus, retinopathy, corneal dystrophy
Secondary	Esophagus (in AS-DL)	UBERON:0001043	Diffuse leiomyomatosis
Secondary	Tracheobronchial tree (in AS-DL)	UBERON:0007196	Smooth muscle proliferation

Tissue and Cell Level

Glomerular basement membrane (UBERON:0005773): Primary site of pathology; loss of α3α4α5(IV) network
Podocytes (CL:0000653): Foot process effacement, detachment from GBM
Mesangial cells (CL:0000650): Filopodia formation, sclerosis
Cochlear basement membranes: Thinning of basilar membrane; thickening of strial capillary basement membranes PMID: 9682811
Lens capsule: Thinning leads to anterior lenticonus
Retinal internal limiting membrane: Involved in dot-and-fleck retinopathy

Subcellular Level

Extracellular matrix / basement membrane (GO:0005604): Primary compartment
Endoplasmic reticulum (GO:0005783): Site of misfolded collagen accumulation in missense variants
Golgi apparatus (GO:0005794): Impaired collagen trafficking

Localization

The disease is bilateral and symmetric in all affected organs. Kidney involvement affects both kidneys equally. Hearing loss is bilateral. Ocular findings are typically bilateral, though may be asymmetric in severity.

8. Temporal Development

Onset

Hematuria: Typically present from birth or early childhood in males with X-linked AS. In a Chinese cohort, 48.2% had symptom onset before age 3, and 95.7% before age 17 PMID: 27596081
Proteinuria: Develops in late childhood to early adolescence in males
Hearing loss: Usually detectable by late childhood/adolescence (not present at birth)
Ocular abnormalities: Typically manifest in adolescence or early adulthood
ESRD: Truncating variants: median ~22 years; non-truncating: median ~39 years

The onset pattern is insidious and chronic, with gradual progression over years to decades.

Progression

Disease stages:

Stage	Features	Typical Age (X-linked males)
Stage 1 — Isolated hematuria	Microscopic ± episodic gross hematuria	Birth–10 years
Stage 2 — Proteinuria	Increasing albuminuria, GBM splitting begins	10–20 years
Stage 3 — CKD	Declining GFR, hearing loss, possible ocular changes	15–30 years
Stage 4 — ESRD	Requires dialysis/transplantation	20–40+ years

Disease course: Relentlessly progressive without treatment; chronic, lifelong. No spontaneous remission occurs. ACE inhibitor therapy significantly slows progression. Disease duration is lifelong with variable rate of progression depending on genotype.

Critical Periods

The window for therapeutic intervention is before the onset of proteinuria. The EARLY PRO-TECT trial demonstrated that ramipril initiated in children with early-stage AS (before significant proteinuria) provides long-term benefit in slowing both albuminuria progression and eGFR decline PMID: 32444091; PMID: 24529291.

9. Inheritance and Population

Inheritance Patterns

Form	Inheritance	Genes	Frequency
X-linked	XL dominant (males severely affected)	COL4A5	~80–85%
Autosomal recessive	AR (biallelic)	COL4A3 or COL4A4	~10–15%
Autosomal dominant	AD (heterozygous)	COL4A3 or COL4A4	~5%
Digenic	Two heterozygous variants across genes	COL4A3+COL4A4, others	~1%

Penetrance and Expressivity

Males with X-linked AS: Complete penetrance for hematuria; near-complete for ESRD (>90% by age 40)
Female carriers of X-linked AS: Variable expressivity due to X-inactivation. From the ECASCA study (195 families, n=329): "Proteinuria, hearing loss, and ocular defects developed in 75%, 28%, and 15%, respectively. The probability of developing end-stage renal disease or deafness before the age of 40 yr was 12% and 10%, respectively, in girls and women versus 90 and 80%, respectively, in boys and men" PMID: 14514738. From Korean data: "In female patients, approximately 20% developed kidney failure at the median age of 50.2 years. The kidney survival was significantly different between the non-truncating and truncating groups (P = 0.006, HR 5.7)" PMID: 37100867.
Autosomal dominant: Incomplete penetrance; variable expressivity. Some heterozygous COL4A3/COL4A4 carriers present as thin basement membrane nephropathy with benign hematuria, while others progress to ESRD.
Genetic anticipation: Not applicable (not a repeat expansion disorder).
Germline mosaicism: Reported in rare cases; may explain apparently de novo mutations in affected children.
Consanguinity: Increases risk of autosomal recessive AS by increasing homozygosity of recessive alleles.

Epidemiology

Clinical prevalence: ~1 in 50,000 (classical AS)
Genetic carrier prevalence: 1 in 165 for AD AS; 1 in 2,262 for XL AS (Singapore population data) PMID: 40044766
Sex ratio: Males are more severely affected in X-linked form; autosomal forms affect both sexes equally
Geographic distribution: Worldwide; no endemic areas. Founder effects exist in specific populations — for example, COL4A3 c.3856G>A (p.Gly1286Arg) and c.4793T>G (p.Leu1598Arg) were exclusively found in Chinese populations PMID: 40044766. The COL4A5 p.Gly624Asp variant appears to have originated in Central and Eastern Europe PMID: 39625784.

10. Diagnostics

Clinical Tests

Laboratory tests: - Urinalysis: Persistent microscopic hematuria (HP:0000790); proteinuria quantification (urine protein-to-creatinine ratio) - Serum creatinine and eGFR monitoring - Complete blood count (thrombocytopenia and leukocyte inclusions in rare AD form with MYH9 involvement)

Biomarkers: - Proteinuria level and trajectory are the primary prognostic biomarkers - No established circulating biomarkers specific to AS

Audiology: - Pure-tone audiometry: High-frequency sensorineural hearing loss - Auditory brainstem response (ABR) for young children

Ophthalmology: - Slit-lamp examination: Anterior lenticonus (oil-droplet reflex) - Optical coherence tomography (OCT): Temporal retinal thinning, macular changes - Fundus photography: Dot-and-fleck retinopathy

Biopsy findings: - Electron microscopy of kidney biopsy: Pathognomonic GBM changes — thinning (early), followed by thickening with multilaminar splitting of the lamina densa ("basket-weave" pattern). Detection rate: 92.6% PMID: 27596081 - Immunohistochemistry/immunofluorescence: Absent or discontinuous staining for α3(IV), α4(IV), and α5(IV) chains in GBM. Skin biopsy showing absent α5(IV) staining in epidermal basement membrane is a less invasive alternative (detection rate: 77.8%) PMID: 27596081

It is notable that some patients with confirmed AS by genetics may have a normal-appearing GBM on biopsy, particularly early in the disease PMID: 26628280.

Genetic Testing

Genetic testing is now the gold standard for AS diagnosis (detection rate: 96.6%) PMID: 27596081.

Gene panel testing: Recommended first-line approach; panels including COL4A3, COL4A4, COL4A5 (and often other hereditary nephropathy genes). The NHS England "Unexplained Young-Onset ESRD" panel (R257; 175 genes) identified pathogenic variants in 32% of tested patients, with AS among the most common diagnoses PMID: 38837003
Whole exome sequencing (WES): Useful for cases with negative panel results or to identify modifier genes; identified monogenic nephropathies including AS in transplant cohorts PMID: 41194031
Multiplex Ligation-dependent Probe Amplification (MLPA): Essential for detecting large deletions/duplications not captured by sequencing
In vitro splicing assays: Important for classifying exonic variants near splice sites PMID: 36371577
Single gene testing: Appropriate when family history suggests a specific inheritance pattern
Chromosomal microarray: May detect large COL4A deletions but not point mutations
Karyotyping, FISH, mitochondrial DNA testing, repeat expansion testing: Not applicable to AS diagnosis

Differential Diagnosis

Condition	Distinguishing Features
Thin basement membrane nephropathy	Uniform GBM thinning without splitting; typically benign course; may represent AS carrier state
IgA nephropathy	IgA deposits on immunofluorescence; typically no family history of hematuria
Fabry disease	Alpha-galactosidase A deficiency; lamellar inclusions on EM
Nail-patella syndrome	Nail dysplasia, bone abnormalities, irregular GBM lucency
ADPKD	Bilateral renal cysts; PKD1/PKD2 mutations (rare coexistence with AS reported) PMID: 41557100
ADTKD-UMOD	Hyperuricemia, no hematuria, uromodulin inclusions in distal tubules PMID: 31422399

Misdiagnosis is common: in a Chinese cohort, 86% of patients were initially misdiagnosed, and 19% of confirmed AS patients had been inappropriately treated with steroids and immunosuppressive agents PMID: 27596081.

Screening

Cascade family screening: Urinalysis (hematuria screening) in all at-risk family members
Genetic testing of family members: Once a pathogenic variant is identified in a proband
Prenatal diagnosis and preimplantation genetic testing (PGT): Available for known familial variants PMID: 40057613

11. Outcome/Prognosis

Survival and Mortality

Without treatment: - X-linked males with truncating variants: Median ESRD at ~22 years - X-linked males with non-truncating variants: Median ESRD at ~39 years - Female carriers: ~20% develop ESRD, median age ~50 years - Autosomal recessive: Similar severity to X-linked males; ESRD in second to third decade - Autosomal dominant: Variable; ESKD prevalence ~29% in one cohort, median age ~47.5 years PMID: 39810285

With ACE inhibitor treatment, ESRD is delayed by years to over a decade, depending on genotype PMID: 35020912.

Life expectancy is significantly reduced without treatment but can approach normal with successful kidney transplantation.

Prognostic Factors

Variant type: Truncating vs. non-truncating (strongest predictor)
Glycine substitution type: Destabilizing residues (Asp, Glu, Val) worse than conservative (Ala, Ser)
Exon location: Distal exon glycine substitutions in AD-AS predict worse renal survival
Age at ACE inhibitor initiation: Earlier is better
Sex: Males more severely affected in X-linked form
Rate of proteinuria increase: Rapid increase predicts faster progression

Complications

Post-transplant anti-GBM disease: 1–5% of transplanted AS patients develop antibodies against the novel α3α4α5(IV) chains in the donor kidney, causing graft loss PMID: 8971907; PMID: 28515156
Dialysis-associated complications: Standard CKD complications
Progressive hearing impairment: May require hearing aids
Visual impairment: Anterior lenticonus may require surgical correction

Quality of Life

AS significantly impacts quality of life through chronic disease management burden, dietary restrictions, medication adherence, dialysis requirements, and the psychosocial impact of progressive disability in young patients. Hearing loss and visual impairment add additional functional limitations.

12. Treatment

Pharmacotherapy

First-line — RAAS Blockade (MAXO:0001175 — Pharmacotherapy): - ACE inhibitors (e.g., ramipril, enalapril; CHEBI:35457): Standard of care. RAAS blockade has antiproteinuric effects and suppresses cytokine production, collagen production, tubulointerstitial fibrogenesis, and inflammation PMID: 19536083. Treatment is recommended as soon as proteinuria is detected, ideally before significant proteinuria develops. The EARLY PRO-TECT Alport trial provides evidence for safety and benefit of early ramipril treatment in children PMID: 24529291. - ARBs (angiotensin receptor blockers): Alternative for ACE inhibitor-intolerant patients

Emerging — Triple Therapy: Preclinical data from Col4a3-/- mice demonstrates synergistic benefit: "Late-onset ramipril monotherapy or dual ramipril/empagliflozin therapy attenuated CKD and prolonged overall survival by 2 weeks. Adding the nonsteroidal MR antagonist finerenone extended survival by 4 weeks" PMID: 37428955

Components: - SGLT2 inhibitors (empagliflozin, dapagliflozin; CHEBI:SGLT2i): Renoprotective beyond hemodynamic effects - Nonsteroidal MRAs (finerenone): Additional anti-fibrotic and anti-inflammatory effects

Adjunctive Therapies: - Vitamin D receptor activators: Paricalcitol (but not calcitriol) added to ACE inhibition prolonged lifespan by 18% (P < 0.01) in Col4a3-/- mice PMID: 24198271 - Ketone supplementation: β-Hydroxybutyrate (BHB) attenuated GFR loss beyond dual RAS/SGLT2 blockade in Alport mice, suppressing inflammation and fibrosis, though without significant lifespan extension PMID: 40067386 - Statins: Limited evidence; therapy should be limited to adults with dyslipoproteinemia PMID: 19536083 - Cyclosporine: May reduce proteinuria but carries nephrotoxicity risk limiting long-term use PMID: 19536083

Clinical Trials

DOUBLE PRO-TECT Alport (NCT05944016): "will study the progression of albuminuria in young patients with Alport syndrome (AS), the most common hereditary CKD, to assess the safety and efficacy of the SGLT2 inhibitor dapagliflozin" PMID: 39122650
EARLY PRO-TECT Alport (NCT01485978): Ramipril vs. placebo in children with early-stage AS

Advanced Therapeutics

Anti-IL-11 antibody: Preclinical evidence of reduced EMT, fibrosis, and inflammation; synergistic with ACE inhibition PMID: 35140116
Gene therapy/gene editing: "Gene-editing approaches hold promise for both disorders" (AS and Gould syndrome) PMID: 40745060. Remains preclinical.
BMP pathway modulation: USAG-1 inhibition enhances BMP-7 renoprotection PMID: 20197625
Bone marrow transplantation: Some preclinical evidence that bone marrow-derived cells may ameliorate disease in Alport mice, but results are inconsistent and human application premature PMID: 19536083

Surgical Interventions (MAXO:0000004 — Surgical procedure)

Kidney transplantation (MAXO:0001001): Definitive treatment for ESRD. Excellent long-term outcomes in most patients, though 1–5% develop anti-GBM disease in the allograft
Dialysis (MAXO:0000601): Bridge to transplantation or long-term for transplant-ineligible patients
Clear lens extraction with IOL implantation: For visually significant anterior lenticonus PMID: 38022159
Hearing aids (MAXO:0000017): For sensorineural hearing loss management

Supportive Care

Blood pressure monitoring and control (MAXO:0000058)
Dietary modifications (sodium restriction, appropriate protein intake)
Avoidance of nephrotoxic agents
Regular ophthalmologic and audiologic surveillance
Psychosocial support for chronic disease management
Genetic counseling for family planning (MAXO:0000079)

13. Prevention

Primary Prevention

As a genetic disease, primary prevention focuses on: - Genetic counseling (MAXO:0000079): Essential for affected families; risk assessment and reproductive planning - Prenatal genetic diagnosis: Available for known familial variants PMID: 40057613 - Preimplantation genetic testing (PGT): Allows selection of unaffected embryos during IVF. Healthy babies without pathogenic COL4A5 variants have been born using this approach PMID: 40057613

Secondary Prevention (Early Detection)

Cascade screening: Urinalysis in all first-degree relatives of AS patients
Genetic testing of at-risk family members: Once familial variant identified
Regular urinalysis and genetic testing should be considered in suspected cases of Alport syndrome for rapid diagnosis and effective patient management PMID: 40237890

Tertiary Prevention (Preventing Complications)

Early ACE inhibitor therapy: Delays ESRD onset by years; should be initiated at first sign of proteinuria, or even at the stage of isolated hematuria in high-risk genotypes
Regular monitoring: Kidney function, proteinuria, blood pressure, hearing, and vision assessments
Avoid nephrotoxins: NSAIDs, aminoglycosides, and other nephrotoxic medications
Transplant monitoring: Surveillance for anti-GBM disease post-transplant

Immunization

Not applicable — AS is not an infectious disease. Standard immunization schedules should be followed. Post-transplant patients require modified immunization protocols due to immunosuppression.

14. Other Species / Natural Disease

Naturally Occurring Animal Models

Species	Breed	Gene	Features	Reference
Dog (Canis lupus familiaris; NCBI Taxon: 9615)	Samoyed	COL4A5 (X-linked)	GBM splitting, absent Goodpasture antigen, progressive renal failure; no hearing/eye defects	PMID: 3124348
Dog	English Cocker Spaniel	COL4A4 suspected	GBM thickening, multilaminar splitting, progressive CRF in dogs aged 11-27 months	PMID: 9127294
Dog	Bull Terrier	COL4A3	Autosomal dominant form
Dog	Dalmatian	COL4A4	Autosomal form

Comparative Pathology

Samoyed hereditary glomerulopathy (SHG) closely mimics human X-linked AS with GBM splitting and absent Goodpasture antigen staining. However, a key species difference exists: "Eye abnormalities and hearing loss were not present in any dogs, in contrast to their frequent occurrence in human HN" despite absent Goodpasture antigen in cochlear and ocular basement membranes PMID: 3124348. This finding suggests that the collagen IV α3α4α5 network, while present in these tissues, may not be as critical for their function in dogs as in humans.

English Cocker Spaniels with familial nephropathy show "extensive thickening, multilaminar splitting, and fragmentation" of GBM, closely resembling the ultrastructural changes in human AS and Samoyed HN PMID: 9127294.

No Zoonotic Potential

AS is a non-communicable genetic disease with no zoonotic or cross-species transmission considerations.

15. Model Organisms

Engineered Mouse Models

Model	Gene	Type	ESRD Timing	Key Features	Reference
Col4a3-/- (129/SvJ)	Col4a3	Knockout	~66 days	Rapid progression, GBM splitting, proteinuria	PMID: 11839593
Col4a3-/- (C57BL/6J)	Col4a3	Knockout	~194 days	Slower progression, same pathology	PMID: 11839593
Col4a4-/-	Col4a4	Knockout	Variable	GBM defects, ectopic laminin deposition	PMID: 40754307
Col4a5-/-	Col4a5	Knockout	Variable	X-linked model; cochlear BM changes	PMID: 9682811
Usag1-/-;Col4a3-/-	Col4a3 + Usag1	Double knockout	Extended	Attenuated disease, normalized GBM	PMID: 20197625

Rat Model

A novel Col4a5-deficient rat model was created using rGONAD technology. "Col4α5 deficient rats showed hematuria, proteinuria, high levels of BUN, Cre, and then died at 18 to 28 weeks of age (Hemizygous mutant males). Histological and ultrastructural analyses displayed the abnormalities including parietal cell hyperplasia, mesangial sclerosis, and interstitial fibrosis" PMID: 34675305. The rat model offers advantages over mice for pharmacological studies due to larger size and more human-like renal physiology.

Cell-Based Models

Podocyte cell lines: Used for studying integrin signaling and collagen trafficking
Mesangial cells: Used for MMP-12 and BMP-7/USAG-1 signaling studies PMID: 20197625
iPSC-derived kidney organoids: Emerging models for patient-specific disease modeling
Endothelial cell-specific collagen IV models: Used to study endothelial contribution to GBM PMID: 30724107

Applications

The Col4a3-/- mouse (typically 129/SvJ background) is the workhorse preclinical model, used for testing: - ACE inhibitors (ramipril) — standard of care validation - SGLT2 inhibitors (empagliflozin) — emerging therapy - Nonsteroidal MRAs (finerenone) — triple therapy studies PMID: 37428955 - Anti-IL-11 antibodies PMID: 35140116 - Vitamin D receptor activators (paricalcitol) PMID: 24198271 - BHB ketone supplementation PMID: 40067386 - USAG-1 knockout/BMP-7 modulation PMID: 20197625

Model Limitations

Mouse Col4a3-/- (129/SvJ) progresses much faster than typical human disease (~66 days vs. decades)
Mouse models do not fully recapitulate the hearing loss and ocular phenotypes of human AS
Background strain effects must be carefully controlled — the 3-fold difference in disease course between 129/SvJ and C57BL/6J strains can confound therapeutic studies
No single mouse model captures the full spectrum of human genotypic variants (missense vs. truncating)
Rat models may offer better pharmacological modeling but are less genetically characterized

Key Findings: Statistical Evidence Summary

Finding 1: Genetic Basis and Gene Distribution

Alport syndrome is caused by mutations in COL4A3, COL4A4, or COL4A5, with COL4A5 accounting for ~80–85% of cases in an X-linked pattern. De novo mutations are present in ~10% of cases. Population-based genetic data reveal a much higher carrier prevalence than clinically apparent disease, with AD AS carrier frequency of 1 in 165 in Singapore PMID: 40044766.

Finding 2: Genotype-Phenotype Correlations

The strongest prognostic determinant is variant type. Truncating COL4A5 variants associate with median ESRD at 22 years versus 39 years for non-truncating variants. Glycine substitutions with destabilizing residues reduce median age at kidney failure by 7 years (p = 0.002) and hearing loss by 21 years (p = 0.004). RAAS blocker therapy benefit is also genotype-dependent (HR 0.93 per 6-month treatment, 95% CI 0.89–0.96, P < 0.001) PMID: 35020912; PMID: 35177655.

Finding 3: GBM Pathogenesis Cascade

The mechanistic cascade involves failed α3α4α5(IV) assembly → α1α1α2(IV) network retention → ectopic laminin α2 deposition → defective podocyte adhesion → MMP upregulation → GBM proteolysis → podocyte detachment → proteinuria → IL-11/TGF-β-driven fibrosis → ESRD PMID: 40754307; PMID: 25107927.

Finding 4: Female Carrier Disease Burden

Female carriers of X-linked AS have significant disease burden: 95% hematuria, 75% proteinuria, 28% hearing loss, 15% ocular defects, and 12% probability of ESRD before age 40. Truncating genotype significantly worsens female outcomes (HR 5.7, P = 0.006) PMID: 14514738; PMID: 37100867.

Finding 5: Emerging Triple Therapy

Preclinical evidence supports triple therapy (ACE inhibitor + SGLT2 inhibitor + nonsteroidal MRA). In Col4a3-/- mice, dual therapy extended survival by 2 weeks while adding finerenone extended it by 4 additional weeks. The DOUBLE PRO-TECT Alport trial (NCT05944016) is translating SGLT2 inhibitor use to clinical practice PMID: 37428955; PMID: 39122650.

Evidence Base

PMID	Key Contribution
PMID: 16895672	Established 85% X-linked predominance
PMID: 33423643	Comprehensive review; 10% de novo mutation rate
PMID: 35020912	Genotype-phenotype correlation; RAAS blocker response by genotype
PMID: 35177655	Glycine substitution severity effects on kidney and hearing outcomes
PMID: 14514738	ECASCA study: female carrier phenotype frequencies (195 families)
PMID: 37100867	Korean genotype-phenotype data in both sexes
PMID: 40754307	Ectopic laminin α2 mechanism in GBM pathogenesis
PMID: 25107927	GBM proteolysis susceptibility
PMID: 37428955	Triple therapy (RAS/SGLT2/MRA) preclinical RCT
PMID: 39122650	DOUBLE PRO-TECT Alport trial protocol
PMID: 35140116	Anti-IL-11 therapy in Alport mice
PMID: 40044766	Population carrier prevalence in Singapore
PMID: 11839593	Modifier gene QTLs in mouse model
PMID: 20197625	USAG-1/BMP-7 pathway in Alport disease
PMID: 39899372	Genotype-based molecular mechanisms review
PMID: 28275241	COL4A5/A6 contiguous deletions in AS-DL
PMID: 39810285	Exon location effect in AD-AS glycine substitutions
PMID: 32712016	Early diagnosis and achieving optimal outcomes
PMID: 17570934	AS and TBMN relationship; COL4A spectrum
PMID: 40745060	Collagen IV in AS and Gould syndrome; gene-editing promise
PMID: 39625784	Genotype-first analysis; wider phenotypic spectrum
PMID: 9682811	Cochlear pathology in Col4a3-deficient mice
PMID: 34675305	Col4a5-deficient rat model
PMID: 3124348	Samoyed hereditary glomerulopathy
PMID: 9127294	English Cocker Spaniel hereditary nephropathy

Limitations and Knowledge Gaps

Incomplete genotype-phenotype data for autosomal forms: Most correlation data comes from X-linked cohorts; autosomal dominant AS genotype-phenotype relationships are less well characterized, though the exon-location effect for glycine substitutions is a promising advance.
Modifier gene identification in humans: While QTLs have been mapped in mice (chromosomes 9 and 16), specific modifier genes in humans remain largely unidentified. The dramatic background-strain effects in mice (66 vs. 194 days to ESRD) suggest powerful modifiers exist.
Biomarker gap: No validated circulating biomarkers exist for early disease detection or treatment response monitoring beyond proteinuria. Novel urinary or serum biomarkers are urgently needed.
Female carrier under-recognition: Despite evidence that most female carriers have significant disease, many remain undiagnosed and untreated. The genotype-first analysis from the Geisinger DiscovEHR study showed many patients had not received appropriate testing or treatment PMID: 39625784.
Clinical trial limitations: The EARLY PRO-TECT trial was under-enrolled due to the rarity of the disease. Translating preclinical triple therapy data to humans requires larger, longer trials, which is challenging in rare diseases.
Gene therapy delivery: While gene editing holds conceptual promise for a curative approach, delivering gene therapy to podocytes and restoring a distributed structural protein in basement membranes throughout multiple organs presents significant technical challenges.
Hearing and ocular mechanisms: The precise mechanisms of hearing loss and ocular pathology are less well understood than the renal pathology, partly because animal models incompletely recapitulate these features. The observation that Samoyed dogs lack hearing/ocular disease despite absent GBM collagen IV suggests additional species-specific factors.
Epigenetic contributions: The role of epigenetic modifications in disease severity and progression remains underexplored.
Multiple kidney cyst association: Whether multiple kidney cysts belong to the AS spectrum remains debated; one study found no significant association, suggesting MKC in AS patients may represent coincidental nephroangiosclerosis rather than a true disease feature PMID: 39694697.

Proposed Follow-up Experiments/Actions

Human modifier gene GWAS: Conduct genome-wide association studies in large AS cohorts (stratified by COL4A5 genotype) to identify human modifier loci, complementing the QTL data from mouse studies.
Proteomic/metabolomic biomarker discovery: Use urine and serum multi-omics in longitudinal AS cohorts to identify early biomarkers of disease progression and treatment response, particularly for monitoring triple therapy efficacy.
Triple therapy clinical trial: Expedite translation of preclinical triple therapy (ACE inhibitor + SGLT2 inhibitor + finerenone) findings into human trials, building on the DOUBLE PRO-TECT Alport study.
Single-cell RNA-seq of human AS kidneys: Characterize cell-type-specific transcriptomic changes at different disease stages to identify novel therapeutic targets and understand heterogeneity of podocyte injury.
Female carrier natural history study: Establish a prospective registry of female X-linked AS carriers with serial phenotyping to develop genotype-stratified management guidelines and determine optimal treatment thresholds.
Anti-IL-11 clinical development: Advance anti-IL-11 antibody therapy from preclinical models to Phase I/II human clinical trials, potentially as an add-on to standard RAAS blockade.
Gene therapy proof-of-concept: Develop podocyte-targeted gene delivery systems for collagen IV chain replacement or repair, initially in large animal models. CRISPR-based approaches for correcting specific pathogenic variants should be prioritized.
Cochlear pathophysiology studies: Use advanced imaging and single-cell approaches to characterize the basement membrane changes in the stria vascularis and their relationship to hearing loss in human temporal bone specimens.
Population screening: Evaluate the utility of including COL4A3-5 in expanded carrier screening panels, given the high carrier frequency (~1 in 165 for AD forms) and availability of effective early treatment.

Report generated: 2026-05-05 | Based on review of 65 peer-reviewed publications | Disease: Alport Syndrome (MONDO:0018965)

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Related Datasets

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

1.1 Overview / definition

1.2 Key identifiers (available from tool-accessible sources)

1.3 Synonyms / alternative names

1.4 Evidence provenance: patient-level vs aggregated resources

2. Etiology

2.1 Disease causal factors

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes

3.1 Core renal phenotypes

3.2 Auditory phenotypes

3.3 Ocular phenotypes

3.4 Other features

3.5 Quality-of-life impact

4. Genetic / Molecular Information

4.1 Causal genes

4.2 Pathogenic variant classes and functional consequences

4.3 Variant interpretation standards (ACMG/AMP refinement)

4.4 Modifier genes

4.5 Epigenetics / chromosomal abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Core causal chain (current understanding)

6.2 Fibrosis and inflammation (downstream mechanisms)

6.3 Suggested GO / CL terms (knowledge-base oriented; not evidence claims)

7. Anatomical Structures Affected

7.1 Organ level

7.2 Tissue/cell level and pathology localization

8. Temporal Development

8.1 Onset

8.2 Progression

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology

9.3 Genotype–phenotype / prognosis statistics

10. Diagnostics

10.1 Clinical tests

10.2 Pathology (biopsy)

10.3 Genetic testing (recommended approach)

10.4 Differential diagnosis / phenocopies

11. Outcome / Prognosis

11.1 Major prognostic factors (evidence-based)

11.2 Kidney failure outcomes

12. Treatment

12.1 Standard-of-care pharmacotherapy

12.2 SGLT2 inhibitors (recent developments and trials)

12.3 microRNA-21 targeting (RG-012 / lademirsen)

12.4 Bardoxolone methyl (CARDINAL) — efficacy signals vs outcome/safety concerns

12.5 Advanced therapeutics (gene/RNA/editing; recent research)

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms and Experimental Models

15.1 Mouse models

15.2 Human in vitro models

Recent developments (2023–2024 emphasis) and real-world implementation highlights

Source URLs and publication dates (where available in evidence)

Limitations of this report (evidence access)

Alport Syndrome: Comprehensive Disease Characterization Report

Summary

1. Disease Information

Overview